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 Cell-based therapies have demonstrated potency and efficacy as cancer 
treatment modalities. T cells can be dichotomized by their T cell receptor (TCR) 
complexes where αβ T cells (95% of T cells) and γδ T cells (<5% of T cells) express 
α/β and γ/δ TCR heterodimers, respectively. γδ T cells have inherent anti-tumor 
immunity, but their use in the clinic is hampered by a lack of clinically-relevant 
expansion protocols. In contrast, αβ T cells do not have predictable anti-tumor 
immunity so they can be re-directed to specific molecules on the tumor surface through 
introduction of tumor-specific molecules such as chimeric antigen receptors (CARs) for 
reproducible tumor killing. CARs are constructed with the extracellular specificity of a 
monoclonal antibody to a tumor antigen, e.g. CD19 or receptor tyrosine kinase-like 
orphan receptor-1 (ROR1), fused to intracellular T cell signaling domains (CD3ζ, 
CD28, CD137). A comparative study was done between αβ T cells re-directed with 
ROR1-specific CARs signaling through CD3ζ and either CD28 (ROR1RCD28) or 
CD137 (ROR1RCD137) in the first specific aim of this dissertation. CAR+ T cells 
proliferated to clinically significant numbers and ROR1+ tumor cells were effectively 
targeted and killed by both ROR1-specific CAR+ T cell populations, although 




ROR1RCD137 were superior to ROR1RCD28 in clearance of leukemia xenografts in 
vivo. The second specific aim focused on generating bi-specific CD19-specific CAR+ γδ 
T cells with polyclonal TCRγδ repertoire on CD19+ artificial antigen presenting cells 
(aAPC). Enhanced cytolysis of CD19+ leukemia was observed by CAR+ γδ T cells 
compared to CARneg γδ T cells, and leukemia xenografts were significantly reduced 
compared to control mice in vivo. The third specific aim looked at the broad anti-tumor 
effects of polyclonal γδ T cells expanded on aAPC without CAR+ T cells, where Vδ1, 
Vδ2, and Vδ3 populations had naïve, effector memory, and central memory phenotypes 
and effector function strength in the following order: Vδ2>Vδ3>Vδ1. Polyclonal γδ T 
cells eliminated ovarian cancer xenografts in vivo and increased survival compared to 
control mice. Thus, translating these methodologies to clinical trials will provide cancer 
patients novel, safe, and effective options for their treatment.  
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Cancer is caused by the uncontrolled and abnormal growth of cells that leads to disease 
and remains the second most common cause of death in the United States of America 
behind heart disease.(1) It is more prevalent in women than men where the median time 
at diagnosis is in their 60’s and 70’s, respectively.(2) Overall, the median age at 
diagnosis is 66 years old for all cancer types and more than 1.5 million people are 
estimated to have been diagnosed with cancer in 2012, according to the most current 
statistics from the National Cancer Institute (NCI) Surveillance Epidemiology and End 
Results (SEER; http://seer.cancer.gov/statistics). Of these diagnoses, >200,000 are 
represented from each of the three most common cancers: prostate, breast, and lung. 
The other groups of cancers, therefore, affect roughly 900,000 people per year in the 
United States, and some of the diagnoses carry dismal chances for survival. For 
example, roughly 22,000 women are expected to have a new diagnosis of ovarian 
cancer in 2013 where only 44% of them are expected to survive 5 years, and over 
186,000 women are currently estimated to have a history of ovarian cancer in the 
United States. Similarly, greater than 48,000 new leukemia diagnoses, with 5-year 
overall survival rate of 56% are predicted for 2013, and more than 287,000 people in 
the United States have leukemia at present. Cancers can either arise from either (i) the 
hematopoietic compartment, i.e. bone marrow, blood, and lymphatic system, giving rise 




to hematological tumors or (ii) tissues outside of the hematological systems that are 
generically termed solid tumors. Despite the many treatments that exist for cancer, 
novel therapies are desperately needed to decrease the mortality and morbidity of this 
disease. 
 
I.A.1. Hematological Tumors 
Hematological cancers are delineated by their hematopoietic differentiation status and 
the tissue from which the tumor arises. In regards to leukemia, the different types are 
separated first by either myeloid or lymphoid lineages and then into acute or chronic 
stages. Thus, they are classified as (i) acute myeloid leukemia (AML), (ii) chronic 
myeloid leukemia (CML), (iii) acute lymphoblastic leukemia (ALL), or (iv) chronic 
lymphocytic leukemia.(3) Immunotherapy targeting tumor associated antigens (TAA), 
e.g. CD19 or Receptor tyrosine kinase-like orphan receptor-1 (ROR1), have potential to 
lead to tumor regressions and, in some cases when targeting CD19, complete responses 
have been observed in the clinic.(4-7) The main focus of this dissertation is on 
developing immunotherapies for the lymphoid subsets of leukemia. 
 
I.A.1.a. B-cell Acute Lymphoblastic Leukemia 
The most common pediatric malignancy known is ALL but also affects many adults.(8-
10) The median age at ALL diagnosis in 2012 was estimated to be 13 years old.(2) For 
B-cell ALL (B-ALL), tumors typically arise from the pro-B cell stage and retain 




primitive characteristics without undergoing further differentiation.(11) A common 
subtype of B-ALL halted in normal B cell development is t(1;19) ALL, where the 
translocation results in an E2A-PBX1 fusion protein that functions in promoting 
developmental arrest and oncogenic transformation simultaneously.(12) Therapies are 
being actively sought after for treatment of this B-ALL group by targeting unique or 
dysregulated proteins resulting from aberrant E2A-PBX1 gene regulation.(13) 
Cytogenetics and flow cytometric staining of the tumor cell surface molecules are two 
key tools in the diagnosis of B-ALL, which has clinical presentation consistent of 
common ailments, i.e. fever, bleeding, pain, fatigue, and lethargy, but is commonly first 
detected due to high white blood cell counts (WBC).(14, 15) Aggressive treatment, 
including chemotherapy, radiation therapy, and hematopoietic stem cell transplantation 
(HSCT), has dramatically improved overall survival, but long-term health problems 
frequently arise following therapy particularly amongst children.(16, 17) More 
specifically, children in remission commonly develop secondary malignancies later in 
life, and most commonly develop AML.(18) Unfortunately, few effective treatments 
exist for AML. Incomplete eradication of the primary tumor can result in minimal 
residual disease (MRD) of the primary tumor and is also a common cause of 
malignancies later in life that are usually resistant to conventional therapies.(16, 19) 
Thus, it is of paramount importance that safe and effective therapies are developed for 
B-ALL patients in order to fully remove their primary tumor, reduce risk the for 
development of secondary tumors, and improve their expected quality of life as adults. 
 
 




I.A.1.b. T-cell Acute Lymphoblastic Leukemia 
T-cell ALL (T-ALL) accounts for less than 25% of ALL cases and has a dismal 
prognosis relative to B-ALL.(20)  The differentiation stage of T-ALL has importance as 
more immature T cells are correlated to more aggressive disease.(14, 21) Diagnosis and 
treatment are, in general, similar to those for B-ALL, although one unique and common 
clinical manifestation of T-ALL is a large mediastinal mass causing shortness of 
breath.(20, 22) Prognostic indicators for T-ALL response to therapy are widely sought 
after but are not yet predictive of response. However, particular emphasis on NOTCH 
mutations and chromosomal translocations has generated much enthusiasm for being 
able to stratify patients into potential responders and non-responders.(23, 24) As with 
B-ALL, MRD is a primary concern as it contributes to relapse in many cases and can be 
diagnosed by amplification of specific TCR alleles.(25) Currently, no adoptive T cell 
therapies directly targeting their neoplastic T cell counterparts exist for T-ALL. 
Therefore, development of T cells capable of fratricide may improve the outcomes for 
T-ALL patients in dire need of therapeutic intervention. 
 
I.A.1.c. Chronic Lymphocytic Leukemia 
In contrast to ALL, CLL occurs much later in life and is not as aggressive as ALL.(26) 
CLL often arises from activated or memory B cells and progresses slowly but is deadly 
nonetheless with a 5-year median survival.(27) Furthermore, a CLL profile with (i) 
alterations in chromosomes 11 or 17, (ii) unmutated immunoglobulin heavy chain 
(IgVH) genes, (iii) expression of zeta-chain associated protein kinase-70 (ZAP70), (iv) 




expression of CD38, (v) rapid doubling time of tumor lymphocytes, or (vi) increased 
serum β2-microglobulin, soluble CD23, and thymidine kinase activity have been 
correlated with a more aggressive disease status and markedly decreased median 
survival.(28) CLL is generally asymptomatic and high WBC commonly results in early 
diagnosis that is later corroborated with cytogenetics and flow cytometry. Most current 
therapies are not curative and often require palliative care, but some strategies, e.g. 
chemotherapy, antibody therapy, and stem cell transplant, can extend survival up to 
multiple years.(29) T cell immunotherapy is an actively pursued therapy for CLL due to 
the many targetable TAA, e.g. CD19, CD20, CD23, CD52, and CD40, and monoclonal 
antibody therapies directed at these TAA have resulted in objective clinical responses in 
CLL treatments.(30) Furthermore, mAbs can be also adapted to T cell therapies in the 
form of chimeric antigen receptors (CARs) by linking a single chain antibody specific 
for the TAA to T cell intracellular activation domains.(31) Indeed, several clinical trials 
with CAR-based T cell therapies targeting CD19 have generated complete responses in 
both B-ALL and B-CLL (discussed further in Chapter I.D.3.).(4-7, 32) Because CLL 
can be sensitive to immunotherapy, it is a prime disease target for T cell treatments. 
 
I.A.2. Solid Tumors 
There are many different types of solid tumors but this dissertation will focus on 
generating T cell therapies for two model cancers with hopes of future applications to 
other solid tumors. Ovarian and pancreatic cancers were chosen because of (i) their poor 




prognostic outcome, (ii) lack of efficacious T cell immunotherapies, and (iii) favorable 
responses targeting these tumors in initial pre-clinical tests. 
 
I.A.2.a. Ovarian Cancer 
Ovarian cancer (OvCa) is commonly referred to as “the most common gynecological 
malignancy.”(33) The median age at diagnosis is 63 years old, and most patients are 
diagnosed in late stage (III or IV) which has a 5-year overall survival rate of 27%.(34-
36) OvCa typically arises from the ovary, fallopian tube, or peritoneal cavity, and is 
unique in that traditional metastasis is not common outside of the intraperitoneal 
cavity.(37) Growth within the intraperitoneal cavity can grossly impact the ability of 
surrounding organs to function properly and, in some case, can be sites for local 
metastases. The most useful prognostic indicator for OvCa is CA125, also known as 
mucin 16 (MUC16), which is shed into the bloodstream and is predictive of progressive 
OvCa disease status.(38) Standard of care for women facing OvCa treatment is surgical 
resection and aggressive chemotherapy.(39, 40) Many immunotherapy approaches have 
been tried with few objective clinical responses.(41-44) Even though OvCa appears to 
have sensitivity to immunomodulation, a cell-based therapy that results in objective 
clinical responses has yet to be developed. As the survival rate is dismal for advanced 
OvCa, novel therapies are urgently needed to combat this disease. 
 
 




I.A.2.b. Pancreatic Cancer 
Pancreatic cancer (PaCa) is one of the worst cancer diagnoses because 1-year and 5-
year overall survival rates are 20% and 5%, respectively.(45) It is commonly 
differentiated based on the anatomical location of the tumor where the tail, neck, and 
head of the pancreas are distinct locations and the pancreatic head is the most common 
site where tumors arise.(46) Similar to many of the cancer types discussed above, 
common health ailments, i.e. pain, weight loss, and appetite-related problems, are used 
in diagnosis, and patients are usually asymptomatic until metastases have already 
developed thereby limiting the ability of surgery to cure PaCa.(47) Diabetes is also a 
common diagnostic tool and is one of many risk factors, in addition to smoking, 
pancreatitis, genetic predisposition, and nutritional status.(46) Tumor resection 
dramatically improves outcome, but most cases involve metastases (liver and lymph 
nodes commonly) that are very difficult to control and treat with standard care.(48) 
Radiation and Gemcitabine is the standard of care for PaCa but elicits limited efficacy 
outside of palliative care.(49) Combinational approaches with other chemotherapies 
were also tested in clinical trials with some promising results but were not curative.(50) 
Perhaps the most promising results that have been generated are with vaccines (peptide, 
tumor lysate, or dendritic cells (DCs)) to boost resident immune responses to PaCa.(51, 
52) Clinical data support that PaCa is sensitive to T cell responses and suggests that 
direct adoptive transfer of PaCa-reactive T cells could result in robust clinical 
responses. 
 




I.B. Tumor Associated Antigens 
The choice of which tumor associated antigen (TAA) to target is crucial for the success 
of the immunotherapy.(53, 54) The ideal TAA is not expressed on any normal tissues 
but highly expressed on the tumor cell surface. Most TAAs known thus far are cell 
surface glycoproteins that are involved in tumor growth or survival, e.g. growth factor 
receptors, that drive proliferation of the tumorigenic cells. Furthermore, optimal TAAs 
are often required for the growth of tumor cells meaning the cancer is dependent on the 
TAA, and removal or inhibition of the TAA or elimination of cells expressing the 
dependent TAA can lead to effective treatment. Dependence on the TAA is sought after 
in order to avoid antigen escape of tumor cells, i.e. no longer expressing the targeted 
TAA but continuing to proliferate, which can lead to relapse and disease 
progression.(55) Ideally, the TAA would exist on multiple tumor types to allow for 
targeting of many cancers with a single therapy. With these considerations in mind 
these studies focus on two TAAs, CD19 and ROR1, which have great promise as targets 
for cellular immunotherapy. 
 
I.B.1. CD19 
CD19 is a B-cell lineage-specific protein not expressed on other tissues and is, 
therefore, an ideal TAA for B-cell malignancies because B cells are not required for 
survival.(4, 6, 31, 56, 57) Similar to T cells, B cells have a B cell receptor (BCR) 
expressed on the cellular surface specific for a single cognate Ag.(58) Upon BCR/Ag 
binding, the B cell will proliferate and produce antibodies with specificity identical to 




that of the BCR that are secreted into the circulation for opsonization and pathogen 
clearance.(59) The BCR complex is crucial for signal transduction, and is composed of 
CD19, CD21, and CD81, where CD19 is crucial for intracellular signaling.(60-62) 
CD19 is expressed from the early pro-B cell stage until memory stage and is lost as B 
cells differentiate into plasma cells. Because of its importance in B-cell function and 
persistence throughout B cell development, almost all (95%) of B-cell non-Hodgkin’s 
leukemia (NHL) express CD19.(31) Successful removal of CD19+ tumors results in B-
cell aplasia, which can be treated with serum immunoglobulin infusions to restore 
humoral immunity.(4, 6, 32, 56, 63) Thus, targeting CD19 has proven to be safe and 
effective means for eliminating B-cell neoplasms, albeit with diminished quality of life. 
 
I.B.2 Receptor Tyrosine Kinase-like Orphan Receptor-1 
In contrast to CD19, much less is known about ROR1, but what is known is that ROR1 
(i) is a cell surface protein involved in Wnt5a signal transduction, (ii) plays a critical 
role in development, (iii) is no longer expressed post-parturition and is not found on 
almost all adult tissues, and (iv) has aberrant expression later in life on tumor cells 
making it a candidate TAA target.(64-67) ROR1 and its redundant partner in 
development, ROR2, were originally cloned and named neurotrophic tyrosine kinase 
receptor-related-1 and -2 (NTRKR1 and NTRKR2), respectively.(68) An analysis of the 
ROR1 protein structure reveals that it consists of signal peptide trailed by extracellular 
Ig-like C2 domain, Frizzled cysteine-rich domain (Fz-CRD), and Kringle domain that 
are followed by transmembrane (TM) alpha helix, intracellular protein kinase, 




serine/threonine-rich domain, and proline-rich domains (Figure 1a). Sequence 
alignment shows that ROR1 is 57% identical and 81% homologous to ROR2 where 
there is homology in signal peptide (62%), Ig-like C2 (85%), Fz-CRD (93%), Kringle 
(90%), TM (95%), protein kinase domain (90%), serine/threonine-rich (87%), and 
proline-rich (54%) domains between the two proteins (Figure 1b). Single and double 
knockout mice for ROR1 and ROR2 were established that had multiple developmental 
problems leading to death shortly after birth.(69, 70) More specifically, ROR1-/- mice 
died of respiratory distress following birth, while ROR2-/- mice died of more advanced 
cardiovascular problems as well as skeletal abnormalities, and ROR1-/-ROR2-/- double 
knockout mice had exacerbated disease including transposition of the great arteries, 
pubic bone dysplasia, and sternal defects. Furthermore, ROR2 continues to be critical 
for skeletal development during life as autosomal recessive diseases resulting in bone 
dysmorphia and have been mapped to ROR2 gene mutations (chromosome 9q22) but 
not ROR1 gene (chromosome 1p32-31).(71-74) To date, ROR1 has not been linked to 
inherited genetic disease in adults, indicating that its major roles are only in fetal 
development. In 2008, three independent investigators published reports of ROR1 
expression in tumors, and each described ROR1 expression in ~95% of CLL patients 
with confirmation of absent expression on most normal tissues.(65, 75, 76) 
Subsequently, ROR1 has been detected in breast cancer, pancreatic cancer, ovarian 
cancer, melanoma, gastric carcinoma, non-small cell lung cancer, t(1;19) B-ALL, and 
mantle cell lymphoma, but some reports indicate that cytosolic expression of ROR1 
exists in some tissues and that there may be surface expression on hematogones (normal 
B cell developmental precursors), the pancreas, and adipose tissue.(13, 66, 67, 77-81) 




The discovery of ROR1 expression on tumor cell lines enabled a number of 
biochemical studies to determine the role of ROR1 in neoplastic transformation. IL6 
leads to transcriptional activation of signal transducer and activator of transcription-3 
(STAT3) that then increases gene expression of ROR1 transcripts, which may give 
insight to a potential autocrine or paracrine loop for oncogenic transformation and/or 
disease progression.(82) Wnt5a binding of ROR1 (presumably to the Fz-CRD) leads to 
casein kinase-1ε (CK1ε) activation of phosphoinositol-3 kinase (PI3K) that 
phosphorylates Akt and results in activation of the transcriptional activator cAMP-
response-element-binding protein (CREB), which upregulates genes important for 
proliferation and, thus, is likely to result in oncogenic transformation (Figure 1c).(67, 
79) The discovery of ROR1 on tumor cells is relatively new, so other signaling 
pathways have not been elucidated and direct targeting of ROR1 in humans has not 
been tested to date. Nonetheless, all indications suggest that ROR1 is an ideal TAA 
target for cellular immunotherapy with broad applicability, and immunotherapies 
targeting ROR1 in humans will be the ultimate test of its safety as a TAA. 
  





Figure 1. ROR1 Protein Structure. (a) Diagram of protein sequence of ROR1 protein 
domains where abbreviations are as follows: SP; signal peptide, Fz-CRD; Frizzled 
cysteine-rich domain, TM; transmembrane alpha helix, S/T; serine/threonine-rich 
domain, P-rich; proline-rich domain. (b) Sequence alignment between ROR1 and ROR2 
proteins by ClustalOmega (http://www.ebi.ac.uk/Tools/msa/clustalo/). Lines above text 
correspond to colors in (a), (*) describes identical amino acids, (:) denotes analogous 
closely related amino acids, and (.) describes similar amino acids. (c) Diagram for 
ROR1 protein structure in the cellular membrane where Wnt5a binding Fz-CRD leads 
to the following signal transduction pathway: casein kinase-1ε (CK1ε)  
phosphoinositol-3 kinase (PI3K)  Akt  cAMP-response-element-binding protein 
(CREB)  transcriptional activation of genes for proliferation. 
  




I.C. T cell Immunity 
The immune system is critical for pathogen clearance and prevention of disease. It is 
broadly partitioned into innate and adaptive immune systems, but interplay between 
innate and adaptive immunity is essential to an effective immune response.(83-86) The 
innate immune system is composed of many cell types, e.g. macrophages, natural killer 
(NK) cells, that have broad ranges of specificity to pathogens to remove them upon 
their primary encounter, and therefore serve as the first line of defense.(87) In contrast, 
the adaptive immune system is highly specific for a particular part of a pathogen and 
develops as a secondary and long-lasting response to a individual pathogen. The two 
major sections of adaptive immunity are the cellular and humoral immune systems.(88) 
B cells mediate humoral immunity primarily through the production of antibodies (Ab), 
which coat the surface of pathogens to label them as foreign for direct lysis through 
complement activation, which forms holes in the membrane thereby destroying the 
target cells, or by phagocytosis and elimination during the process known as 
opsonization.(89) In contrast, T cells mediate cellular immunity through direct contact 
with their target and either directly or indirectly mediate destruction of the pathogenic 
cell. T cells are typically dichotomized into helper (TH) or cytotoxic/killer (TC) T cells 
based on their expression of CD4 and CD8, respectively.(90) The combined interaction 
of these components of the adaptive immune system allow for its unique characteristics 
of (i) generating highly specific responses to pathogens, (ii) memory formation for more 
rapid and stronger responses to pathogens upon a repeated or secondary exposure, and 
(iii) adaptation to increase sensitivity through maturation.(88) Because T cells can exert 




direct cellular cytotoxicity and create memory responses, they have been used 
successfully to target and kill cancer cells. 
 
I.C.1. αβ T cells 
The quintessential T cell lineage is the αβ T cell subset, which comprises up to 95-99% 
of circulating T cells, and are the object of most canonical T cell paradigms.(58) In 
addition to staining for either CD4 or CD8, these T cells are typically identified by co-
staining with CD3 and their αβ T-cell receptor (TCRαβ). Effector functions are 
endowed upon αβ T cells through an extensive educational process that results in a 
unique specificity to an antigen and a corresponding response in the form of T cell help 
(CD4) or cytolysis (CD8). Therefore, it is important to understand the nuances of αβ T 
cell development and education in order to maximize their impact in adoptive 
immunotherapy. 
 
I.C.1.a. T-cell Receptor Genetics 
TCRs are subjected to genetic rearrangement events during development to randomly 
arrange distinct gene segments into an extremely high number of combinations and thus 
corresponding antigen affinities.(91) Four TCR loci, i.e. TCRα, TCRβ, TCRγ, and 
TCRδ exist in the human genome, which lead to two distinct T cell lineages based on 
TCR pairing.(92) More specifically, the αβ T cell lineage is defined by the pairing of 
TCRα and TCRβ chains whereas the γδ T cell lineage is defined by T cells expressing 




TCRγ and TCRδ heterodimers. Each TCR allele is further compartmentalized into 
variable (V), diversity (D), junction (J), and constant (C) regions.(93) TCRα and TCRγ 
genes have V and J regions while TCRβ and TCRδ genes have V, D, and J regions and 
all TCRs contain C regions (Figure 2). Each specific region is termed based on its 
region and origin, i.e. Vα describes the variable region from the alpha locus or Jδ 
describes the junction region from the delta locus. The V regions contain 
complementarity determining regions (CDR) that confer high degrees of antigen 
specificity, and are therefore important for defining T cell affinity.(94) These V, D 
(where applicable), J, and C segments are recombined into unique combinations in each 
T cell during T cell development in a process known as V(D)J recombination.(95, 96) 
The TCRγ (Gene ID: 6965) and TCRβ (Gene ID: 6957) loci are in distinct locations at 
7p14 and 7q34, respectively, but TCRδ locus (Gene ID: 6964) exists within the TCRα 
(Gene ID: 6955) locus at 14q11.2 (Figure 2). Upon V(D)J recombination of the Vα and 
Jα, the entire δ-chain locus is deleted from the T cell genome in a T-cell receptor 
excision circle (TREC).(97) Thus, once the α-chain locus has recombined for a 
particular T cell, it can no longer become a γδ T cell. Programmed mutation of the T 
cell germline DNA allows for unbiased generation of many TCR specificities for 
extremely high combinational probabilities (at least 1016 possible combinations for αβ 
T cells) for binding any potential foreign pathogen.(98) It is in this random genetic 
process through which T cells acquire exquisite abilities to mediate cellular immunity. 
  





Figure 2. Genetic Loci for TCR alleles.  Simplified schematic of exons encoding V, J, 
and C regions with D regions for β and δ chains for TCRγ (blue), TCRβ (red), TCRα 
(green), and TCRδ (black). V(D)J recombination of Vα, Jα, and Cα results in excision 
of the TCRδ locus in a T cell Receptor Excision Circle (TREC). 
 
  




I.C.1.b. αβ T cell Development 
The thymus is crucial for T cell development as it is the location for both V(D)J 
recombination and thymic selection. Thymic selection is important for maintaining 
central tolerance by eliminating poorly-reactive T cells and over-reactive T cells from 
the T cell pool by neglect and negative selection, respectively, following V(D)J 
recombination.(99, 100) Positive selection only allows for T cells with intermediate 
reactivity to their antigen to be released into the periphery.(101, 102) Thymic selection 
is carried out by thymic cortical epithelial cells which express high levels of major 
histocompatibility complex (MHC) molecules along with a wide array of proteins, 
including self-antigens, that are then processed and presented in the context of MHC on 
the epithelial cell surface.(103, 104) Both MHC Class-I (MHC-I) and Class-II (MHC-
II) are expressed by the thymic cortical epithelial cells to stimulate CD8 and CD4 T 
cells, respectively. The developing T cells express both CD4 and CD8 in the thymus, 
and based on their TCRαβ binding affinity to either MHC-I or MHC-II and subsequent 
TCRαβ signaling they will become single positive for either CD8 or CD4, 
respectively.(105, 106) In this way, both affinity and peripheral T cell function is 
acquired in the thymic cortex. 
 
I.C.1.c. αβ T cell Activation 
T cells need to escape the thymus, encounter their corresponding antigen, and have a 
licensing event towards the antigen in order to become functionally responsive. At least 
two signals are required for T cell activation but 3 total signals are ideal for full T cell 




activation.(107-109) Signal 1 comes from TCRαβ interaction with MHC/peptide 
complexes mediated by CD4 or CD8 co-receptors.(110) However, the intracellular 
domain of TCR is very short and not able to generate its own intracellular signal. 
Signaling comes from CD3 molecules that are bound to TCR in the transmembrane 
through non-covalent interactions.(111) A complex of CD3 subunits surrounds the TCR 
composed of CD3γ/CD3ε and CD3δ/CD3ε heterodimers and CD3ζ/CD3ζ homodimer. 
Each of the CD3γ, CD3δ, and CD3ε subunits has an immunoreceptor tyrosine activation 
domain (ITAM) motif and the CD3ζ subunit has three ITAM motifs for a total of ten 
ITAMs surrounding each TCR. Upon TCRαβ binding to peptide/MHC complex, co-
receptors (CD4 or CD8) bind to the constant regions of MHC and begin the signaling 
process through Lck and Fyn phosphorylation of tyrosine (p-Tyr) residues on the 
ITAMs.(112) Then ZAP70 can bind to p-Tyr through SH2 domains and becomes 
activated by Lck. Activated ZAP70 leads to a cascade of downstream activation events 
resulting in transcriptional and post-translational modifications for the molecules 
responsible for T cell proliferation and differentiation.(113) However, only receiving 
signal 1 will lead to functional unresponsiveness otherwise known as anergy.(114, 115) 
Therefore, the second signal is required and is termed co-stimulation. Examples of 
activating co-stimulatory molecules expressed on the T cell surface are CD27, CD28, 
and CD137 (41BB), which bind to CD70, CD80/CD86, and CD137L (41BB-L), 
respectively, expressed on the antigen presenting cell (APC).(116-118) Some co-
stimulatory molecules are inhibitory, e.g. cytotoxic T-lymphocyte antigen-4 (CTLA4) 
and programmed death-1 (PD1), for immune regulatory purposes.(119) Dendritic cells 
(DCs) are professional APCs because of their ability to process and present a wide 




milieu of peptides, high expression of MHC molecules, and expression of co-
stimulatory molecules.(120) DCs are present in tissues and following activation by the 
innate immune system to foreign antigens/pathogens, they migrate to secondary 
lymphoid organs to present their environmental data and license T cells to fight the 
pathogens.(121, 122) It is also important to note that cytokine support, e.g. interleukin-
12 (IL12), IL15, and type I interferon (IFN), is generally regarded as signal 3 for T cell 
activation.(123) In summary, the combination of (i) TCRαβ engagement with 
MHC/peptide complex with appropriate co-receptor (CD4 or CD8) binding to MHC, 
(ii) co-stimulation, and (iii) cytokine support licenses T cells to find their corresponding 
antigen expressed on damaged or pathogenic cells and to eliminate those cells. 
 
I.C.1.d. CD4+ αβ T cell Subsets 
CD4+ T cell subsets are numerous and typically described by the effector cytokines they 
release, and they can be stratified into TH0 (naïve), TH1, TH2, TH17, regulatory T cells 
(TREG), and natural killer T (NKT) cells.(124) Naïve TH0 cells can be polarized to 
differentiate based on environmental cues that then translate into distinct transcriptional 
programs and result in lineage commitment.(125) TH1 encourage inflammation and help 
promote CD8 memory responses by producing IL2, IL12, interferon-γ (IFNγ), and 
tumor necrosis factor-α (TNFα) while TH2 cells inhibit inflammatory TC response and 
foster humoral immunity by secreting IL4, IL5, IL6, and IL10.(126) The primary role of 
TH17 cells is to enhance neutrophil responses, and these cells are most often 
characterized by their ability to produce IL17.(127) There is plasticity between TH17 
cells and TREG cells as both require transforming growth factor-β (TGFβ) but addition 




of IL6 polarizes towards TH17 lineage. TREG cells are infrequent and can exert strong 
blockades against other T cell effector functions through both cell-to-cell contact 
mechanisms and through production of IL10 and TGFβ.(128) Thus, they are critical for 
maintaining peripheral tolerance, and when dysregulated can contribute to diseases such 
as cancer (in the case of overactive TREGS) or autoimmune disorders (in the case of 
underactive TREGS). An extremely rare subset of CD4+ T cells are NKT cells, which 
express invariant TCRαβ alleles, e.g. Vα24/Jα18 with Vβ11, and are known to produce 
both TH1 and TH2 cytokines.(129) The best described antigen for NKT cells is α-
galactosylceramide (αGalCer) presented to NKT cells in the context of CD1d, a non-
classical MHC molecule, which leads to NKT expansion and effector function, but the 
“natural” ligands for NKT in humans are not fully known to date.(130) Some NKT cells 
express CD8 instead of CD4 and others express neither co-receptor, but their roles are 
less well known. In aggregate, CD4+ T cells are an important arm of the cellular 
immune response and can generate a wide range of effects towards eliminating 
pathogens. 
 
I.C.1.e. CD8+ αβ T cell Subsets 
In contrast to CD4+ T cell subsets, CD8+ T cells subsets are usually defined in terms of 
their memory response from previous encounters with antigens.(131) As mediators of 
direct cellular cytotoxicity, CD8+ T cell memory responses are commonly studied in the 
context of pathogenic infection or in the context of long-lived tumor-reactive T 
cells.(132-134) After antigen exposure, naïve T cells (TN) proliferate rapidly and exert 




cytotoxicity as effector T cells (TEFF). The large numbers of antigen-specific T cells 
then needs to be reduced as to not increase the total peripheral T cell pool each time a 
pathogen elicits a response, so there is a contraction phase marked by TEFF sensitivity to 
extrinsic apoptosis. However, the numbers of antigen-specific cells surviving the 
contraction phase are greater than the initial antigen-specific T cell pool so that 
exposure to the same pathogen will result in a faster and stronger attack on the 
pathogen. These remaining cells are termed memory T cells (Figure 3). Three memory 
T cell subsets have been described and are called central memory (TCM), effector 
memory (TEM), and effector memory RA (TEMRA) T cells.(135) TN express CD45RA, 
CD27, CD28, and CCR7 where CD45RA expression is lost on both TCM and TEM but is 
re-expressed on TEMRA without CD27, CD28, and CCR7. The TEM and TCM groups can 
be distinguished by CD28 and CCR7 where the former expresses neither and the latter 
expresses both. TCM cells have the greatest proliferative capacity with limited effector 
functions and serve as long-lasting antigen-specific pools. In contrast, TEM have 
immediate effector functions, limited replicative capacity relative to TCM, and serve as 
the main memory cytotoxicity mediators.(136) Lastly, TEMRA cells are terminally 
differentiated cells that have effector functions without much proliferative capacity. 
Even though CD4+ T cells are not typically stratified in this manner, memory 
populations have been detected that could produce cytokines following subsequent 
antigen exposure.(137, 138) Furthermore, CD4+ T cells are necessary for generating 
CD8+ T cell memory, suggesting that even though they may not fit into clear subsets 
they are present and required for memory cytotoxicity.(139) The application of these 
groupings to cancer immunotherapy also comes with caveats due to the high degree of 




differences in their disease pathologies, i.e. virus versus cancer. CD27 expressed on TN, 
TCM, and TEM was correlated with greatest responses in cancer immunotherapy, and can 
be used to predict therapeutic efficacy.(134) While immediate effector function towards 
cancer in adoptive T cell immunotherapies is desired, it appears that TN and TCM cells 
are better for this particular task.(131) Generation of persistent CD8+ populations with 
memory to the tumor, therefore, is an important consideration for immunotherapy 
efficacy.  





Figure 3. CD8+ Memory T cell Subsets. (a) Limited quantities of antigen-specific 
naïve T cell (TN) pool exist prior to exposure to antigen (Ag). Upon Ag contact, massive 
Ag-specific T cell proliferation occurs in the effector T cell (TEFF), which is followed by 
apoptotic contraction phase. Memory T cells (TM) are developed from the increase in 
Ag-specific T cell population relative to the TN starting population. (b) Prior to Ag 
exposure TN cells express CD45RA, CD27, CD28, and CCR7 where CD45RA 
expression is lost in the formation of TCM and both CD28 and CCR7 are lost with TEM 








I.C.2. γδ T cells 
γδ T cells are a completely separate T cell lineage from αβ T cells, and γδ T cells have 
both innate and adaptive immune cell functions.(140) In contrast to αβ T cells, γδ T 
cells have predictable inherent anti-tumor immunity mediated directly through their 
TCR.(141) However, γδ T cells comprise only 1 – 5% of the circulating T cell 
repertoire, making them difficult to work with because of a relative lack of robust 
protocols for polyclonal γδ T cell expansion and their infrequent quantities in peripheral 
blood.(142, 143) They are identified by co-expression of CD3+TCRγδ+ where 
expression of CD4 or CD8 is rare, and can be stratified into Vδ1, Vδ2, and Vδ3 subsets 
based on TCRγδ alleles.(144) Targets of γδ T cells include tumor cells, viruses, 
bacteria, mycobacteria, and cell stress-associated proteins.(145, 146) Therefore, γδ T 
cells are a promising T cell immunotherapy option despite their limited frequencies in 
blood if they can be expanded. 
 
I.C.2.a. Unique Characteristics of γδ T cells 
There are three variable TCRδ chains and 14 variable TCRγ chains expressed in 
humans, and fewer unique TCRγδ combinations are observed in γδ T cells compared to 
the immense combinational diversity seen with αβ T cells following V(D)J 
recombination.(92, 144) Expression of TCRγδ heterodimers on the T cell surface in the 
thymus inhibits recombination of β-chain locus during the CD4negCD8neg stage thereby 
committing the T cell to the γδ T cell lineage.(147) This double negative status is often 




maintained after exit from the thymus, most likely because TCRγδ recognizes antigens 
outside of MHC-restriction in many cases, making co-receptor expression dispensable 
for function and endowing them with an ability to recognize antigens outside of the 
signaling constraints imposed by classical thymic selection.(148) However, the thymus 
is not required for all γδ T cell development, as many of these γδ T cells take up 
residence in peripheral tissues and exhibit immediate effector functions against 
pathogens.(149) Resident γδ T cells can be found in the mucosa, tongue, vagina, 
intestine, lung, liver, and skin and can comprise up to 50% of the T cell populations in 
intestinal epithelial lymphocytes (IEL).(144, 150) In contrast, circulating γδ T cells can 
be found in the blood and lymphoid organs, and are canonically dominated by γδ T cells 
expressing Vδ2 TCR isotype (called Vδ2 cells) with few γδ T cells expressing the Vδ1 
TCR isotype (called Vδ1 cells) that are more frequently associated with resident γδ T 
cells.(146) Moreover, Vδ2 cells most commonly pair with Vγ9, but Vδ1 and Vδ3 have 
broad γ-chain pairing potential.(141, 146) Therefore, the location of γδ T cells can lead 
to their subset diversity and effector functions that can be mediated through specific 
combinations of γ and δ TCR chains to recognize pathogens upon encounter in their 
resident or circulating locations. 
 
I.C.2.b. Vδ1 γδ T cells 
Vδ1 cells have a wide range of effector functions and are located in a variety of 
anatomical locations.(151) They can, theoretically, pair with any of the TCRγ chains, 
and there are a variety of known ligands for Vδ1 cells.(140) In fact, the crystal structure 




of Vγ1Vδ1 has been solved in combination with one of its antigens, MHC Class-I 
chain-related A (MICA).(152, 153) Cellular stress and/or viral infection result in MICA 
and its analog, MICB, to become expressed on the stressed/infected cell’s surface, so 
MICA/B is commonly present on tumor cell surface.(154) MICA is also recognized by 
NKG2D, a receptor expressed by γδ T cells, NK cells, and, less frequently, αβ T 
cells.(155) Other non-classical MHC molecules and cell stress proteins are also 
recognized by γδ T cells. For instance, Vγ4Vδ1 T cells have been shown to have 
specificity towards heat shock proteins and the non-classical MHC molecule 
CD1d.(156) Heat shock proteins are commonly over-expressed in tumor cells to handle 
their high protein translation loads.(157) The CD1d molecule is best described in its 
ability to expand NKT αβ T cells, but γδ T cells have also been described to have direct 
NKT-like functions, enhance NKT αβ T cells reactivity to αGalCer, and have even 
been shown to have specificity to cardiolipin with CD1d.(158-160) Also, murine 
Vγ5Vδ1 cells are well described in their ability to serve as dendritic epidermal T cells 
(DETCs) with APC function.(161-163) Lastly, correlative studies have implicated Vδ1 
T cells to have immunity towards cytomegalovirus (CMV) and human 
immunodeficiency virus (HIV).(164, 165) In aggregate, Vδ1 cells have immunity 
towards microbial pathogens, have antigen presenting capabilities, and can target 








I.C.2.c. Vδ2 γδ T cells 
The most extensively studied subset of γδ T cells is the Vδ2 lineage, which similar to 
Vδ1 cells, recognize microbial pathogens, serve as APCs, and target cell-stress proteins 
expressed on tumor cells.(141, 166) Bacterial alkylamines and Listeria monocytogenes 
are recognized by Vδ2 cells when paired with Vγ2.(167-169) In contrast to Vδ1, a 
strong preference towards Vδ2 heterodimerizing with Vγ9 has been well documented. 
Vγ9Vδ2 cells have been shown to react to phospho-antigens (isopentenyl 
pyrophosphate; IPP), F1-ATPase expressed on the cell surface, and Mycobacterium 
tuberculosis.(170-172) Furthermore, Vγ9Vδ2 cells are reactive to cells treated with 
aminobisphosphonates, e.g. Zoledronic Acid (Zol), which is the only current means of 
propagating γδ T cells ex vivo in the clinic.(173, 174) Aminobisphosphonates inhibit 
cholesterol synthesis and build up intermediates in the mevalonate-CoA pathway, 
including IPP, which is a ligand for Vγ9Vδ2.(175) This process was serendipitously 
discovered when patients with bone disorders who were treated with 
aminobisphosphonates to resume bone growth experienced large in vivo expansions of 
Vγ9Vδ2 T cells, and aminobisphosphonates methods were subsequently translated into 
laboratory practice to expand Vγ9Vδ2 cells ex vivo.(176) Thus, Vδ2 cells are the only 
γδ T cells that have been used for adoptive T cell therapy. Utility of the Vδ1 and Vδ3 
lineages is appealing, but there are no current means to rapidly expand them to 
clinically-significant numbers and the existing polyclonal γδ T cell population is too 
few in number for direct infusion. Nonetheless, numerous clinical trials treating cancer 
patients with (i) infusions of Zol for in vivo Vγ9Vδ2 expansions and/or (ii) infusions of 




ex vivo expanded Vγ9Vδ2 cells have generated objective clinical responses but 
complete responses have been unpredictable and have not always been directly 
correlated to the Vγ9Vδ2 cells.(177-182) Thus, the extensive work studying Vδ2 cells 
has generated much interest in using γδ T cells for adoptive immunotherapy. 
 
I.C.2.d. Vδ3 γδ T cells 
In contrast to Vδ1 and Vδ2 cells, very little is known about γδ T cells expressing Vδ3 
TCR alleles (called Vδ3 cells). The limited quantities in peripheral blood and lack of 
commercially available reagents for Vδ3 inhibit attempts to study this subset. Vδ3 cells 
are indirectly correlated with CMV and HIV immune responses, but nothing is known 
about their anti-tumor immunity.(165, 183) Developing a means with which to study 
this lineage could have important scientific and clinical significance. 
 
I.D. Chimeric Antigen Receptors 
Chimeric Antigen Receptors (CARs) re-direct T cells to antigens independent of their 
endogenous TCR specificity.(184, 185) These recombinant molecules contain in order 
from N-terminus to C-terminus: (i) a single chain variable fragment (scFv) derived from 
a monoclonal antibody with specificity to a TAA, (ii) an extracellular stalk, (iii) a 
transmembrane domain, and (iv) T-cell signaling endodomains (Figure 4). Binding of 
the scFv to its corresponding TAA leads to T cell activation resulting in proliferation, 




cytokine release, and cytotoxicity.(186) Thus, CAR+ T cells are re-directed to TAA 
outside of their thymically-selected affinities. 
 
I.D.1. CAR Generations 
Successive modifications to the design of CARs have improved their ability to re-direct 
T cells to TAAs.(187) CAR technology was invented by Dr. Zelig Eshhar (Weizmann 
Institute of Science, Rehovot, Israel) in 1989, and the original CAR differed from the 
more modern CARs by (i) having only CD3ζ and (ii) TCR constant domain 
scaffold.(188) Second generation CARs have shown the most efficacy in re-directing T 
cells and are superior to first generation CARs by adding in a co-stimulatory 
endodomain, e.g. CD28 or CD137 (41BB), to supplement CD3ζ signaling strength 
present in both generations (Figure 4).(189-193) Third generation CARs, therefore, 
contain three endodomains, and the most common combination has been CD28, CD137, 
and CD3ζ.(194-196) The order of endodomains does appear to have importance in the 
ability to stimulate the T cell in both second and third generation CARs, where CD3ζ 
works best at a position most distal to the membrane.(192, 197) The scaffold sequence 
used has the most difference between investigators where IgG4 constant regions (used 
in this dissertation), CD8α, no stalk, and flexible spacers have been used 
successfully.(13, 32, 192, 193, 198, 199) Although there exist some differences between 
groups in their CAR-modified T cell products in tumor killing, CARs in general have 
been shown as a consistent and effective means to target desired antigens and change 
the T cell response outside of their endogenous specificity. 





Figure 4. Schematic Representation of CARs. (a) First generation CARs were 
constructed with single chain variable fragments (scFv) composed of heavy (VH) and 
light (VL) variable fragments from monoclonal antibodies specific for TAA, followed 
by IgG4 constant region (CH2 and CH3 domains displayed), a transmembrane α-helix, 
and CD3ζ signaling endodomain. (b) Second generation CARs added a co-stimulatory 
domain, e.g. CD28 or CD137, between CD3ζ and transmembrane domain. (c) Third 









I.D.2. Tumor-associated Antigens Targeted with CARs 
Effective targeting of different TAAs using CAR-modified T cells has generated 
enthusiasm around CAR-based immunotherapies. B-cell malignancies have been 
targeted with CARs specific for ROR1, κ-light chain, CD19, CD20, CD22, CD23, and 
CD30, which are all confined to the hematopoietic compartment and are not expressed 
on solid tissues.(57, 77, 200-208) Moreover, CD30 is also expressed on T cells, making 
CD30-specific CAR+ T cells candidates for T-ALL therapy, but no T-ALL-specific 
CARs have been generated to date. Only one report of CARs targeting CML has been 
made thus far but the actual TAA was not examined.(209) CARs specific for CD33 and 
CD123 have been generated to target AML, but may have off-target effects due to the 
importance of CD33 and CD123 in hematopoiesis and viral immunity because of their 
expression on plasmacytoid dendritic cells that are critical producers of type-I 
interferons needed for viral clearance.(210-214) OvCa has been the target of multiple 
CARs including those specific for mesothelin, α-Folate Receptor (αFR), and folate-
binding protein (FBP).(42, 215-219) Renal cell carcinoma has been targeted through the 
carbonic anhydrase IX (CAIX), which has minimal expression in normal tissues and is 
increased in hypoxia.(220-222) Carcinoembryonic antigen (CEA) is a developmental 
antigen absent on normal tissue and up-regulated in malignant cells, and CARs 
targeting CEA have been developed for pancreatic and colorectal cancers.(223, 224) 
Similarly, the oncofetal antigens h5T4 and ROR1 (discussed in Chapter I.B.2) are only 
expressed during development and CARs specific for these antigens can target multiple 
tumor types.(77, 199, 223) The differences between published ROR1-specific CAR T 
cells and the ones developed in this dissertation are discussed in detail in Chapter II. 




Both CAR and mAb immunotherapies have had much success targeting human 
epidermal growth factor receptor-2 (EGFR2, HER2, or ERBB2), which is expressed 
highly in many cancers.(194, 225-228) However, there is low-level expression of HER2 
on normal tissues, which caused an “on-target/off-target” toxicity in the only trial to 
date testing CAR+ T cells specific for this TAA on breast cancer, thereby limiting its 
application.(229) Other EGFR members have been targeted with CARs, including 
EGFRvIII, which is uniquely expressed on glioblastoma.(230-232) Even glycoproteins 
(Lewis-Y antigen) can be targeted by CARs, and Lewis-Y antigens are typically studied 
in the context of EGFR family members.(233) The ganglioside GD2 and L1-cell 
adhesion molecule (L1-CAM) are common expressed on neuroblastoma, melanoma, 
and sarcoma (GD2 only), and CARs targeting these TAA were shown to control 
neuroblastoma growth.(234-239) In addition to GD2 and L1-CAM, high molecular 
weight melanoma-associated protein was used as a target for melanoma.(240) 
Melanoma is highly responsive to immunotherapy, and complete responses have been 
generated from a single infusion of tumor infiltrating lymphocytes (TILs).(241, 242) 
Prostate cancer has two specific antigens with limited expression outside of the prostate, 
prostate stem cell antigen (PSCA) and prostate-specific membrane antigen (PSMA), 
which were both targeted with CARs.(243-245) MUC1 was also another CAR target for 
both prostate and breast cancers.(246, 247) Other ubiquitous tumor markers, e.g. tumor 
associated glycoprotein-72 (TAG72) and epithelial glycoprotein-2 (EGP-2) have been 
targeted by CARs for multiple cancer therapies.(248, 249) Angiogenesis is even the 
target of a CAR via specificity for Vascular Endothelial Growth Factor Receptor 2 
(VEGFR2), which is crucial for introducing new blood vessels into the tumors.(250, 




251) However, there are major concerns of long-term persistence of these VEGFR2-
specific cells in terms of regular vasculature growth. Lastly, receptors expressed on 
tumors can be targeted by “zetakines,” which function like CARs but replace the scFv 
of the CAR with the ligand for a receptor of interest. For example, IL13-Receptor-α-2 
(IL13Rα2) was targeted by an IL13 fused to T cell signaling domains to target 
glioblastoma multiforme and neuroblastoma.(252-255) As outlined, many tumor 
antigens have been targeted by CARs, highlighting the enthusiasm given to this 
immunotherapy. 
 
I.D.3. Clinical Trials with CAR+ T cells 
Many of the CARs described above have been translated into T cell immunotherapies 
for cancer patients and have resulted in promising objective clinical responses.(200, 
241, 242, 256, 257) The majority of the trials have been focused on CARs developed 
from the FMC63 mAb specific for CD19.(186, 258, 259) CD19-specific CAR+ T cells 
have eliminated tumor from patients resulting in B cell aplasia, a litmus test for long-
lived clinical responses.(4-7, 260) It was in this model that second generation CARs 
proved to have superior anti-leukemia effects compared to first generation CARs. 
Furthermore, long-lived persistence of CAR+ T cells has been achieved by rendering 
them bi-specific to TAA and Epstein-Barr virus (EBV)-specific antigens through 
skewing TCR repertoire in ex vivo co-cultures with EBV-transformed lymphoblastoid 
cell lines (LCL).(206, 211, 212, 236, 237) The most striking clinical responses, 
including maintained complete responses, have been achieved with second generation 




CD19-specific CAR+ T cells signaling through CD137 and CD3ζ.(4, 7, 32) The exact 
reason why these cells out-performed other CARs signaling through CD28 and CD3ζ is 
unknown at present, and pre-clinical models have not shown many differences between 
CD28 and CD137 CARs.(5, 6) This is an active area of investigation and Chapter II 
focuses on this question directly with ROR1-specific CARs that are in the approval 
stages for a Phase I clinical trial. The focus of all Phase I clinical trials, of which most 
CAR trials have been, is safety and establishing a maximum tolerated dose. 
Unfortunately, there have been 2 deaths on CAR+ T cell clinical trials. The first death 
followed administration of CD19-specific T cells to an elderly patient, who later died of 
complications not thought to be directly linked to the immunotherapy.(261) In contrast, 
the second death was directly attributed to the CAR+ T cells. In this study, a third 
generation CAR (CD28, CD137, and CD3ζ) specific for HER2 (based on the 
monoclonal antibody trastuzumab) was used to treat breast cancer, and following 
infusion of 1010 T cells, the patient died of cytokine storm in response to basal levels of 
HER2 on the lungs.(229) This tragedy has heightened the safety concerns around CAR+ 
T cell immunotherapy, and TAA choice, CAR design, and T cell dose are being closely 
monitored in current and future trials.(262) Nonetheless, clinical trials are currently 
accruing with CAR+ T cells targeting HER2 for sarcoma (NCT00902044), glioblastoma 
multiforme (NCT01109095), and multiple cancer (NCT00889954) treatments 
(http://www.clinicaltrials.gov/). Clinical trials with CAR-modified T cells specific for 
αFR were not effective at treating advanced ovarian cancer, and the lack of efficacy 
was attributed to lack of persistence of T cells in vivo.(42) Other trials targeting solid 
tumors with TAA, e.g. GD2, L1-CAM, CAIX, and IL13Rα2, which are similar to 




HER2 expression in that there is some expression on normal tissues, have been safe and 
sometimes effective at reducing tumor burden.(186, 220, 221, 235-237) Therefore, the 
safety and efficacy of a particular CAR+ T cell clinical trial may vary from investigator 
to investigator due to nuance in a number of variables surrounding propagation and 
CAR design and/or from variability between individual patients. 
 
I.E. Ex Vivo Propagation of T cells 
Many platforms exist for the propagation of T cells ex vivo, and this dissertation focuses 
on the use of Sleeping Beauty (SB) transposition for gene transfer into T cells followed 
by propagation on artificial antigen presenting cells (aAPC). This non-viral system for 
propagating T cells can be contrasted to viral-mediated gene transfer in that the latter 
requires previous expansion, e.g. with agonistic antibodies or stimulating beads, in 
order to transduce cells with the transgene of interest and the former does not require 
previous expansion but rather propagates the T cells ex vivo following gene transfer. 
The SB/aAPC strategy has been translated into the clinic, and modification of the 
current SB/aAPC will be used to streamline translation of therapies developed in this 
thesis to the clinic. 
 
I.E.1. Sleeping Beauty Transposition-mediated Gene Transfer 
Non-viral gene transfer with SB transposition establishes stable transgene expression in 
human cells.(263, 264) SB genes are originally derived from fish that were undergoing 




active transposition in their evolutionary maturation and were adapted for transposition 
into human cells.(265) In short, a DNA transposon with flanking inverted repeats and 
direct repeats is ligated into the human genome at TA dinucleotide repeats by the SB 
transposase enzyme.(266) TA dinucleotide repeats are randomly distributed in the 
human genome, yielding potential for random integration into the genome and has 
shown to be safe in regards to transgene insertion in pre-clinical studies.(267-269) This 
is of particular importance in gene therapy as inappropriate integration at gene start sites 
or promoters, within exons, or even distal to genes within enhancers or repressors can 
cause cellular transformation. Lentiviruses and γ-retroviruses have higher efficiency in 
transgene delivery than SB, but these vectors are known to integrate near genes or 
within genes.(186) Moreover, this was a particular problem in gene therapy trials 
treating X-linked severe combined immunodeficiency syndrome (X-SCID) where 
roughly half of the patients receiving transduced cells later developed leukemia as a 
result of integration near the LMO2 gene.(270, 271) In contrast, no preference towards a 
particular chromosome or gene “hotspot” has been detected with SB.(267) Application 
of SB to human T cells has worked as a two DNA plasmid system, where one plasmid 
contains the SB transposon with the transgene of interest, e.g. CAR, and the other 
plasmid encodes the SB transposase.(272) Electro-transfer of the DNA plasmids by 
Amaxa nucleofection into quiescent peripheral blood mononuclear cells (PBMC) results 
in transient expression of SB transposase that then ligates the CAR transposon into the 
genome. As soon as the SB transposase mRNA is degraded translation of SB 
transposase protein is halted, thereby limiting the chances of additional transposition 
events. CAR expression can be encouraged through the co-culture of T cells on aAPC 




that express cognate antigen for the CAR.(273) aAPC serve as feeder cells, and 
recursive stimulations with γ-irradiated aAPC promote CAR-specific growth. Typically, 
after 30 days of co-culture >90% of cells will express CAR (Figure 5). Thus, SB 
transposition is an efficient gene transfer modality in T cells and modified T cells can 
be expanded ex vivo by aAPC co-culture. 
  





Figure 5. Schematic of CAR+ T cells Expansion on aAPC. PBMC are isolated by 
Ficoll-Hypaque or steady state apheresis and are electroporated with plasmids encoding 
either (i) Sleeping Beauty transposase or (ii) Sleeping Beauty transposon containing 
CAR. Transient expression of CAR is observed the following day, and recursive 
stimulations with K562-derived aAPC are performed weekly with exogenous IL2 
and/or IL-21. Pictured here are the clone#1 aAPC that expresses CD19, ROR1, CD64, 
CD86, CD137L, and IL15/IL15Rα. Following a month of co-culture on aAPC, stable 
CAR expression is achieved and clinically-relevant numbers of CAR+ T cells are ready 
for cryopreservation and then infusion into cancer patients. 
  




I.E.2 Artificial Antigen Presenting Cells 
CARs stimulate T cells independent of their TCR specificity, and a primary aim of this 
propagation schema is to stimulate the CAR without affecting TCR repertoire by 
avoiding TCR/MHC interactions. Classical dendritic cells, thought of as “professional” 
APC, are infrequent in peripheral blood, laborious to manipulate, have limited 
replicative ability, and would need to be generated in the autologous setting for each 
immunotherapy patient. For these reasons, an alternative means for CAR-specific 
proliferation was sought after with the goal of serving as a global “off-the-shelf” bank 
of aAPCs to stimulate T cells independent of their MHC typing. 
 
I.E.2.a Unique Features of K562 for Antigen Presentation 
K562 has become an efficient aAPC line because it (i) lacks most MHC Class-I 
molecules, (ii) can be genetically modified easily, and (iii) proliferates robustly for easy 
cell banking and scale-up purposes.(273-276)  The lack of MHC Class-I molecules (no 
A or B but limited C) on the K562 surface is advantageous because CD8-specific 
allogeneic reactivity is minimized or could be tailored to certain HLA restriction for 
TCR-specific responses.(277, 278) Expansion of T cells on aAPC has shown that 
polyclonal TCR repertoire is readily achieved, suggesting that the aAPCs do not skew 
endogenous TCR-response to a particular affinity or antigen.(263) Another important 
characteristic of using K562-derived aAPC is their susceptibility to further gene 
modification by either non-viral or viral mediated gene transfer. For instance, a master 
aAPC cell bank was modified with both IL15 fusion protein to IL15 receptor-α 




(IL15/IL15Rα) and ROR1 antigen for memory formation and propagation of ROR1-
specific T cells, respectively (Chapter II). Also, HLA-Cw3 was detected on K562 
cells, so Cw3 was efficiently removed with zinc-finger nucleases to create HLA-/- K562 
cells (Torikai H, Cooper LJN, and Lee DA, unpublished observations) in order to 
generate new aAPC completely devoid of HLA Class-I molecules. Thus, working cell 
banks can be easily re-tooled to ask biological questions regarding aAPC mechanics 
and/or maximize therapeutic cell output. Given the apparently unlimited proliferative 
capacity of K562 cells and their genetically modified counterparts, optimization of 
stimulations can be done easily and changed at will with options to use high ratios of 
aAPC to T cells. Furthermore, γ-irradiation of aAPC prior to co-culture with T cells is 
well tolerated by K562 in acute phases but eventually subjects the aAPC to death 
(typically 3 days) thereby eliminating most risk for unintended transfer of this tumor 
cell line into patients.(273) Therefore, K562 cells are an ideal source for antigen 
presentation and T cell stimulation. 
 
I.E.2.b. Established aAPC Cell Banks and Clinical Trials with aAPC 
As of now, four clinical trials have used K562-derived aAPC as T cell and NK cell 
expansion platforms at MD Anderson (NCT01653717, NCT01619761, NCT00968760, 
NCT01497184). Clone#4 aAPC generated at University of Pennslyvania (UPenn) was 
used successfully to expand CD19-specific CAR+ T cells in both autologous and 
allogeneic settings.(57, 263, 272, 273, 279-281) The surface phenotype of clone#4 is 
characterized by expression of: (i) CD19, (ii) CD32 (as an endogenous protein), (iii) 




CD64, (iv) CD86, (v) CD137L, and enhanced green fluorescence protein (eGFP; 
surrogate marker for IL15 expression). Similarly, clone#9 aAPC was also generated at 
UPenn and has a surface phenotype of: (i) CD19, (ii) CD32 (as an endogenous protein), 
(iii) CD64, (iv) CD86, and (v) CD137L. Clone#9 aAPC was further modified to express 
membrane-bound IL21 for trials propagating NK cells.(275) Translation of expansion 
protocols into the clinic was readily achieved and validated this approach. Patients 
treated with aAPC-expanded lymphocytes did not show toxicity, suggesting that this is 
a safe approach (Cooper LJN, unpublished observations). Thus, aAPC will be used for 
the propagation of T cells in this dissertation for direct clinical application. 
 
I.F. Dissertation Specific Aims 
This dissertation has three major specific aims, which attempt to solve the gaps in the 
above knowledge and/or application of immunotherapy. More specifically, these aims 
are directed at either harnessing the inherent anti-tumor immunity of T cells for cancer 
therapy, modifying T cells with natural anti-tumor capacity with CARs for enhanced 
specificity, or re-directing T cells with unpredictable anti-tumor immunity to cancer 
through CAR expression. This multivariate approach has resulted in approval of one 
Phase I clinical trial and holds the potential to result in other clinical trials for treatment 
of both solid and hematological tumors. 
 
I.F.1 Specific Aim#1: To evaluate whether ROR1-specific T cells can target ROR1+ 
tumor cells while sparing normal tissues. The hypothesis of this specific aim is that 




ROR1-specific CARs will re-direct the specificity of T cells to target ROR1+ 
malignancies and that CARs signaling through CD137 will be superior to CD28 in 
therapeutic efficacy. The rationale for this specific aim is that (i) ROR1 is a candidate 
TAA because it is expressed on a number of tumors but is not on most normal tissues, 
(ii) the 4A5 monoclonal antibody specific for ROR1 can be adapted to generate a CAR, 
(iii) CARs can re-direct T cells to TAA and empower them to kill TAA+ malignancies, 
and (iv) cancer patients treated with CAR+ T cells have achieved complete responses. 
Sub-Aim 1.1. To generate ROR1-specific CAR+ T cells. Sequences from 4A5 antibody 
hybridoma will be constructed into second generation ROR1-specific CARs signaling 
through (i) CD28 and CD3ζ (ROR1RCD28) or (ii) CD137 and CD3ζ (ROR1RCD137), 
which will be part of SB transposons for stable CAR expression in T cells. CAR+ T 
cells will be propagated on γ-irradiated ROR1+ aAPC (clone#1), and CAR+ T-cell 
numeric expansion will be monitored by inferred cell counts and flow cytometry for 28 
days. Sub-Aim 1.2. To phenotype ROR1-specific CAR+ T cells. Extended phenotyping 
for memory and homing markers will be performed by flow cytometry at the end of the 
co-culture period. Genotyping will also be performed with nCounter gene expression 
platform for TCR isotype expression and lymphocyte-associated genes. Sub-Aim 1.3. To 
assess whether CAR+ T cell function is specific for ROR1. Cytokine production and 4-
hour chromium release assay (CRA) will be used to evaluate CAR+ specificity in 
responding to ROR1+ targets with ROR1neg targets as negative controls. ROR1+ 
leukemia xenografts will be established in immunocompromised mice which will be 
treated with CAR+ T cells to evaluate tumor clearance in vivo. 




I.F.2. Specific Aim#2: To assess whether a CD19-specific CAR expressed on γδ T cells 
will render them bi-specific to tumors through their TCR and CAR. The hypothesis of 
this specific aim is that enforced CAR expression on γδ T cells would stimulate them 
independent of their TCRγδ, thus leading to expansion of γδ T cells with polyclonal 
TCRγδ repertoire, and would amplify the anti-tumor effects from TCRγδ towards TAA+ 
malignancies through the CAR. The rationale for this specific aim is that (i) γδ T cells 
have inherent anti-tumor immunity through a number of combinations of TCRγ and 
TCRδ pairings, (ii) the use of γδ T cells in the clinic is currently restricted to Vγ9Vδ2 
even though other γδ T cell lineages have anti-tumor reactivity, (iii) CARs stimulate T 
cells independent of their TCR, (iv) electroporation of SB transposons containing the 
CAR can be achieved in quiescent PBMC with a polyclonal repertoire of γδ T cells, and 
(v) CD19-specific CAR transposon plasmids and CD19+ aAPC are currently in clinical 
trials at MD Anderson and these reagents can be used to quickly translate findings from 
this specific aim into clinical trials. Sub-Aim 2.1. To propagate CAR+ γδ T cells on 
aAPC. The second generation CD19-specific CAR (CD19RCD28) currently in clinical 
trials is available as highly pure DNA and will be used for gene transfer into quiescent 
PBMC from which CAR+ γδ T cells will be propagated on CD19+ aAPC. CAR 
expression and inferred cell counts will be used to evaluate CAR+ γδ T cell numeric 
expansion. Sub-Aim 2.2. To phenotype CAR+ γδ T cells. After a month of expansion on 
aAPC, CAR+ γδ T cell surface phenotypes will be evaluated for T cell and memory 
molecules by flow cytometry and TCRγδ allele expression will be assessed by nCounter 
gene expression analysis. Sub-Aim 2.3. To determine the ability of CAR+ γδ T cells to 




functionally respond to tumors. Cytokine production and 4-hour CRA assays will be 
tested against CD19+ tumor targets with CD19neg targets serving as negative controls. 
Autologous CARneg γδ T cells will be used to compare CAR-specific responses to 
CD19+ tumors. CD19+ leukemia xenografts will be established in immunocompromised 
mice which will be treated with CAR+ γδ T cells to evaluate anti-tumor effects in vivo. 
 
I.F.3. Specific Aim#3: To evaluate the inherent anti-tumor activity of aAPC-expanded 
γδ T cells against solid and hematological cancers. The hypothesis of this specific aim is 
that aAPC will expand polyclonal γδ T cells that will have broad anti-tumor immunity. 
The rationale for this specific aim is that (i) CARneg polyclonal γδ T cells proliferated in 
parallel to CAR+ γδ T cells described in specific aim#2 on aAPC, (ii) no current 
expansion protocols exist for polyclonal γδ T cells for the clinic, (iii) aAPC are 
currently in clinical trials and are available as a master cell bank in the manufacturing 
facility at MD Anderson, (iv) γδ T cells expressing Vδ1 are correlated with long-term 
remissions in cancer therapy but have not been directly infused as an adoptive 
immunotherapy, (v) γδ T cells expressing Vδ2 have shown anti-tumor effects as direct 
adoptive immunotherapies, (vi) γδ T cells expressing Vδ3 have not been described to 
have direct anti-tumor immunity leaving a gap in the field of knowledge, and (vii) a 
polyclonal approach to γδ T cell immunotherapy could target multiple ligands on the 
tumor through a diverse repertoire of TCRγδ. Sub-Aim 3.1. To propagate γδ T cells on 
aAPC. PBMC or UCB will be sorted for γδ T cells, and then co-cultured with aAPC 
used in clinical trials at MD Anderson. Flow cytometry and inferred cell counts will be 




used to evaluate proliferation of γδ T cells. Subsets of γδ T cells will also be sorted and 
expanded as co-cultures with clinical aAPC to assess differences in γδ T cell lineages. 
Sub-Aim 3.2. To phenotype γδ T cells expanded on aAPC. After one month of co-culture 
on aAPC, the surfaces of polyclonal or sorted γδ T cells will be evaluated for T cell and 
memory markers by flow cytometry and TCR allele expression will be assessed on 
nCounter gene expression platform. Sub-Aim 3.3. To examine the range of killing 
capabilities by aAPC-expanded γδ T cells. Polyclonal or sorted γδ T cells will be 
evaluated for their ability to produce cytokines in response to TCR stimulation or co-
culture with tumor cells derived from solid and hematological cancers. Standard 4-hour 
CRA will be used to assess acute cytolysis and long-term co-cultures will evaluate 
durable killing abilities. Neutralizing antibodies will be employed to determine the 
specificity of killing. OvCa xenografts will be established in immunocompromised mice 
which will be treated with polyclonal γδ T cells to test their tumor clearance in vivo. 
 
  





Clinical Implications for ROR1-specific T cells 
 
II.A. Hypothesis and Rationale 
 The hypothesis of this chapter is that ROR1-specific CARs will re-direct the 
specificity of T cells to target ROR1+ malignancies and that CARs signaling through 
CD137 will be superior to those signaling through CD28 in therapeutic efficacy. The 
rationale for this chapter is that (i) ROR1 is a candidate TAA because it is expressed on 
a number of tumors but not on most normal tissues, (ii) the 4A5 monoclonal antibody 
specific for ROR1 can be adapted to generate a CAR, (iii) CARs can re-direct T cells to 
TAA and empower them to kill TAA+ malignancies, and (iv) cancer patients treated 
with CAR+ T cells have achieved complete responses. This chapter describes pre-




Current clinical trials use T cells expressing CARs specific for CD19, an antigen 
expressed on the surfaces of all B cells, to eliminate refractory B-cell malignancies.(4, 
57, 184, 186) However, there is also loss of normal CD19+ B cells in patients 
undergoing this therapy, which can result in serious health complications including loss 
of humoral immunity.(7, 32) Furthermore, loss of CD19+ B cells in an elderly patient 




treated with CD19-specific CAR+ T cells resulted in death from an opportunist viral 
infection.(261) ROR1 is absent on most normal B cells and other healthy tissues 
(Chapter I.B.2.), but is expressed on many B-cell tumors (mantle cell lymphoma 
(MCL), ALL with t(1:19) translocations, and >95% of CLL) and solid tumors (lung and 
breast cancer, OvCa, PaCa, renal cell carcinoma, and melanoma) where ROR1 
expression is required for cellular growth and survival.(13, 64, 66, 67, 75, 79, 80, 282) 
Thus, CARs targeting ROR1 instead of CD19 would allow for tumor elimination while 
sustaining the normal B cell repertoire, and ROR1-specific T cells have the potential for 
use in a number of solid tumors. 
The design of the CAR is a source of debate at present. Striking clinical data, 
including complete responses, were observed in ALL and CLL patients treated with 
second generation CD19-specific CARs having CD137 (41BB) endodomain or the 
more frequently used CD28 region.(5-7, 32) However, the differences between the two 
CARs or their mechanisms of improved efficacy over other CAR clinical trials are 
unknown at present. CAR clinical trials targeting CD19 open at MD Anderson use the 
CD28 moiety (NCT01653717, NCT00968760, NCT01497184), but are being adapted 
to (i) directly compare CD28 to CD137 CARs and/or (ii) replace CD28 CARs with 
CD137 CARs. These trials, and those performed at other independent centers, will aim 
to validate these remarkable responses and determine whether CD28 or CD137 is the 
ideal co-stimulatory domain for CD19-specific CARs. 
However, these results may not necessarily hold true for targeting different 
antigens due to differences in antibody affinity and/or antigen expression. Direct 
immunotherapy of ROR1-specific antibody (through clone 2A2) has been proposed as 




an option for leukemia and broader cancer treatment, but this antibody appears to have 
strong cytoplasmic staining in a number of normal tissues (despite absence of ROR1 
mRNA expressed in these tissues) and directly binds to adipocytes that express small 
amounts of ROR1 mRNA.(77, 81, 283) CARs have been developed from the 2A2 
(mouse) and R12 (goat) antibodies, and CAR+ T cells were generated in central memory 
T cells (TCM) that could then efficiently lyse ROR1+ tumor, but their reactivity towards 
normal tissues outside of normal B cells was not evaluated.(77, 199) The optimal 2A2 
and R12 CARs for expression in TCM cells had short extracellular domains (14 amino 
acids) with CD137 and CD3ζ signaling endodomains. In contrast to other ROR1-
specific antibodies, the 4A5 clone developed by Dr. Thomas J Kipps (Moores Cancer 
Center, UCSD) has not been shown to bind any normal tissues, except hematogones 
(dispensable B-cell precursors), but is highly reactive to a number of cancers, including 
leukemia, OvCa, and PaCa.(66, 67, 75, 79) Therefore, this clone was chosen for 
generation of ROR1-specific T cells in the expansion system developed at MD 
Anderson that has a number of differences to the previous studies, including (i) 4A5 
antibody specificity, (ii) expression of CAR in polyclonal peripheral T cells containing 
naïve and TCM reported to have maximal efficacy as CAR+ T cells,(131) (iii) 
propagation of CAR+ T cells on aAPC containing membrane-bound IL15/IL15Rα 
fusion protein for optimal cytokine signaling potency and memory formation, and (iv) 
expansion schema without the need for sorting steps that can complicate clinical 
translation. Thus, CARs developed based on this strategy are hypothesized to have 
efficient killing of ROR1+ malignancies and could answer some of the same 
fundamental CAR questions in a broader set of peripheral T cells. 




Clinical trials have not yet tested ROR1-specific CARs in humans, so this report 
of pre-clinical testing of ROR1-specific CARs aims to directly test CD28 and CD137 
signaling CARs to streamline trial design and clinical efficacy for cancer treatments. 
“First-in-man” clinical trials open at MD Anderson translated (i) co-electro-transfer of 
CD19-specific CAR Sleeping Beauty (SB) transposon with SB transposase and (ii) 
expansion of CD19-specific CAR+ T cell on CD19+ aAPC into clinical manufacturing 
and were successfully transplanted into leukemia patients without toxicity or adverse 
event, suggesting that this is an effective and safe strategy (Cooper LJN, unpublished 
observation). This study builds upon these successes and adapts current (i) CAR 
plasmids, (ii) working aAPC cell banks expressing co-stimulatory molecules for 
endogenous co-stimulation of CD28 and CD137, and (iii) protocols for direct clinical 
application. A phase I clinical trial has been approved by the National Institutes of 
Health (NIH) DNA Recombinant Advisory Committee (RAC) based on the data herein 
and is currently under review at the MD Anderson Cancer Center Institutional Review 




II.C.1. ROR1 Surface Expression on Tumor Cells  
Surface expression of ROR1 was detected on a number of leukemia cell lines, OvCa 
cell lines, and primary leukemia patient samples before proceeding with generating 
ROR1-specific CARs. The 4A5 monoclonal antibody has been shown to have high 




affinity binding to ROR1,(75) and it was provided by Dr. Thomas J Kipps (UCSD) for 
testing ROR1 expression at MDACC. EL4 is a murine T-cell lymphoma cell line with 
low cross-reactivity with human T cells most likely due to their differences in MHC 
molecules. This cell line does not express human ROR1, thus they were genetically 
modified to express ROR1 in order to assess CAR-specific responses independent of 
their TCR interaction with MHC (Figure 6a).  Human B-cell ALL cell lines were 
readily accessible and were profiled for ROR1 expression. As expected, ROR1 was 
present on some, but not all, B-ALL cell lines. More specifically, NALM6 and Kasumi2 
tested negative and positive for ROR1, respectively (Figure 6b). ROR1 was also 
expressed on most (11 of 12) OvCa cell lines tested, which are best exemplified by 
ROR1+ EFO27 cells and the only ROR1neg OvCa cell line tested, A2780 (Figure 6c). 
ROR1 was originally described as a cancer antigen in B-cell CLL, so primary B-cell 
CLL patient samples were acquired for testing in parallel with LCL derived from 
healthy donor B cells immortalized with EBV. Indeed, CLL samples stained for ROR1 
while LCL did not (Figure 6d). These results corroborated the previous literature and 
gave us confidence to go forward with generating a ROR1-specific CAR designed from 
the 4A5 antibody.  





Figure 6. Surface Expression of ROR1 on Tumors. The 4A5 mAb specific for ROR1 
was used to assess ROR1 expression on the surface of (a) EL4 parental (ROR1neg) and 
genetically modified EL4-ROR1 cells, (b) B-ALL cell lines NALM6 and Kasumi2, (c) 
OvCa cell lines A2780 and EFO27, and (d) primary patient B-CLL cells or healthy 
donor LCL by flow cytometry. Mean fluorescence intensities (MFI) are displayed near 
corresponding histograms and legends are displayed above corresponding graphs. 
  




II.C.2. ROR1-specific CAR Plasmid Construction 
Two SB transposons were constructed with second generation ROR1-specific CARs for 
side-by-side comparison between the CD28 (ROR1RCD28) and CD137 
(ROR1RCD137) endodomains (Figure 7a and 7b, respectively). CD19 constructs were 
prepared in parallel with the CD28 (CD19RCD28) and CD137 (CD19RCD137) 
endodomains as controls for current standard T cell therapy and were identical to 
ROR1-specific CARs except in two pieces. First, the single chain variable fragment 
(scFv) differ between the CD19 and ROR1 constructs where the FMC63 and 4A5 
monoclonal antibodies specific for CD19 and ROR1 were used, respectively. Second, 
CD19 CARs use the colony-stimulating factor-2 receptor (CSF2R) signal peptide 
whereas ROR1 CARs use the murine IgGκ signal peptide. Human elongation factor-1α 
promoter was used to drive CAR expression of all CARs. Following the promoter, the 
CAR open reading frame was composed of (from 5’ to 3’): signal peptide, scFv with 
Whitlow linker, modified extracellular IgG4-Fc stalk,(272) CD28 transmembrane 
domain, CD28 or CD137 endodomains, and intracellular CD3ζ containing three ITAM 
domains. Interspaced between the STOP codons and the polyadenylation (polyA) tail 
were unique oligonucleotides to distinguish the two CAR transposons by polymerase 
chain reaction (PCR). The CD28 constructs could be distinguished from CD137 
constructs by the “SIM” and “FRA” oligonucleotides, respectively. Thus, detection of T 
cell persistence in patients undergoing ROR1-CAR T cell therapy can be monitored and 
can corroborate flow cytometry data. SB indirect repeats flanking the promoter (5’ end) 
and the polyA tail (3’ end) defined the CAR transposons to be integrated within TA 
repeats in the human T cell genome. Lastly, kanamycin resistance was used to 




selectively amplify CAR plasmids in bacteria to large quantities (0.5 – 1.0 mg), which 
were cleared for transfection after testing negative for endotoxin. In summary, these two 
ROR1-specific CAR plasmids mimic current plasmids used for CD19-specific CAR 










Figure 7. ROR1-specific CAR Transposons. DNA plasmid vector maps for (a) 
ROR1RCD28 and (b) ROR1RCD137. Abbreviations are as follows, IR/DR: Sleeping 
Beauty Inverted Repeat, hEF-1alpha/p: Human Elongation Factor-1 alpha region hybrid 
promoter, ROR1RCD28CD3z: Human codon optimized ROR1-specific 
scFvFc:CD28zeta chimeric antigen receptor, ROR1RCD137CD3z: Human codon 
optimized ROR1-specific scFvFc:CD137zeta chimeric antigen receptor, SIM: “SIM” 
PCR tracking oligonucleotides, FRA: “FRA” PCR tracking oligonucleotides, BGH 
polyA; bovine growth hormone polyadenylation sequence, ColE1: A minimal E.coli 
origin of replication, Kanamycin (Kan/R): Bacterial selection gene encoding 
Kanamycin resistance, Kanamycin promoter (Kan/p); Prokaryotic promoter. Digestion 
with BsrGI enzyme can distinguish the two plasmids, which have high degrees of 
similarity. The entire plasmid sequences were verified by Sanger-based sequencing 
techniques. 
  




II.C.3. Development of ROR1+ aAPC (clone#1) 
aAPC have been shown to propagate T cells ex vivo through (i) expression of cognate 
antigen or (ii) activation through membrane-bound antibody. However, current clinical 
K562-based aAPC cell banks at MD Anderson do not express ROR1. Therefore, a new 
aAPC was developed to express ROR1 and an IL15 fusion protein to the IL15 receptor-
α (IL15/IL15Rα) along with the other molecules present on aAPC surfaces. Trans-
presentation of IL15 by IL15Rα has been shown to have higher signaling potency than 
IL15 alone in other models.(284, 285) Clone#1 feeder cells were derived from the K562 
cell line, which was previously made to express CD19 antigen, co-stimulatory 
molecules (CD86 and CD137L), and Fc receptors (endogenous CD32 and introduced 
CD64) for loading of agonistic anti-CD3 antibody (OKT3). Thus, the CAR+ T cells had 
the potential to receive co-stimulation through the CAR and from endogenous binding 
of CD28 and CD137 on the T cell to CD86 and CD137L, respectively, on the aAPC. 
Prior to co-culture, aAPC were γ-irradiated (100 Gy) and typically die within 3 days of 
co-culture. Clone#1 aAPC were phenotyped prior to co-culture to ensure that all 
markers were present at >80% (Figure 8 right panels). Negative and positive controls 
were parental K562 cells (Figure 8 left panels) and clone#4 aAPC (Figure 8 middle 
panels) used in CD19-specific CAR+ T cell clinical trials at MD Anderson, 
respectively. The expression of IL15 by clone#4 is detected with eGFP as a surrogate 
marker but IL15 was directly detected on the surface of the clone#1 cells. Cytokine 
support, co-stimulation, and antigen expression by clone#1 aAPC gave us confidence in 
its ability for use in CAR+ T cell propagation. 
  









Figure 8. Surface Phenotype of Clone#1 aAPC Used for ROR1-specific T cell 
Expansion. Parental K562 (left), clone#4 aAPC (middle), and clone#1 aAPC (right) 
were stained for surface marker expression and were analyzed by flow cytometry. Top 
plots are forward scatter (FSC; x-axes) by side scatter (SSC; y-axes). Other plots were 
eGFP (x-axes) with the following on the y-axes from top to bottom: CD19, CD32, 
CD64, CD137L, ROR1, IL15, and CD86. Quadrant frequencies are displayed in the 
upper right corners. 
  




II.C.4. CAR+ T-cell Expansion on Clone#1 aAPC 
Healthy donor PBMC were electroporated with (i) no DNA as a negative control for 
CAR expression, (ii) SB11 transposase and ROR1RCD28 transposon plasmids, or (iii) 
SB11 transposase and ROR1RCD137 transposon plasmids. The following day, cells 
were phenotyped for CAR expression on their surfaces where “no DNA” and isotype 
antibodies served as negative controls. Transient expression of CAR was detected in T 
cells at 41% ± 6% and 41% ± 8% (mean ± SD; n=3) for ROR1RCD28 and 
ROR1RCD137, respectively, as evidenced by co-staining for Fc (IgG4-Fc extracellular 
stalk of CAR) and CD3 (Figure 9a). Co-cultures were then initiated with γ-irradiated 
clone#1 aAPC and CAR+ T cells at a 1:1 ratio. Similarly, γ-irradiated OKT3-loaded 
clone#4 aAPC and “no DNA” T cells were co-cultured at 1:1 ratio of total cells. Co-
cultures were supplemented with IL21 (30 ng/mL) at the outset of co-culture and every 
2-3 days thereafter. Recursive stimulations were performed every 7 days as above for 
four total stimulations, except that (i) IL2 (50 U/mL) was supplemented with IL21 
starting at the  second stimulation and (ii) NK cells were depleted from cultures with 
CD56 microbeads at day 15. At day 29, stable CAR expression was observed 
suggesting that clone#1 aAPC enforced CAR expression in T cells (Figure 9b). More 
specifically, CAR was expressed in T cells at 90% ± 3% and 79% ± 11% (mean ± SD; 
n=3) for ROR1RCD28 and ROR1RCD137, respectively, at the end of the co-culture. 
There was a difference between the transient and stable populations for ROR1RCD28 
(p = 0.006) and ROR1RCD137 (p = 0.009), but the populations did not have significant 
differences in CAR expression (p = 0.184) following expansion. ROR1RCD137 had 
consistently lower mean fluorescence intensity (MFI) compared to ROR1RCD28 (51 ± 




8 vs 102 ± 68, respectively) after expansion, but the reason for this is unknown at 
present. Recombinant rROR1 (rROR1; soluble extracellular domain) was purified and 
directly conjugated to a fluorescent marker (courtesy of Dr. Thomas J Kipps, USCD) 
for detection of antigen binding by CAR+ T cells. CD19-specific CAR+ T cells were 
expanded in parallel to serve as negative controls for rROR1 binding (Figure 10a). The 
CD19RCD28 had higher CAR expression than did ROR1RCD28, which could be 
explained by the differences in signal peptides used (human CSF2R and murine IgGκ, 
respectively). Nonetheless, ROR1RCD28 bound to rROR1, but CD19RCD28 and 
CARneg T cells did not bind to rROR1 (Figure 10b). Proliferation kinetics between the 
two ROR1 CAR populations was similar in total cells counts (p = 0.66; Two-way 
ANOVA) and in CAR+ T cell counts (p = 0.74). Total cell proliferation closely 
coincided with CAR+ T cell proliferation kinetics for both ROR1RCD28 and 
ROR1RCD137 (Figure 11). ROR1RCD28 resulted in an average of 2.5x109 total 
inferred cell counts (range 1.4x109  – 4.0x109) and 2.2x109 CAR+ T cells (range 1.3x109 
– 3.6x109), and ROR1RCD137 resulted in an average of 3.6x109 total inferred cell 
counts (range 3.7x109 – 8.2x109) and 2.9x109 CAR+ T cells (range 2.4x109 – 6.7x109). 
Thus, SB transposition resulted in stable CAR expression and co-culture on clone#1 
aAPC led to clinically-relevant numbers of ROR1-specific T cells.  





Figure 9. CAR Expression in T cells Before and After Expansion on Clone#1 
aAPC. (a) Transient expression of ROR1RCD28 (middle) and ROR1RCD137 (right) T 
cells the day following electroporation where “no DNA” T cells (left) were used as 
negative controls. (b) Stable CAR expression in ROR1RCD28 (middle) and 
ROR1RCD137 (right) populations. T cells were marked by CD3 staining and 
CAR+ cells were detected with anti-Fc antibody. Quadrant frequencies are displayed in 
upper right corners. 
  





Figure 10. rROR1 Antigen Binding by ROR1-specific T cells. Recombinant ROR1 
(rROR1) was purified and conjugated to fluorescent tag for detection of ROR1-specific 
T cells (ROR1RCD28). CD19-specific CAR+ T cells (CD19RCD28) and “no DNA” 
CARneg T cells were used as negative controls. (a) Fc detection of CARs and (b) rROR1 
binding. 
  





Figure 11. Sustained Proliferation of CAR+ T cells. (a) Total cells and (b) CAR+ T 
cell proliferation on clone#1 aAPC. ROR1RCD28 represented on the left and 
ROR1RCD137 shown on the right. Each symbol represents a different healthy donor. 
 
  




II.C.5. Immunophenotype of ROR1-specific T cells 
II.C.5.a. T cell Immunophenotype of ROR1RCD28 and ROR1RCD137 
Following 29 days of expansion on irradiated clone#1 aAPC, ROR1RCD28 and 
ROR1RCD137 cells were profiled for (i) gene expression using the nCounter gene 
expression array platform (NanoString) and (ii) T cell surface proteins and memory 
markers by flow cytometry. A unique panel of lymphocyte genes was assembled for 
analysis on the nCounter and was termed “Lymphocyte CodeSet Array” or LCA 
(Appendix A). As expected, both δ and ε isoforms of CD3 (CD3D and CD3E, 
respectively) were highly expressed by both CAR+ T cell populations, and there was 
higher expression of both CD3D and CD3E in ROR1RCD28 cells (Figure 12a). 
Expression of CD3ζ was not evaluated at the mRNA level because it could not be 
distinguished from CD3ζ on CAR intracellular domains. Nonetheless, >97% of CAR+ T 
cells were CD3+ on the cell surface (Figure 12b). There was also a trend of decreased 
expression of CD4 and CD8A transcripts in ROR1RCD137 cells relative to 
ROR1RCD28 and there was ~100 times more CD8A transcript than CD4 (Figure 12a 
middle panels). The same was observed at the protein level where both CARs 
preferentially expanded CD8+ T cells over CD4+ T cells and on average there were 
fewer CD4 and CD8 T cells in the ROR1RCD137 culture (Figure 12b top panels and 
12c). This phenomenon of fewer CD4+ and CD8+ T cells is most likely attributed to 
small frequencies of γδ T cells (identified by CD3+TCRγδ+) that were present in the 
ROR1RCD137 cultures and not in the ROR1RCD28 cultures (Figure 12b bottom 
panels), because γδ T cells are commonly negative for both CD4 and CD8 but express 




CD3.(286) Indeed, γδ T cells can proliferate on aAPC (Chapters III and IV), which 
suggests that they may compete for clone#1 for proliferative signal and diminish 
ROR1RCD137 cells from reaching >90% CAR+ T cells. NK cells were present in 
cultures at Day 15 and were depleted with CD56 microbeads from all cultures, so 
negligible quantities of CD3negCD56+ NK cells were detected at the end of the co-
culture period two weeks later (Figure 12b, middle panels). CD56 was also expressed 
by T cells at the end of the co-culture period and is associated with MHC-unrestricted 
cytolysis (Figure 12a and 12b).(287) Significant differences between T cell surface 
protein expression were not observed (p = 0.322) between the two CARs in respect of 
CD3, CD4, CD8, CD56, NK cells, or γδ T cells (Figure 12c). These results suggest that 
CAR+ T cells have canonical T cell phenotype features and on the basis of these 
evaluated markers were highly similar.  





Figure 12. Basic Immunophenotype of CAR+ T cells. After 29 days of expansion on 
clone#1 aAPC, ROR1RCD28 and ROR1RCD137 cells were (i) lysed for mRNA 
expression analysis or (ii) phenotyped for T cell surface markers by flow cytometry. (a) 
RNA lysates were interrogated on nCounter gene expression array with “lymphocyte 
CodeSet array” (LCA) and normalized CD3 (far left), CD4 (middle left), CD8A (middle 
right), and CD56 (far right). mRNA expression are displayed for ROR1RCD28 (open 
shapes) and ROR1RCD137 (closed shapes). Student’s paired, 2-tailed t-test was used 




for statistical analysis (n = 3). *p<0.05 (b) CD4 (x-axes) and CD8 (y-axes) expression 
(top panels), CD3 (x-axes) and CD56 (y-axes) expression (middle panels), and CD3 (x-
axes) and TCRγδ (y-axes) expression (bottom panels) of one of 3 representative donors. 
Gate frequencies are in the upper right corners and correspond to gate quadrants. (c) 
Frequencies of cells staining positive for each lymphocyte marker where each shape 
represents an individual donor, ROR1RCD28 are in open shapes and ROR1RCD137 are 
in closed shapes, NK cells were defined as CD3negCD56+, γδ T cells were defined as 
CD3+TCRγδ+, and data are mean ± SD (n = 3). 
  




II.C.5.b. Memory Phenotype of ROR1-specific T cells 
Naïve (TN) and central memory (TCM) T cells have been associated with long-term 
CAR+ T cell therapeutic efficacy due to their ability to achieve persistence in vivo.(131) 
Both ROR1RCD28 and ROR1RCD137 cells predominantly expressed memory markers 
associated with TN and TCM memory phenotypes at Day 29 of co-culture (Figure 13). 
The mRNA expression of memory-associated genes was first evaluated with LCA, 
which identified a significant reduction in the inhibitory regulatory gene CTLA4 and an 
increase in expression of the transcription factor Lef1, which has been described to 
participate in CD8+ T cell memory formation, in ROR1RCD137 cells relative to 
ROR1RCD28 cells (Figure 13a).(119, 288) As seen with the mRNA gene expression 
data, surface protein expression of CD28 was significantly (p = 0.003; Student’s paired, 
2-tailed t-test) higher in ROR1RCD137 cells compared to ROR1RCD28, whereas 
CD27 was highly expressed in both CAR+ T cell populations suggesting they have not 
reached terminal differentiation (Figure 13a, 13b, and 13d). CAR+ T cells populations 
were also similar in their high surface protein expression of lymphoid organ homing 
and memory markers CD62L and CCR7, suggesting they could home to organs 
harboring leukemia (Figure 13a, 13c, and 13d). A trend of decreased gene expression 
of SELL (CD62L) gene was observed in ROR1RCD137 cells, whereas CCR7 
transcripts were roughly equivalent between the two CAR populations and protein 
expression was roughly equivalent for both sets as well. There was also a trend of 
higher expression of the antigen-experienced marker CD45RO over the more naïve-
associated marker CD45RA in both populations (Figure 13d). Both groups were similar 
overall (p = 0.251; Two-way ANOVA) in expression of CD27, CD28, CD45RA, 




CD45RO, CD62L, and CCR7. To further analyze memory potential, multi-parameter 
gating was used to define specific memory populations as naïve (TN; 
CD45RA+CD27+CD28+CCR7+), central memory (TCM; 
CD45RAnegCD27+CD28+CCR7+), effector memory (TEM; 
CD45RAnegCD27+CD28negCCR7neg), and effector memory RA (TEMRA; 
CD45RA+CD27negCD28negCCR7neg).(131, 289) Most CAR+ T cells belonged to TN and 
TCM groups with few TEM and TEMRA (Figure 13e). ROR1RCD137 had a trend of higher 
frequencies of cells belonging to TN and significantly higher TCM groups than 
ROR1RCD28, and overall the two CAR+ T cell populations were different (p = 0.019; 
Two-way ANOVA). In aggregate, the surface phenotypes of ROR1-specific CAR T 
cells suggest their potential for memory and effector functions against ROR1+ 
malignancies.  





Figure 13. Memory Markers on CAR+ T cell Surfaces. After 29 days of expansion 
on clone#1 aAPC, ROR1RCD28 and ROR1RCD137 cells were (i) lysed for mRNA 
expression analysis or (ii) phenotyped for T cell surface markers by flow cytometry. (a) 
RNA lysates were run on the nCounter LCA and normalized expression of CTLA4 (far 
left), Lef1 (middle left), CCR7 (center), SELL (CD62L; middle right), and CD28 (far 
right) are displayed. Student’s paired, 2-tailed t-tests were done for statistical analyses. 
*p<0.05 (b) CD27 (x-axes) and CD28 (y-axes) expression and (c) CCR7 (x-axes) and 
CD62L (y-axes) expression of one of 3 representative donors. (d) Frequencies of cells 




staining positive for each memory marker. Student’s paired, 2-tailed t-tests were done 
for statistical analyses. ***p<0.001 (e) Frequencies of cells staining positive for 
memory groups (TN: naïve, TCM: central memory, TEM: effector memory, TEMRA: 
effector memory RA). Statistical analysis was Student’s paired, 1-tailed t-test between 
CAR groups for each memory group. *p<0.05 For (a), (d) and (e), each shape 
represents an individual donor, ROR1RCD28 are in open shapes and ROR1RCD137 are 
in closed shapes, and data are mean ± SD (n = 3).  
  




II.C.6. TCR Repertoire of ROR1-specific T cells 
Multiplex gene expression analysis was used to assay differences in TCR genes. 
Skewing towards a particular TCR clonotype was evaluated between the two CAR 
populations to assess whether CD28 or CD137 CARs particularly expand a select group 
of TCRs (Figure 14). The “direct TCR expression array” or DTEA was developed to 
analyze all 45 Vα and 46 Vβ TCR isotypes in a single reaction using the nCounter gene 
multiplex array platform.(290) After 22 days of expansion on clone#1 aAPC, 
ROR1RCD28 and ROR1RCD137 were assessed for TCR isotype expression by DTEA 
(Figure 14). Frequencies of TCRα regions were not statistically different between the 
two CARs (p = 0.25; Repeated measures Two-way ANOVA), no obvious trends were 
observed, and comparisons for each TCRα (Student’s paired, two-tailed t-test) resulted 
in p values >0.05 for all alleles (Figure 14a). Similarly, TCRβ isotypes were not 
significantly different between ROR1RCD28 and ROR1RCD137 when analyzed 
together (p = 0.33) or as individual genes (Figure 14b). TCRα and TCRβ were both 
polyclonal suggesting that skewing to a particular TCR isotype did not occur. 
Additionally, DTEA measured TCRγ and TCRδ expression where all Vδ counts were 
0.9% and 1.9% of the ROR1RCD28 and ROR1RCD137 total TCR frequencies, 
respectively, and Vγ counts were 6.2% and 8.1% of the ROR1RCD28 and 
ROR1RCD137 total TCR frequencies, respectively. These results showed that γδ T 
cells were minor contributors to the total CAR+ T cell pools, which were mainly αβ T 
cells as determined by DTEA. Thus, CAR endodomain signaling was not preferential to 
a particular TCRαβ clonotype but rather generated polyclonal αβ T cells.  





Figure 14. TCRα and TCRβ Expression in ROR1RCD28 and ROR1RCD137 cells. 
nCounter gene multiplex array was used to interrogate TCR isotype expression  with 
“direct TCR expression array” (DTEA) in CAR-modified T cells after expansion on 
clone#1 aAPC. Cells were lysed at day 22 of co-culture period. (a) TCRα and (b) 
TCRβ expression in ROR1RCD28 (filled bars) and ROR1RCD137 (open bars) T cells. 
  




II.C.7. IFNγ Production by CAR+ T cells in Response to ROR1 
In order to assess whether CAR+ T cells were functional and specific for ROR1+ tumor 
cells, IFNγ production was measured by flow cytometry after activation with leukemia 
cells or TCR agonists. Brefeldin-A was co-cultured with T cells to inhibit IFNγ 
secretion. Collectively, the data suggest that CAR+ T cells were specific and functional 
in responding to ROR1+ tumors. 
 
II.C.7.a. TCR Stimulus with Leukocyte Activation Cocktail 
Phorbol myristate acetate (PMA) and Ionomycin were used as leukocyte activation 
cocktail (LAC) to stimulate the T cells for evaluation of maximal TCR response. LAC 
mimics TCR activation by activating protein kinase C (PKC) and increasing 
intracellular Ca2+ levels and, therefore, is a measure of non-specific T cell 
activation.(291, 292) ROR1RCD28 and ROR1RCD137 T cells were mock activated 
(media only) as a negative control or activated with LAC for 6 hours. Significant 
expression of IFNγ was measured in response to LAC as seen in example histograms 
(Figure 15a) and average mean fluorescence intensities (MFI) of IFNγ staining (Figure 
15b). There was a trend of higher production of IFNγ by ROR1RCD28 compared to 
ROR1RCD137 that was not statistically different (p = 0.120). These results established 
that IFNγ was produced when CAR+ T cells were activated through canonical TCR 
signaling pathways and suggested that ROR1RCD28 had higher propensity to express 
IFNγ relative to ROR1RCD137 cells. 




II.C.7.b. Specific IFNγ Production to ROR1+ Leukemia Cells 
Both Kasumi2 and NALM6 are B-cell ALL cell lines that express CD19, but only 
Kasumi2 expresses ROR1 (Figure 6a). Thus, they were used to assess responsiveness 
of CAR+ T cells to human leukemia cells in 6 hours of co-culture. As expected, 
ROR1RCD28 and ROR1RCD137 T cells produced IFNγ when co-cultured with 
Kasumi2 cells but not with NALM6 (Figure 15c). Similarly to LAC activation, 
ROR1RCD137 cells produced less IFNγ than ROR1RCD28 cells (Figure 15d) in 
response to the ROR1+ cell line. Nonetheless, ROR1-specific CAR+ T cells responded 
specifically to ROR1+ leukemia. 
 
II.C.7.c. CAR+ T cells Produce IFNγ in Response to Primary ROR1+ Leukemia Cells 
but not Healthy ROR1neg B cell LCL 
It was important to ensure that ROR1-specific T cells would respond to primary ROR1+ 
leukemia samples and spare normal B cells. LCL cell lines are immortalized healthy B 
cells, which served as negative controls in experiments where primary patient samples 
were used as targets. No IFNγ was produced by CAR+ T cells when co-cultured for 6 
hours with allogeneic LCL cell lines (Figure 15e). In contrast, significant (p = 0.004, 
Student’s paired, 2-tailed t-test) IFNγ was produced by ROR1RCD28 and there was a 
trend of increased IFNγ production by ROR1RCD137 with CLL but did not reach a 
measure for statistical significance (Figure 15e and 15f). This was the same 
observation seen in an independent study testing ROR1-specific T cells, albeit with 
CARs derived from different mAbs specific for ROR1, where less cytokine production 




was seen with CARs signaling through CD137 relative to those signaling through 
CD28.(199) Thus, ROR1-specific CAR+ T cells were functionally responsive to 
primary ROR1+ leukemia and not to healthy B cells.  





Figure 15. IFNγ Production by ROR1-specific T cells in Response to ROR1+ 
Targets. Brefeldin-A (GolgiPlug) was added to T cells to block IFNγ secretion in order 
to measure functional responses to agonistic stimulation. At day 29 of co-culture, CAR+ 
T cells were co-cultured for 6 hours at 37oC and cells were gated for CD3+Fc+ to assess 
CAR responses to: (a)/(b) complete media (Mock) or PMA and Ionomycin (leukocyte 
activation cocktail; LAC), (c)/(d) B-ALL cell lines NALM6 (ROR1neg) or Kasumi2 
(ROR1+), or (e)/(f) healthy donor LCL cell line (ROR1neg) or CLL patient sample 
(ROR1+). Mean fluorescence intensities (MFI) are displayed next to histograms in (a), 
(c), and (e), which are representative of three CAR+ T cell donors. Mean ± SD (n = 3) 
are displayed in (b), (d), and (f). Student’s paired, 1-tailed t-test for statistical analysis. 
*p<0.05 and **p<0.01  




II.C.8. ROR1-specific Cytotoxicity by CAR+ T cells 
Cytotoxicity was another important assessment of ROR1-specific CAR+ T cell function. 
Four-hour chromium release assays (CRA) are the gold-standard technique for in vitro 
killing assays. Thus, CRA was used to test specific lysis of ROR1+ control cells, 
established tumor cell lines, and primary tumor cells. Significant lysis was only 
observed against ROR1+ cells suggested that CAR+ T cells were specific in their lytic 
abilities. 
 
II.C.8.a. CAR+ T cells Lyse Leukemia but not Healthy B cells 
The clinical trial based on these data will treat patients with B-cell CLL, so primary B-
cell CLL samples were tested as targets by allogeneic ROR1-specific CAR+ T cells. 
ROR1neg LCLs were used for negative controls for CLL samples (Figure 6a). As 
expected, minimal lysis was observed by ROR1RCD28 and ROR1RCD137 against 
LCL (Figure 16a). In contrast, both ROR1RCD28 and ROR1RCD137 killed patient 
CLL cells in a dose-dependent manner (Figure 16b). More variability was observed in 
ROR1RCD28 samples in their lysis of CLL compared to ROR1RCD137, which was 
almost identical amongst donors. These data indicated specific lysis of ROR1+ leukemia 
by CAR+ T cells while sparing normal B cells. 
  





Figure 16. Specific Cytolysis of Primary ROR1+ B-cell CLL by CAR+ T cells. (a) 
Established ROR1neg B-cell LCL and (b) Primary patient ROR1+ CLL cells were tested 
for cytolysis by ROR1-specific CAR+ T cells in standard 4-hour CRA. Specific lysis by 
ROR1RCD28 (left) and ROR1RCD137 (right) at decreasing effector to target (E:T) 
ratios. Each line and shape represents a different effector donor. Data are mean ± SD of 
triplicate measurements in CRA. 
  




II.C.8.b. ROR1-restricted Killing of Tumor Cell Lines 
A number of established tumor cell lines express ROR1 as an endogenous or introduced 
protein (Figure 6), so they were used for killing assays in parallel to cell lines lacking 
ROR1 expression. As expected, both ROR1RCD28 and ROR1RCD137 efficiently 
lysed EL4-ROR1+ but showed minimal lysis of EL4-ROR1neg cells (Figure 17a). 
Similar to EL4 data, ROR1+ B-ALL cell line Kasumi2 was lysed at significantly higher 
levels (p < 0.0001) compared to ROR1neg B-ALL cell line NALM6 by ROR1RCD28 
(Figure 17b left). The same was observed for ROR1RCD137 where Kasumi2 was 
lysed at significantly higher levels (p < 0.0001) compared to NALM6 (Figure 17b 
right). In contrast to ROR1-specific CAR+ T cells, donor-matched CD19+ specific 
CAR+ T cells lysed all three cell lines, which were all CD19+ (data not shown), and 
suggested that ROR1RCD28 and ROR1RCD137 were more discriminant in their killing 
abilities. Furthermore, ROR1+ OvCa cell line EFO27 was lysed at significantly 
(p<0.0001) higher levels than ROR1neg OvCa cell line A2780 by both ROR1RCD28 
and ROR1RCD137 (Figure 17c). In summary, ROR1-specific CAR+ T cells 
demonstrated effective and specific lysis of ROR1+ tumor cells in vitro. 
 
  





Figure 17. Specific Cytolysis of Established ROR1+ Tumor Cell Lines by CAR+ T 
cells. Standard 4-hour CRA were used to assess specific lysis of (a) EL4-ROR1neg 
(circles) or EL4-ROR1+ (squares) cells, (b) ROR1neg NALM6 (circles) or ROR1+ 
Kasumi2 (squares) cells, and (c) ROR1neg A2780 (circles) or ROR1+ EFO27 (squares) 
cells by ROR1RCD28 (left) and ROR1RCD137 (right) at decreasing E:T ratios. Each 
line and shape represents a different target where data are mean ± SD of three donors 
with triplicate measurements in CRA.  




II.C.9. In Vivo Leukemia Clearance by ROR1-specific T cells 
In order to test the anti-tumor activity of ROR1-specific CAR+ T cells in vivo, a mouse 
model of MRD was implemented for leukemia and ROR1-specific CAR+ T cells were 
tested as treatment arms. Kasumi2 cells were sensitive to ROR1-specific T cells lysis, 
so they were genetically modified to express mKate red fluorescence protein to sort 
transduced cells (Figure 18a) and Firefly Luciferase (ffLuc; bioluminescence reporter) 
for non-invasive bioluminescence imaging (BLI) of tumor burden in vivo (Figure 18b). 
NOD.scid.γc-/- (NSG) mice were used because they lack functional adaptive immune 
systems and can, therefore, accept human tumor xenografts well. Mice engrafted with 
Kasumi2-ffLuc-mKate had consistent log10-fold increases in bioluminescence flux from 
their tumors and succumbed to disease after 27 (average) days after engraftment 
(Figure 18c circles and 18d top panel). ROR1RCD28 was able to diminish tumor 
burden significantly (p = 0.0004) above untreated mice as measured by tumor BLI flux 
(Figure 18c squares and 18d middle panel) and was able to increase survival 
significantly (p = 0.002) to an average of 30 days post-engraftment. Furthermore, 
ROR1RCD137 eliminated tumor burden significantly above both untreated mice (p = 
0.0001) and ROR1RCD28-treated mice (p = 0.002) as measured by tumor BLI flux 
(Figure 18c triangles and 18d bottom panels), and was able to increase survival 
significantly longer compared to both untreated mice (p < 0.001) and ROR1RCD28-
treated mice (p = 0.03) to 34 days (average) post-engraftment and up to 11 days relative 
to the first mouse that died in the untreated group and the last mouse that died in the 
ROR1RCD137 group. ROR1RCD137 cells had consistently lower frequencies of CAR+ 
T cells (94%, 62%, and 46% at doses 1, 2, and 3, respectively) prior to infusion relative 




to ROR1RCD28 cells, which expressed CAR at >90% for all three doses. The T cell 
doses were given based as 107 total cells/mouse, so a greater anti-tumor effect was seen 
with ROR1RCD137 with fewer total CAR+ T cells, which highlights their ability to 
outperform ROR1RCD28 in tumor killing in vivo. In summary, ROR1-specific CAR+ T 
cells can efficiently treat ROR1+ leukemia and, therefore, can now be moved into the 
clinic for testing in patients with ROR1+ malignancies. 
  





Figure 18. In vivo Tumor Clearance by ROR1-specific CAR+ T cells. ROR1+ B-
ALL cell line Kasumi2 was transduced with mKate-ffLuc lentiviral particles and cells 
were sorted for uniform mKate expression by FACS. (a) mKate expression in parental 
cell line (black histogram) or transduced cell line (red histogram). (b) In vitro luciferase 
activity of parental Kasumi2 cell line (without ffLuc) and transduced Kasumi2-ffLuc-
mKate cells. NSG mice were engrafted with 4x104 Kasumi2-ffLuc-mKate cells 
intravenously (i.v.) and were treated with three doses of 107 T cells i.v. to assess the 
ability of ROR1-specific T cells to manage MRD. High dose (60 kIU) IL2 was given 
intraperitoneally (i.p.) the day of T cell dosing and the following day. (c) Non-invasive 
bioluminescence imaging (BLI) flux kinetics during experiment where untreated mice 
are in circles, ROR1RCD28-treated mice are in squares, and ROR1RCD137-treated 
mice are in triangles. Two-way ANOVA was used for statistical analysis. **p<0.01 and 
***p<0.001 (d) Representative BLI images at day +23 post-engraftment. 
  





II.D.1. Importance of Developing ROR1-specific T cells for Leukemia Patients 
This work aimed to develop pre-clinical data to support a “first-in-man” Phase I clinical 
trial of ROR1-specific T cell treatments for ROR1+ malignancies. The major advantage 
of this therapy over the current anti-CD19 cellular therapies is that normal B cells 
would be spared when targeting ROR1 as CD19 is uniformly expressed on most B cells 
and is required for B cell function.(56, 57) B cells are the primary arm of the humoral 
response and are critical for the adaptive immune response in clearance of microbial 
pathogens.(89) However, people can survive without B cells, albeit under threat of 
novel pathogens, if they receive serum immunoglobulin replacement therapy.(63) Thus, 
quality of life would be certainly improved if CAR+ T cell therapy patients had a normal 
repertoire of healthy B cells as would be achieved by targeting ROR1 instead of CD19. 
 
II.D.2. ROR1 as a Tumor Target and Safety Concerns in Immunotherapy 
ROR1 was originally identified on the surface of CLL cells with absent expression on 
normal tissues, including cells in the hematopoietic compartment.(66, 75) Subsequently, 
ROR1 has been described on t(1;19) B-ALL and a number of solid tumors, e.g. breast, 
ovarian, and pancreatic cancers.(13, 67, 79) Some expression of ROR1 mRNA species 
was identified in normal lung, pancreas, and adipose tissue, by qPCR of healthy donor 
tissue panels, and protein expression was later corroborated on the cell surface in 
adipocytes and in the cytoplasm in pancreatic islet cells and alveolar macrophages by 
immunohistochemical staining with the 2A2 ROR1-specific antibody.(77, 81) However, 




this antibody also displayed cytosolic staining of a number of tissues that do not express 
ROR1 mRNA transcripts, e.g. adrenal glands, cardiac muscle, neurons, colon, 
endometrium, hypophysis, larynx, liver, ovary, salivary, small intestine, skin, stomach, 
and thymus, which means that (i) the mRNA expression data is inaccurate or (ii) the 
2A2 antibody is not completely specific for ROR1. Testing of the R12 goat antibody 
specific for ROR1 binding to normal tissues has not yet been reported.(293) In contrast 
to the 2A2 data, RNAseq analysis did not corroborate ROR1 mRNA presence in normal 
healthy tissues (Kipps TJ, UCSD, unpublished observations). Moreover, the 4A5 
ROR1-specific mAb from which the CAR was developed in this study did not detect 
ROR1 in healthy tissues by both Western blot and immunohistochemistry.(67, 75) The 
only reported staining of ROR1 with the 4A5 mAb outside of malignancies was 
described on hematogones, which are B-cell precursors, and loss of hematogones would 
impact B cell differentiation but not the mature B cell pool.(66) There is always the risk 
of potential “on-target/off-target” toxicity of proper antigen recognition by CAR+ T 
cells on undesired tissues expressing low levels of antigen, but we are confident that our 
approach is safe because (i) 4A5 did not stain normal tissue and the CAR was derived 
from this Ab, (ii) homing to pancreas and or adipose tissue is unlikely given the homing 
repertoire expressed by CAR+ T cells which predicted for homing to lymphoid organs 
(CCR7 and CD62L), and (iii) high tumor burden in many CLL patients will likely be 
seen first and occupy the T cells from other organs. As a control for adverse events, 
suicide genes, e.g. inducible Caspase9, can be co-expressed with CAR in order to 
eliminate T cells in vivo with drugs specific for the suicide gene of choice.(294) In the 




end, these questions will only be answered once clinical trials test these hypotheses in 
humans. 
 
II.D.3. CD28 versus CD137 in CAR Design 
A common debate in CAR immunotherapy at present is whether to use CD28 
endodomain, as most investigators have done, or CD137 endodomain, both of which 
have led to objective clinical responses.(4-7, 32) A direct comparison of CD28 versus 
CD137 signaling in CD19-specific CARs developed at MDACC (and analogous to the 
ROR1-specific CARs in design) resulted in almost indistinguishable characteristics in 
vitro but CD137 was superior in vivo in leukemia clearance compared to CD28 (Singh 
H, unpublished observations). In this study, the most notable differences between the 
two ROR1-specific CARs were in (i) memory phenotype, (ii) in vitro IFNγ production, 
and (iii) in vivo tumor clearance. In regards to surface phenotype, both ROR1RCD28 
and ROR1RCD137 T cells were almost completely naïve (TN) and central memory T 
cells (TCM) after ex vivo expansion, and there were more of both TN and TCM 
populations in ROR1RCD137 cells (Figure 13). Indeed, both of these populations have 
been correlated to limited effector functions including reduced cytokine production and 
cytolysis.(132, 135) It is consistent then that ROR1RCD137 cells produced less IFNγ 
when challenged with ROR1+ targets (Figures 15), and fewer cytokine mRNA 
transcripts were produced by ROR1RCD137 relative to ROR1RCD28 as evaluated by 
nCounter LCA (data not shown). Indeed, the ability to produce cytokines was inversely 
correlated with CD8+ T cell efficacy in other T cell immunotherapies.(295) Again, 




reduced cytokine production was also observed with ROR1-specific CARs signaling 
through CD137 that were derived from the 2A2 mAb and its higher affinity counterpart 
R12 mAb.(199) Similar killing was detected by both CAR populations against ROR1+ 
targets, with a minor exception of primary cell lines where ROR1RCD28 was highly 
variable in cytolysis between donors and exceeded ROR1RCD137 in killing for 2 out of 
3 donors (Figure 16b). In contrast to the in vitro results, ROR1RCD137 was 
significantly (p = 0.0001) better at eliminating ROR1+ leukemia compared to 
ROR1RCD28, which was significantly better (p < 0.0001) than no treatment (Figure 
18). Furthermore, these results were achieved with fewer total CAR+ T cells infused 
into each mouse, because the same total number was injected but CAR percentage was 
lower in ROR1RCD137 relative to ROR1RCD28. Possible explanations of the 
differences are (i) higher frequencies of TN and TCM memory cells that are correlated 
with highest CAR+ T cell responses relative to other classification,(131) (ii) lower 
expression of inhibitory molecules like CTLA4 (Figure 13), (iii) production of other 
inflammatory molecules other than IFNγ such as IL17, and/or (iv) longer persistence in 
the mice which has been correlated to memory formation and increased anti-tumor 
activity.(6, 189, 215, 237) The NSG mice used for in vivo studies lack human 
homeostatic cytokines, e.g. IL7 and IL15, that can improve persistence in patients 
treated with ROR1-specific T cells and therefore increase the potential of the anti-tumor 
effects observed in the mouse studies. A side-by-side comparison of the two CARs in 
clinical trials will be the ultimate test of which CAR is better for cancer treatment. 
 
 




II.D.4. Immediate Plans for ROR1-specific T cells in Leukemia Treatment 
A Phase I clinical trial has been approved by the NIH RAC and is in process for MD 
Anderson IRB approval. The trial design is to co-infuse ROR1RCD28 and 
ROR1RCD137 cells in a competitive repopulation experiment to maximize potential 
therapeutic efficacy and determine which CAR will persist longer in the patients. PCR 
will be used as a highly-sensitive means to detect persistence of one population over 
another based on unique oligonucleotides present in the two CAR transposons (SIM for 
CD28 and FRA for CD137). As this will be the first time ROR1-specific T cells are 
infused into humans, it is the primary endpoint to determine toxicity and maximum 
tolerated doses. There is strong evidence that this will work as means to eliminate 
leukemia while maintaining normal B cells, and will be the first time that ROR1 has 
been a target of immunotherapy for cancer treatment.  





Bi-specific T cells Expressing Polyclonal Repertoire of Endogenous γδ T-cell 
Receptors and Introduced CD19-specific Chimeric Antigen Receptor 
 
III.A. Hypothesis and Rationale 
 The hypothesis of this chapter is that enforced CAR expression on γδ T cells will 
stimulate them independent of their TCRγδ, thus leading to expansion of γδ T cells with 
polyclonal TCRγδ repertoire, and would amplify the anti-tumor effects from TCRγδ 
towards TAA+ malignancies through the CAR. The rationale for this specific aim is that 
(i) γδ T cells have inherent anti-tumor immunity through a number of combinations of 
TCRγ and TCRδ pairings, (ii) the use of γδ T cells in the clinic is currently restricted to 
Vγ9Vδ2 even though other γδ T cell lineages have anti-tumor reactivity, (iii) CARs 
stimulate T cells independent of their TCR, (iv) electroporation of SB transposons 
containing the CAR can be achieved in quiescent PBMC with a polyclonal repertoire of 
γδ T cells, and (v) CD19-specific CAR transposon plasmids and CD19+ aAPC are 
currently in clinical trials at MD Anderson and these reagents can be used to quickly 
translate findings from this chapter into clinical trials. Therefore, using a polyclonal set 
of γδ T cells for CAR-based immunotherapy would allow for targeting the tumor 
through both CAR and multiple TCRγδ pairings to maximize anti-tumor immunity 
through bi-specific T cells. 
 





“Chimeric antigen receptors (CARs) re-direct T-cell specificity to tumor-
associated antigens (TAAs), such as CD19, independent of major 
histocompatibility complex (MHC).(57, 186, 189, 272, 296) This genetic 
modification of T cells has clinical applications as adoptive transfer of CAR+ T 
cells with specificity for CD19 can lead to anti-tumor responses in patients with 
refractory B-cell malignancies.(6, 7, 32, 56) Current trials administer CAR+ T 
cells co-expressing αβ T-cell receptor (TCRαβ) derived from a population that 
represents 95% of the peripheral T-cell pool. However, the remaining 1-5% of 
circulating T cells expressing TCRγδ (γδ T cells) have clinical appeal based on 
their endogenous cytotoxicity towards tumor cells as well as their ability to 
present TAA and elicit an anti-tumor response.(177, 297, 298) This population 
of T cells directly recognizes TAA, e.g., heat shock proteins, MHC class I chain-
related gene A/B (MICA/B), F1-ATPase, and intermediates in cholesterol 
metabolism (phosphoantigens), in humans.(299) Therefore, broad recognition of 
tumor cells and anti-tumor activity is achieved by these T cells expressing a 
diverse TCRγδ repertoire (combination of Vδ1,  Vδ2,  or Vδ3  with one of 
fourteen Vγ chains).(300) 
More specifically, T cells expressing Vδ1 and Vδ2 have been associated 
with anti-tumor immunity, but current adoptive immunotherapy approaches are 
limited to the Vδ2 sub-population due to limited expansion methods of Vδ1 to 
clinically-sufficient numbers of cells for human applications. For the most part, 




γδ T cells have been numerically expanded in vivo and ex vivo using Zoledronic 
acid (Zol),(301) an aminobisphosphonate that results in selective proliferation of 
T cells expressing Vγ9Vδ2 TCR.(175, 177, 297) This treatment modality has 
resulted in objective clinical responses against both solid and hematologic 
tumors, but has not been curative as a monotherapy. Vδ1 γδ T cells have not yet 
been infused, but their presence has correlated with complete responses 
observed in patients with B-cell acute lymphoblastic leukemia (B-ALL) after 
undergoing αβ T cell-depleted allogeneic hematopoietic stem-cell 
transplantation (HSCT).(302-305) As both of these sub-populations of γδ T cells 
are associated with anti-tumor activity, but have not been combined for cell 
therapy, we sought a clinically-appealing approach to propagate T cells that 
maintain a polyclonal TCRγδ repertoire. 
Recognizing that a CD19-specific CAR can sustain the proliferation of 
αβ T cells on artificial antigen presenting cells (aAPC) independent of 
TCRαβ usage,(280) we hypothesized that CAR+ γδ T cells would expand on 
aAPC independent of TCRγδ. Our approach was further stimulated by the 
observation that K562, the cell line from which the aAPC are derived, are a 
natural target for γδ T cells.(303) We report that CAR+ γδ T cells can be 
propagated to clinically-relevant numbers on designer aAPC while maintaining 
a polyclonal population of TCRγδ as assessed by our "direct TCR expression 
assay" (DTEA), a novel digital multiplexed gene expression analysis that we 
adapted to interrogate all TCRγδ isotypes.(290) These CAR+ γδ T cells 




displayed enhanced killing of CD19+ tumor cell lines in vitro compared to 
polyclonal γδ T cells not expressing CAR. Leukemia xenografts in 
immunocompromised mice were significantly reduced when treated with CAR+ 
γδ T cells compared to control mice. This study highlights the ability of aAPC to 
numerically expand bi-specific T cells that exhibit introduced specificity for 
CD19 and retain endogenous polyclonal TCRγδ repertoire. 
 
III.C. Results  
III.C.1. CAR+ γδ T cells Numerically Expand on aAPC 
To date, it has been problematic to synchronously manipulate and expand 
multiple γδ T-cell subpopulations for application in humans. Viral-mediated 
gene transfer typically requires cell division to achieve stable gene transfer and 
CARs have been introduced into transduced T cells expressing just Vδ2 TCR 
following the use of aminobisphosphonates to drive proliferation.(306) In 
contrast, non-viral gene transfer with Sleeping Beauty (SB) transposition can be 
achieved in quiescent peripheral blood mononuclear cells (PBMC) with the full 
complement of peripheral γδ T cells initially present. Thus, stable expression of 
CAR can be achieved without prior T-cell propagation, enabling us to 
investigate if a population of T cells expressing polyclonal TCRγδ chains could 
then be numerically expanded in a CAR-dependent manner on designer artificial 
antigen presenting cells (aAPC). PBMC were electroporated (Day 0) with SB 
transposon/transposase system to enforce expression of a second generation 




CD19-specific CAR (CD19RCD28)(57) that signals through chimeric CD28 and 
CD3ζ. Electroporated cells were sorted using paramagnetic beads to separate the 
4.0% ± 1.5% (mean ± standard deviation (SD); n = 4)  CAR+ γδ T cells from the 
majority of CAR+ αβ T cells. The CAR+ γδ T cells were selectively propagated 
by the recursive additions of γ-irradiated K562-derived aAPC (clone #4, 
genetically modified to co-express CD19, CD64, CD86, CD137L, and 
membrane bound IL15)(57) with soluble IL2 and IL21. IL21 is included in the 
manufacture of our CAR+ αβ T cells so it was used to propagate CAR+ γδ T 
cells.(57) Prior experiments predicted that IL2 and IL15 enhance the 
proliferative potential of γδ T cells, and synergy between IL2 and IL21 has led 
to improved anti-tumor activity compared with γδ T cells grown with either IL2 
or IL21 alone.(174, 178, 307-309) Sham electroporations were undertaken to 
provide staining control T cells that were propagated by cross-linking CD3 
using aAPC loaded with OKT3 to numerically expand CARneg αβ T cells.(310) 
As expected, CAR was expressed on the day following electroporation (Day 1) 
in most of the T cells, including γδ T cells, which comprised up to 10% of the 
mononuclear cells (Figure 19a, left). After 36 days of co-culture on aAPC, the 
majority of cells co-expressed CD3 and TCRγδ with 30.7% ± 23.3% (n = 4) 
CAR expression (Figure 19a, right). The absolute CAR proportions at Day 36 
varied in frequency depending on the donor, but increased compared to the 
initial populations of CAR+ γδ T cells at Day 1 (Figure 19b). As we have 
demonstrated, our aAPC co-culture system enforces CAR expression in αβ T 
cells (>90% CAR+ T cells by 28 days of co-culture),(57) but the apparent lack of 




the same degree of selective pressure when combined with γδ T cells was 
attributed to an inherent ability of CARneg γδ T cells to sustain proliferation on 
aAPC derived from K562. Continuous proliferation of both CARneg and CAR+ 
γδ T cells was observed over the tissue culture period. Even so, we could 
generate up to 1.5x109 ± 1.2x109 (n = 3) CAR+ γδ T cells from the 2.8x105 ± 
1.5x105 (n = 3) CAR+ γδ T cells at the start of the culture (Figure 19c). Most of 
the propagated cells co-expressed CD3 and TCRγδ, but did not express TCRαβ 
(Figure 19d). These data demonstrate that aAPC could be used to sustain 
proliferation of CAR+ T cells co-expressing TCRγδ. 
  





Figure 19. CAR+ γδ T cells Propagate on Designer aAPC. (a) Transient (Day 
1) and stable (Day 36) expression of CAR in T cells (top) and γδ T cells 
(bottom) in mock electroporated (“no DNA”) or CD19-specific CAR 
electroporated cells (CD19RCD28). (b) Percentage of CAR+ γδ T cells in the 
culture as transient (Day 1) and stable (Day 36) expression where each shape 
represents an individual donor. (c) Rate of expansion of total γδ T cells 
(triangles), CARneg γδ T cells (squares), and CAR+ γδ T cells (circles) over 
tissue culture period following paramagnetic bead sorting (open arrow) and 
recursive stimulation (closed arrows) with aAPC and exogenous IL2 and IL21 
administration. (d) Percentage-positive cells and mean fluorescence intensity of 
CD3, CAR, TCRαβ, and TCRγδ at day 36. Data are mean ± SD (n = 4) and 
quadrant percentages of flow plots are in upper right corner. This work was 
originally published in Molecular Therapy. Deniger, D. C., K. Switzer, T. Mi, 
S. Maiti, L. Hurton, H. Singh, H. Huls, S. Olivares, D. A. Lee, R. E. Champlin, 
and L. J. Cooper. 2013. Bispecific T-cells Expressing Polyclonal Repertoire of 
Endogenous gammadelta T-cell Receptors and Introduced CD19-specific 
Chimeric Antigen Receptor. Mol Ther. 21(3): 638-647.(311) © Nature 
Publishing Group 
  




III.C.2. Immunophenotype of Numerically Expanded CAR+ γδ T cells 
Multi-parameter flow cytometry was used to gate on CAR+ T cells and analyze 
their expression of cell surface markers (Figure 20). TCRγδ was expressed at 
high and low densities (Figure 20a, top). CD56, a marker of MHC-unrestricted 
lytic ability,(287) was also expressed on T cells, but the culture contained <1% 
CD3negCD56+ NK cells and <1% CD3+Vα25TCR+ NKT cells (data not shown). 
In contrast to αβ T cells, no CAR+ γδ T cells expressed CD4, some were CD8+, 
but most were CD4negCD8neg, which is consistent with what is known for γδ T 
cells.(286) The relative frequencies for each donor are shown in Figure 20b. 
Markers associated with memory, e.g., CD27, CD28, CD62L, and CCR7, were 
expressed by CAR+ γδ T cells (Figure 20a, bottom). Both naïve (CD45RA) and 
antigen-experienced (CD45RO) cells were present after propagation on aAPC, 
and the T cells were not exhausted as measured by low expression of CD57 
(Figure 20b). In aggregate, cultures contained a heterogonous mixture of naïve 
(CD45RA+CD27+CD28+CCR7+; 26.5% ± 6.2%), central memory 
(CD45RAnegCD27+CD28+CCR7+; 7.8% ± 3.6%), effector memory 
(CD45RAnegCD27+CD28negCCR7neg; 10.1% ± 5.4%), and EMRA 
(CD45RA+CD27negCD28negCCR7neg; 7.6% ± 3.4%) T-cell phenotypes.(131, 
289) Co-stimulation by enforced expression of CD86 and CD137L (4-1BBL) on 
aAPC may be important for CAR+ γδ T-cell numeric expansion due to 
expression of their receptors CD28 and CD137 (4-1BB), respectively. 
Molecules associated with homing to bone marrow (cutaneous lymphocyte 
antigen (CLA) and CXCR4) and lymph nodes (CD62L and CCR7) were present 




on CAR+ γδ T cells suggesting that they could migrate to sites known to harbor 
leukemia. In sum, propagated CAR+ γδ T cells expressed T cell-associated 
surface markers that indicate desired potential for memory and homing. 
  





Figure 20. Immunophenotype of Electroporated, Separated, and 
Propagated CAR+ γδ T cells. (a) Expression by flow cytometry of cell-surface 
markers associated with T cells and memory as gated on CD3+CAR+ cells. (b) 
Percentages of CAR+ T cells expressing T-cell markers where each shape 
represents a different donor. Data are mean ± SD (n = 4). Quadrant percentages 
of flow plots are in upper right corner. This work was originally published in 
Molecular Therapy. Deniger, D. C., K. Switzer, T. Mi, S. Maiti, L. Hurton, H. 
Singh, H. Huls, S. Olivares, D. A. Lee, R. E. Champlin, and L. J. Cooper. 2013. 
Bispecific T-cells Expressing Polyclonal Repertoire of Endogenous gammadelta 
T-cell Receptors and Introduced CD19-specific Chimeric Antigen Receptor. 
Mol Ther. 21(3): 638-647.(311) © Nature Publishing Group 
  




III.C.3. Direct TCR Expression Assay to Reveal γ and δ TCR Usage in CAR+ 
γδ T cells 
We sought to determine that aAPC-propagated CAR+ T cells were indeed bi-
specific as defined by the presence of a polyclonal population of TCRγδ alleles. 
Up to now, it has been difficult to determine the pattern of expression of the γ 
and δ TCR chains. Therefore, we adapted our DTEA to assess the complete 
TCRγδ transcriptome. This approach takes advantage of the nCounter assay 
system to measure multiple bar-coded genes in a single reaction with high 
sensitivity and linearity across a broad range of expression.(312) A multiplexed 
CodeSet was designed with two sequence-specific probes for each allele to 
evaluate TCRγδ isotypes. The DTEA was initially validated using Zol to 
preferentially propagate Vγ9Vδ2 cells from PBMC and, as expected, the 
resultant TCR usage was dominated by both Vδ2 and Vγ9 at protein (Figure 
21a) and mRNA levels (Figure 21b and 21c). A second validation employed 
antibodies directed against γδ T-cell subsets (Vδ1 and Vδ2; no commercially 
available antibodies to Vδ3) to measure their mRNA expression. Vδ1negVδ2neg, 
Vδ1+Vδ2neg, and Vδ1negVδ2+ cells were sorted from CARneg T cells (to 
maximize the number of Vδ2 cells recovered by fluorescence-activated cell 
sorting, FACS) and subjected to DTEA (Figure 22a). As expected, Vδ1+Vδ2neg, 
Vδ1negVδ2+, and Vδ1negVδ2neg expressed Vδ1*01, Vδ2*02, and Vδ3*01 mRNA 
species, respectively (Figure 22b). These two strategies supported the validity 
of the DTEA panel enabling the identity of TCRγδ to be determined in CAR+ T 




cells. Therefore, we measured the mRNA levels for all three Vδ alleles as 
present in electroporated, separated, and propagated CAR+ γδ T cells which 
correlated with multi-parameter flow cytometry on gated CAR+ T cells to reveal 
the frequencies of Vδ subsets based on protein expression. The three Vδ 
populations were present in ascending frequency (Vδ1>Vδ3>>>Vδ2) in the 
electroporated and propagated T cells (Figure 22c). CARneg γδ T cells displayed 
similar frequencies of Vδ TCR usage as CAR+ γδ T cells. DTEA array also 
assessed Vγ usage, which is of particular utility because only one antibody 
against Vγ9 is commercially available, thus limiting the tools with which to 
detect Vγ usage. Of note, Vγ2, Vγ7, Vγ8 (both alleles), Vγ9, and Vγ10 were 
present in CAR+ T-cell cultures (Figure 22d). A lack of commercially-available 
antibodies prevented assessment of pairing between individual Vδ and Vγ chains 
on the T cells. The TCR usage described for γδ T cells was that which was 
present at the time of functional assays. Our ability to digitally quantify the 
presence of mRNA species enabled us to determine that the propagated CAR+ T 
cells expressed a polyclonal population of TCRγδ chains. 
  





Figure 21. Distribution of Vδ and Vγ in γδ T cells Expanded on 
Aminobisphosphonate. (a) Representative flow cytometry plot from T cells 
following 36 days of numeric expansion with Zol. (b) Vδ and (c) Vγ allele 
mRNA expression in Zol-expanded T cells. Data are mean ± SD (n = 3). 
Quadrant frequencies of flow plot are displayed. This work was originally 
published in Molecular Therapy. Deniger, D. C., K. Switzer, T. Mi, S. Maiti, 
L. Hurton, H. Singh, H. Huls, S. Olivares, D. A. Lee, R. E. Champlin, and L. J. 
Cooper. 2013. Bispecific T-cells Expressing Polyclonal Repertoire of 
Endogenous gammadelta T-cell Receptors and Introduced CD19-specific 
Chimeric Antigen Receptor. Mol Ther. 21(3): 638-647.(311) © Nature 
Publishing Group 
  





Figure 22. Distribution of Vδ and Vγ in CAR+ γδ T cells. (a) Representative 
FACS of Vδ populations (top) into Vδ1negVδ2neg (left), Vδ1+Vδ2neg (middle), 
and Vδ1negVδ2+ (right) populations and (b) Vδ allele mRNA expression in 
sorted T cells. (c) Vδ1negVδ2neg, Vδ1+Vδ2neg, and Vδ1negVδ2+ frequencies in 
gated CAR+ γδ T-cell populations from four donors. (d) Vγ allele mRNA 
expression in CAR+ γδ T cells. Data are mean ± SD (n = 3). Quadrant 
percentages of flow plots are in upper right corner. This work was originally 
published in Molecular Therapy Deniger, D. C., K. Switzer, T. Mi, S. Maiti, L. 
Hurton, H. Singh, H. Huls, S. Olivares, D. A. Lee, R. E. Champlin, and L. J. 
Cooper. 2013. Bispecific T-cells Expressing Polyclonal Repertoire of 
Endogenous gammadelta T-cell Receptors and Introduced CD19-specific 
Chimeric Antigen Receptor. Mol Ther. 21(3): 638-647.(311) © Nature 
Publishing Group  




III.C.4. T cells Produced Pro-inflammatory Cytokines in Response to 
Stimulation through Endogenous TCRγδ and Introduced CAR 
The functional activity of the CAR+ T cells was assessed by activation with 
leukocyte activation cocktail (LAC), which was comprised of PMA and 
Ionomycin. LAC mimics activation through TCR by simulating protein kinase C 
and increasing intracellular Ca2+ to activate phospholipase C (PLC). 
Measurement of secreted and intracellular cytokines (in the presence of the 
inhibitor GolgiPlug, which contains Brefeldin A) were performed on genetically 
modified T cells with and without LAC (Figure 23a and 23b). A broad range of 
cytokines were produced by γδ T cells, with the highest expression of IFNγ, 
TNFα, and chemokines MIP-1α, MIP-1β, and RANTES (Figure 23b). 
Interleukin-17 (IL17) has been shown to be important for anti-tumor efficacy of 
γδ T cells and this cytokine was secreted by CAR+ γδ T cells. These results 
suggest that TCRγδ can be activated to produce cytokines that could promote 
inflammation within the tumor. Next, CAR-specific cytokine production was 
assessed by activation using the murine T-cell lymphoma line EL4 and a 
genetically modified derivative to enforce expression of human CD19. Both 
TNFα and IFNγ were produced by CAR+ γδ T cells in response to CD19 
(Figure 23c). A less diverse repertoire of cytokines was secreted following CAR 
stimulation when compared with stimulation of TCRγδ, but IFNγ, TNFα, MIP-
1α, MIP-1β, and RANTES were all increased in response to activation through 
CAR (Figure 23d). In aggregate, pro-inflammatory cytokines were upregulated 
by bi-specific CAR+ γδ T cells through their TCR and CAR.  





Figure 23. Bi-specific γδ T cells Produce Pro-inflammatory Cytokines when 
Endogenous TCR and Introduced CAR are Stimulated. (a) CAR+ γδ T cells 
at Day 35 of co-culture on aAPC were stimulated for 4 hours with a mock 
cocktail (media alone) or Leukocyte Activation Cocktail (LAC, 
PMA/Ionomycin) to induce TCR stimulation and then analyzed by flow 
cytometry. CAR+ T cells were gated and tumor necrosis factor-α (TNFα, top) 
and interferon-γ (IFNγ, bottom) production is shown. (b) Luminex array (27-
Plex) of cytokines secreted by CAR+ γδ T cells in conditions described in (a). 
(c) Similar to (a) except that EL4-CD19neg and EL4-CD19+ were used instead of 
Mock/LAC. (d) Same as (b) but with EL4-CD19neg and EL4-CD19+ targets. 
Student’s t-test for statistical analysis between (b) Mock and LAC and (d) EL4-
CD19neg and EL4-CD19+ where *p<0.05, **p<0.01, and ***p<0.001. Data are 
representative of four donors for (a) and (c) and mean ± SD (n = 3) for (b) and 
(d). This work was originally published in Molecular Therapy. Deniger, D. 
C., K. Switzer, T. Mi, S. Maiti, L. Hurton, H. Singh, H. Huls, S. Olivares, D. A. 
Lee, R. E. Champlin, and L. J. Cooper. 2013. Bispecific T-cells Expressing 
Polyclonal Repertoire of Endogenous gammadelta T-cell Receptors and 
Introduced CD19-specific Chimeric Antigen Receptor. Mol Ther. 21(3): 638-
647.(311) © Nature Publishing Group 
  




III.C.5. CAR+ γδ T cells Exhibit Enhanced Anti-tumor Effects against CD19+ 
Targets in vitro 
It was anticipated that γδ T cells would display endogenous cytotoxicity to 
leukemia cells. Therefore, γδ T cells without CAR were numerically expanded 
on aAPC in order to test their anti-leukemia activity. Human CD19+ B-ALL cell 
lines (REH, Kasumi2, and Daudi genetically modified to express β2M) were 
lysed by CARneg γδ T cells while primary, healthy CD19+ B cells were not killed 
by the same effectors (Figure 24a). However, not all B-ALL cell lines were 
susceptible to efficient lysis by CARneg γδ T cells. In particular, EL4 and 
NALM6 cells were largely resistant to cytolysis by γδ T cells. Thus, the ability 
of the CD19-specific CAR to amplify the inherent anti-tumor activity of γδ T 
cells was investigated. Enforced expression of CD19 on the surface of EL4 cells 
improved targeting and killing of this cell line by CAR+ γδ T cells at 
significantly higher (p = 0.0001) levels compared with the parental CD19neg EL4 
cell line (Figure 24b). Similarly, CAR+ γδ T cells exhibited improved ability (p 
= 0.001) to kill CD19+ NALM6 cells compared with CARneg γδ T cells (Figure 
24c). In summary, the introduced CAR enhanced the specific killing capability 
of genetically modified γδ T cells. 
  





Figure 24. Specific lysis of CD19+ Tumor Cell Lines by CAR+ γδ T cells. (a) 
Standard 4-hour CRA of (a) CARneg γδ T cells against CD19+ B-ALL cell lines 
(REH, Kasumi2, and Daudi-β2M) or primary CD19+ B cells from autologous 
(Auto) or allogeneic (Allo) donors, (b) CAR+ γδ T cells against EL4-CD19neg 
(open squares) and EL4-CD19+ (closed squares) tumor cells, and (c) CARneg γδ 
T cells (open squares) and CAR+ γδ T cells (closed squares) against CD19+ 
NALM6 tumor cells. Data are mean ± SD from four healthy donors (average of 
triplicate measurements for each donor) that were pooled from two independent 
experiments. This work was originally published in Molecular Therapy. 
Deniger, D. C., K. Switzer, T. Mi, S. Maiti, L. Hurton, H. Singh, H. Huls, S. 
Olivares, D. A. Lee, R. E. Champlin, and L. J. Cooper. 2013. Bispecific T-cells 
Expressing Polyclonal Repertoire of Endogenous gammadelta T-cell Receptors 
and Introduced CD19-specific Chimeric Antigen Receptor. Mol Ther. 21(3): 
638-647.(311) © Nature Publishing Group 
  




III.C.6. CAR+ γδ T cells can Target CD19+ Tumor in vivo  
The ability of electroporated and propagated γδ T cells to target CD19+ tumor 
was then investigated in vivo. NALM6 is an aggressive CD19+ B-cell leukemia 
model and immunocompromised mice engrafted with 105 NALM6 are moribund 
in 20 to 25 days when untreated. Control of disseminated NALM6 tumor in vivo 
is dependent on the infused T cells homing to tumor and activating cytolytic 
machinery in the tumor microenvironment. After adoptive immunotherapy, the 
burden of tumor was significantly decreased in mice receiving CAR+ γδ T cells 
(Donor#4 from Figure 22c) compared to untreated mice (Figure 25). Mice in 
treatment group receiving CAR+ T cells displayed fewer characteristics of the 
untreated and thus unwell mice, which included lethargy, ruffled coat, 
temporary hind limb paralysis, and difficulty entering and exiting anesthesia at 
late stages of the experiment. A uniform date for euthanasia was chosen to 
measure the anti-tumor effect based on flow cytometry for NALM6 in lymphoid 
tissue. There was significant anti-tumor activity by the CAR+ γδ T cell as 
measured by bioluminescent imaging (BLI) of NALM6-eGFP-ffLuc (Figure 
25b) as exemplified at 22 days after injection of tumor (Figure 25c). Non-
invasive imaging was corroborated by analysis of presence of tumor cells at 
necroscopy. Mice that received CAR+ γδ T cells exhibited significant reductions 
in tumor burden (CD19+eGFP+) in the bone marrow, spleen, and peripheral 
blood (Figure 25d and 25e). These data reveal that polyclonal CAR+ γδ T cells 
exhibit therapeutic activity in vivo.  





Figure 25. In vivo Anti-tumor Activity of CAR+ γδ T cells. (a) Schematic of 
experiment. (b) BLI derived from eGFP+ffLuc+CD19+ NALM-6 tumor and (c) 
representative images of mice at day 22. (d) Post-mortem analysis of tissues and 
blood where tumor cells (CD19+eGFP+) were detected by flow cytometry. (e) 
Representative flow plots from (d). Data are mean ± SD (n = 3 to 5 mice per 
group, representative of two independent experiments) and gating frequencies in 
(e) are displayed. The percentage of tumor cells is derived from detecting 
CD19+eGFP+ NALM-6 by flow cytometry from post-mortem samples. Statistics 
performed with (b) two-way ANOVA with Bonferroni’s post-tests and (d) 
Student’s t-test between treated and untreated mice. **p<0.01 and ***p<0.001 
This work was originally published in Molecular Therapy. Deniger, D. C., K. 
Switzer, T. Mi, S. Maiti, L. Hurton, H. Singh, H. Huls, S. Olivares, D. A. Lee, 
R. E. Champlin, and L. J. Cooper. 2013. Bispecific T-cells Expressing 
Polyclonal Repertoire of Endogenous gammadelta T-cell Receptors and 
Introduced CD19-specific Chimeric Antigen Receptor. Mol Ther. 21(3): 638-
647.(311) © Nature Publishing Group 
  





III.D.1. Polyclonal Bi-specific T cells for Immunotherapy 
We established that introduction of a 2nd generation CAR could (i) drive the 
numeric expansion of T cells independent of usage of TCRγδ chains and (ii) 
augment the lytic potential of CD19+ tumors by γδ T cells. Propagating bi-
specific CAR+ T cells with a broad diversity of TCRγδ chains is desirable based 
on their therapeutic potential. Indeed, γδ T cells other than those expressing 
Vγ9Vδ2 have been generated from PBMC using TCRγδ-specific and CD3-
specific mAbs.(313-315) These prior approaches did not comprehensively 
measure TCRγδ isotype expression nor did they yield Vδ1 and Vδ3 at 
frequencies as high as seen in this study. The Vγ2 TCR chain was detected on 
our T cells, which has been described to pair with Vδ2, and these T cells can 
have antigen presentation capabilities.(166) Our CAR+ γδ T cells expressed 
molecules consistent with antigen presentation, e.g., CD86, CD137L, and HLA-
DR (data not shown), and Vγ9Vδ2 cells have served as aAPC for αβ T 
cells.(298) Future experiments will investigate if our polyclonal CAR+ γδ T cells 
also have an ability to serve as aAPC. Also present were T-cell sub-populations 
expressing Vγ7, and Vγ8, and Vγ10, where the first two chains have been 
associated with intestinal intraepithelial lymphocytes (iIEL)(316, 317) and the 
latter chain’s functional significance is not yet apparent. In all, our approach is 
the first to report expansion of CAR+ T cells that maintained a polyclonal 
TCRγδ expression. 




III.D.2. Changes Observed in Vδ Populations Following Expansion on aAPC  
The repertoire of TCRγδ chains employed by CAR+ T cells was similar to the 
initial pool of γδ T cells in PBMC with two exceptions. We noted an increase in 
Vδ3 usage, but this may be advantageous as it is associated with specificity for 
viruses that could offer enhanced immune responses to viral infections in 
immunocompromised patients receiving therapy.(165) A decrease in Vγ9Vδ2 
usage was also observed compared to the starting frequency of this TCR in 
PBMC, but this could potentially be increased by priming aAPC with Zol to 
increase Vγ9Vδ2 ligand expression in the co-culture. Whether this loss of 
Vγ9Vδ2 TCR expression was due to preferential activation induced cell death or 
selective out-growth of T cells expressing Vδ1 and Vδ3 TCR is not known. 
Nonetheless, Vγ9Vδ2 chains were still present in the final T-cell cultures 
indicating that aminobisphosphonate therapy could drive expansion of this 
subset of T cells after administration. 
 
III.D.3. Improvements upon CAR Expression on γδ T cells 
Recombinant retroviruses have been previously employed to achieve stable 
expression of CARs in γδ T cells, but this required using an 
aminobisphosphonate to achieve numeric expansion of T cells before 
transduction.(175, 318) We now demonstrate propagation of T cells after, rather 
than before, gene transfer using SB-mediated transposition results in a 




polyclonal population of bi-specific γδ T cells capable of CAR-mediated (i) 
production and secretion of pro-inflammatory cytokines in response to CD19, 
(ii) enhanced lysis of CD19+ tumor targets, and (iii) in vivo anti-tumor activity 
against a CD19+ tumor. The ability of these T cells to exhibit effector functions 
was not correlated to a particular Vδ or Vγ usage as cells with different Vδ TCR 
frequencies (Figure 22c) produced the same cytokines (Figure 23) and 
displayed similar cytolysis of CD19+ targets (Figure 24b). We noted that 
frequency of CAR expression was more variable on γδ T cells compared with 
αβ T cells. This was likely due to an endogenous ability of K562 cells to sustain 
proliferation of γδ T cells independent of CAR. Nevertheless, adoptive transfer 
of γδ T cells of which 60% expressed CAR could still yield the same in vitro 
lytic ability as 98% CAR+ γδ T cells (Figure 26). This indicated that (i) CAR+ 
γδ T cells are potent tumor killers and (ii) >90% CAR expression may not be a 
critically limiting parameter for predicting therapeutic efficacy. Nonetheless, we 
are undertaking improvements to increase the expression of CAR on propagated 
γδ T cells. Furthermore, the chimeric signaling molecules in the CAR 
endodomain could be specifically designed to enhance triggering of γδ T cells. 
For example, γδ T cells can be activated through FcγRIIIA (CD16) in the TCR 
complex,(319) which raises the possibility that signaling through chimeric FcRγ 
(as compared with CD3ζ in our current design) in a CAR endodomain may 
improve activation. However, CD16 was not detected on CAR+ γδ T cells in this 
study (data not shown). Since clinical responses against CD19+ lymphocytic 
leukemia have been achieved with T cells expressing a CAR that signaled 




through 4-1BB (CD137) endodomain,(7, 32) another option is to swap CD28 for 
CD137 for activation of γδ T cells. 
  





Figure 26. Specific Lysis of CD19+ Tumor Cell Lines by CAR+, CAR++, and 
CAR+++ γδ T cells. (a) Phenotype of T cells at day 19 of co-culture either 
unsorted (left) or from CAR sorting at day 15 where CARneg and CAR+ fractions 
are displayed in the middle and right, respectively. Four-hour CRA (Day 19 of 
co-culture on aAPC) of γδ T cells genetically modified to enforce expression of 
CD19-specific CAR with 6% (CAR+, circles), 60% (CAR++, triangles), and 98% 
(CAR+++, squares) expression of CAR targeting (b) EL4-CD19neg, (c) EL4-
CD19+, and (d) CD19+ NALM-6 tumor cells. Data are mean ± SD (n = 3). 
Quadrant frequencies of flow plots are displayed. This work was originally 
published in Molecular Therapy. Deniger, D. C., K. Switzer, T. Mi, S. Maiti, 
L. Hurton, H. Singh, H. Huls, S. Olivares, D. A. Lee, R. E. Champlin, and L. J. 
Cooper. 2013. Bispecific T-cells Expressing Polyclonal Repertoire of 
Endogenous gammadelta T-cell Receptors and Introduced CD19-specific 
Chimeric Antigen Receptor. Mol Ther. 21(3): 638-647.(311) © Nature 
Publishing Group  




III.D.4. Improvements on Type of γδ T cell used for CAR Immunotherapy 
In addition to improving CAR expression on γδ T cells, the type of γδ T cell 
arising after electroporation with SB system and propagation on aAPC could be 
manipulated to further improve anti-tumor activity. For instance, some γδ T cells 
were observed to secrete IL17, a pro-inflammatory cytokine that has potent, yet 
context-dependent, anti-tumor effects.(320-324) IL17 producing lineages of T 
cells can be mutually exclusive from those that secrete IFNγ.(325) Inducible co-
stimulator of T cells (ICOS) leads to IL17 polarization in CD4+ T cells and 
CD28 co-stimulation overcame this effect to dictate that CD4+ T cells now 
produce IFNγ.(326) CD86 is one of the co-stimulatory molecules on our aAPC 
and the majority of CAR+ γδ T cells secrete IFNγ in response to CD19 with 
diminished production of IL17. Furthermore, the CAR contains a chimeric 
CD28 endodomain which may contribute to IFNγ polarization in genetically 
modified T cells. Substitution of chimeric CD28 for ICOS in the CAR and 
replacement of CD86 on the aAPC with ICOS-ligand (ICOSL) could potentially 
reverse the polarization to IL17. Given that we can propagate CAR+ γδ T cells 
on aAPC we are prepared to design aAPC to evaluate whether we can skew the 








III.D.5. Clinical Significance of Bi-specific T cells 
The human application of CAR+ γδ T cells is appealing given their inherent 
potential for anti-tumor effects and their apparent lack of alloreactivity.(304) 
The CAR, SB system, and aAPC are all already in use in our clinical trials. 
Therefore, we plan to modify our manufacturing scheme in compliance with 
current good manufacturing practice to generate bi-specific CAR+ γδ T cells. 
Our data provides a clinically-appealing approach to numerically expand and 
manipulate CAR+ T cells with multiple Vγ and Vδ pairings enabling clinical 
trials to evaluate their therapeutic potential.” 
 
This work was adapted from published work in Molecular Therapy. Deniger, D. C., 
K. Switzer, T. Mi, S. Maiti, L. Hurton, H. Singh, H. Huls, S. Olivares, D. A. Lee, R. E. 
Champlin, and L. J. Cooper. 2013. Bispecific T-cells Expressing Polyclonal Repertoire 
of Endogenous gammadelta T-cell Receptors and Introduced CD19-specific Chimeric 
Antigen Receptor. Mol Ther. 21(3): 638-647.(311) © Nature Publishing Group 
  





Artificial Antigen Presenting Cells Propagate Polyclonal Gamma Delta T cells with 
Broad Anti-tumor Activity 
 
IV.A. Hypothesis and Rationale 
 The hypothesis of this chapter is that aAPC will expand polyclonal γδ T cells 
that will have broad anti-tumor immunity. The rationale for this chapter is that (i) 
CARneg polyclonal γδ T cells proliferated in parallel to CAR+ γδ T cells described in 
Chapter III on aAPC, (ii) no current expansion protocols exist for polyclonal γδ T cells 
for the clinic, (iii) aAPC are currently in clinical trials and are available as a master cell 
bank in the manufacturing facility at MD Anderson, (iv) γδ T cells expressing Vδ1 are 
correlated with long-term remissions in cancer therapy but have not been directly 
infused as an adoptive immunotherapy, (v) γδ T cells expressing Vδ2 have shown anti-
tumor effects as direct adoptive immunotherapies, (vi) γδ T cells expressing Vδ3 have 
not been described to have direct anti-tumor immunity leaving a gap in the field of 
knowledge, and (vii) a polyclonal approach to γδ T cell immunotherapy could target 
multiple ligands on the tumor through a diverse repertoire of TCRγδ. Therefore, 
development of an expansion protocol to generate clinically-relevant numbers of 
polyclonal γδ T cells would have implications as both cancer immunotherapies and for 
immunologists studying γδ T cells. 
 





Human γδ T cells exhibit inherent anti-tumor activity and hold promise for 
immunotherapy of cancer. They are distinguished by the heterodimeric pairing of γ and 
δ T-cell receptor (TCR) chains from the more prevalent αβ T cell lineage (~95% of 
circulating T cells), which are defined by TCRα/TCRβ heterodimers.(327) 
TCRαβ recognizes peptide complexed with MHC but TCRγδ ligands are recognized 
independent of MHC restriction.(141, 146, 152) Many of these ligands are present on 
cancer cells, thus raising the possibility that a culturing approach to propagating T cells 
that maintains a polyclonal repertoire of γδ TCRs may have appeal for human 
application. 
γδ T cells represent 1% to 5% of the T-cell pool in peripheral blood, and many 
standard T cell expansion protocols are not applicable to γδ T cells.(314, 328) 
Proliferation of monoclonal γδ T cell populations (Vγ9Vδ2) can be sustained with 
aminobisphosphonates, e.g. Zol, and clinical trials investigating their anti-tumor 
efficacy have yielded objective responses treating both solid and hematological 
cancers.(175, 179, 301) However, this subset of γδ T cells was not curative as a stand-
alone therapy.(318) Novel polyclonal γδ T cell expansion protocols are needed to 
improve upon these findings, but are lacking in clinically-relevant methods to expand 
multiple γδ T cell subsets in one cellular therapy product. 
Since many ligands that signal through γδ TCR are unknown, we hypothesized 
that a tumor cell line may serve as a cellular substrate for activating these T cells and 
sustaining their proliferation. aAPC are used to stimulate CAR+ T cell growth ex vivo 




and are derived from K562 cells, a natural cytolytic target of γδ T cells.(57, 280, 310, 
329) As seen in Chapter III, CAR-modified γδ T cells expanded on aAPC while 
expressing multiple TCRγδ alleles and displayed enhanced cytolysis to antigen-positive 
tumors.(311) Moreover, γδ T cells not expressing CAR were present in CAR+ γδ T cell 
cultures in high frequencies (Figure 19a, bottom right panels). Therefore, we 
hypothesized that γδ T cells could expand on aAPC independent of CAR+ T cells and 
that these γδ T cells would maintain a polyclonal TCRγδ repertoire. Given that the 
aAPC are available as a master-cell bank, these data provide a translational pathway for 
adapting γδ T cells for human application. Thus, this could be the first time that 
polyclonal γδ T cells could be used for cancer immunotherapy. 
 
IV.C. Results 
IV.C.1. Propagation of γδ T cells on aAPC 
As seen in Chapter III, aAPC clone#4 sustained the proliferation of γδ T cells in 
cultures containing CD19-specific CAR+ γδ T cells.(311) To assess whether γδ T cells 
could numerically expand on aAPC without expression of CAR, quiescent γδ T cells 
were isolated from peripheral blood and stimulated by recursive additions of γ-
irradiated aAPC clone#4 in presence of IL2 and IL21 (Figure 27a).  It was observed 
that γδ T cells represented a small fraction of PBMC (3.2% ± 1.2%; mean ± SD; n = 4), 
but after 22 days of co-culture on aAPC the cultures contained a homogeneous 
population of γδ T cells (97.9% ± 0.6%) as assessed by co-expression of CD3 and 




TCRγδ (Figure 27b). Cultures yielded >109 γδ T cells from <106 total cells in three 
weeks of co-culture (Figure 27c), which represented a 4.9x103 ± 1.7x103 fold increase 
over a 22-day culture period. Although γδ T cells were rare in peripheral blood, they 
were readily sorted then expanded on aAPC to sufficient numbers for experiments and 
potential clinical application. 
  





Figure 27. Sustained Proliferation of γδ T cells on aAPC and IL2/21. (a) Schematic 
of experimental design where NK cells are in open shapes, αβ T cells are in light gray 
shapes, and γδ T cells are in dark gray shapes. Columns represent paramagnetic 
isolation. (b) Expression by flow cytometry of CD3 (y-axis) and TCRγδ (x-axis) in 
PBMC prior to isolation of γδ T cells isolation (Day 0) and after 22 days of co-culture 
on aAPC/IL2/IL21. One representative donor is shown and quadrant gate frequencies 
are displayed in the upper right corners of flow plots. (c) Total inferred cell counts of 
viable cells during co-culture period. Black lines are mean ± SD from 4 healthy donors, 
gray lines are individual donors, and arrows represent addition of γ-irradiated aAPC. 
 
  




IV.C.2. Roles for Co-stimulation and Cytokine Support in γδ T cell Proliferation on 
aAPC 
The mechanism of γδ T cell proliferation on aAPC was unknown. Addition of cytokines 
and co-stimulation by aAPC were likely candidates for supporting growth of on aAPC. 
In order to assess which surface molecules on the clone#4 aAPC (membrane-bound 
IL15 (mIL15), CD86, and CD137L) were important for γδ T cell expansion with IL2 
and IL21, parental K562 cells were genetically modified to express (i) mIL15 
(cloneA6), (ii) mIL15 and CD86 (clone A3), or (iii) mIL15 and CD137L (clone D4) and 
were subcloned for uniform transgene expression (Figure 28a). Co-cultures with 
exogenous IL2 and IL21 were initiated with γδ T cells and γ-irradiated (i) parental K562 
cells, (ii) clone A6 aAPC, (iii) clone A3 aAPC, (iv) clone D4 aAPC (Figure 28b), or (v) 
clone#4 aAPC (Figure 8 middle panels) in parallel with T cells receiving cytokines 
only. IL2 and IL21 in combination sustained limited γδ T cell proliferation, which was 
increased when K562 cells were added to co-cultures. Slightly less expansion was 
observed when either mIL15 or mIL15 and CD86 were added to K562 cells. However, 
significantly higher γδ T cell propagation was only observed with mIL15+CD137L+ and 
mIL15+CD86+CD137L+ aAPC over IL2 and IL21 alone. After establishing that co-
stimulation on aAPC was necessary for γδ T cell proliferation, IL2 and IL21 were added 
separately or in combination to assess their contribution to growth on clone#4 aAPC. 
No γδ T cell expansion was observed when both IL2 and IL21 were removed from co-
cultures, addition of IL2 alone resulted in more proliferation than IL21 alone, and 
combination of both IL2 and IL21 displayed additive growth of γδ T cells (Figure 28c). 




This validated our approach to use both IL2 and IL21 for maximum γδ T cell yield 
following co-culture on clone#4 aAPC and strongly suggested that both aAPC co-
stimulation and cytokine support were critical for maximum γδ T cell proliferation ex 
vivo.  





Figure 28. Co-stimulation and Cytokine Requirements for γδ T cell Expansion on 
aAPC ex vivo. (a) Surface phenotype of aAPC expressing single co-stimulatory 
molecules with membrane-bound IL15 (mIL15). (b) γδ T cell proliferation was 
measured after 10 days of growth with IL2 and IL21 on (i) no aAPC, (ii) parental K562 
cells, (iii) mIL15+ aAPC (clone A6), (iv) mIL15+CD86+ aAPC (clone A3), (v) 
mIL15+CD137L+ aAPC (clone D4), or (vi) clone#4 aAPC. All aAPC were γ-irradiated 
prior to co-culture. (c) Co-cultures were initiated with clone#4 aAPC and either (i) no 
cytokines, (ii) 50 U/mL IL2, (iii) 30 ng/mL IL21, or (iv) 50 U/mL IL2 and 30 ng/mL 
IL21. Fold changes were calculated relative to the input cell numbers. Two-way 
ANOVA with Bonferroni’s post-tests was used for statistical analysis. *p<0.05 and 
**p<0.01 
  




IV.C.3. UCB-derived γδ T cells Expansion on aAPC  
Umbilical cord blood (UCB) is a source of γδ T cells with unique use for 
immunotherapy because they have limited immunological education and thus potential 
utility in allogeneic settings. Moreover, UCB-derived γδ T cells should have a younger 
phenotype and could (theoretically) have a longer range of responsiveness before 
anergizing or undergoing senescence. However, UCB has limited volumes and γδ T 
cells are a small fraction of an already limited resource. Fluorescence activated cell 
sorting (FACS) was used to isolate γδ T cells in order to maximize yields and purity of 
this valuable resource. Indeed, clone#4 aAPC induced substantial proliferation of γδ T 
cells derived from UCB (Figure 29a). After 35 days of co-culture on clone#4 with IL2 
and IL21, there was a 10 million-fold increase in cell number as an average of 1011 
UCB-derived γδ T cells (Range: 6x109 – 3x1011; n = 5) were propagated from just 104 
γδ T cells at the start of the culture. Because few cells were isolated (104 per donor), 
two more stimulations were performed for UCB compared to PBMC to highlight their 
potential for proliferating to clinically relevant numbers. As expected, γδ T cell cultures 
were pure as assessed by uniform expression of CD3 (Figure 29b) and TCRγδ (Figure 
29c) without expression of TCRαβ (Figure 29d) or presence of CD3negCD56+ NK cells 
(Figure 29b). Collectively, these data demonstrate that aAPC clone#4 when used with 
IL2 and IL21 could sustain the proliferation of γδ T cells ex vivo from limited starting 
populations. 
  





Figure 29. Expansion of UCB-derived γδ T cells on aAPC. γδ T cells were sorted by 
FACS following staining with CD3 and TCRγδ and were stimulated weekly with 
clone#4 aAPC, IL2, and IL21 (a) Total inferred cell numbers from co-cultures where 
black line represents mean ± SD (n = 5) and gray lines are individual donors. Arrows 
represent stimulations with aAPC. Expression of (b) CD3 (y-axis) and CD56 (x-axis), 
(c) CD3 (y-axis) and TCRγδ (x-axis), and (d) TCRαβ (y-axis) and TCRγδ (x-axis) of 
one representative donor by flow cytometry after 5 weeks of expansion on aAPC with 
IL2 and IL21. Quadrant frequencies are displayed in upper right corners. 
  




IV.C.4. Frequency of γ and δ TCR Usage in aAPC-propagated γδ T cells 
Previously, CAR+ γδ T cells expanded on clone#4 aAPC maintained polyclonal 
repertoire of TCRγ and TCRδ chains, and γδ T cells proliferating in parallel to CAR+ γδ 
T cells also maintained polyclonal TCRγδ distribution (Chapter III).(311) Whether the 
aAPC-expanded γδ T cells would do the same was of great interest, because if so then 
this would represent the first ever clinically-viable approach to expand multiple γδ T 
cells subsets in one cellular product for cancer therapy. 
 
IV.C.4.a. Vδ and Vγ mRNA Expression 
Now that it is established that γδ T cells can expand on aAPC independently of CAR+ T 
cells (Figures 27, 28, and 29), the TCR isotype variable (V) region repertoire was 
evaluated at the mRNA level by DTEA. As anticipated, mRNA species for all three Vδ 
alleles were identified (Figure 30a) and Vγ2, Vγ5, Vγ7, Vγ8 (two alleles), Vγ9, Vγ10, 
and Vγ11 mRNA species were co-expressed in the aAPC-expanded γδ T cells from 
PBMC (Figure 30b). Similar polyclonal TCR expression of Vδ (Figure 30c) and Vγ 
(Figure 30d) was observed in γδ T cells expanded from UCB with fewer Vδ2 cells, 
more Vγ2 and Vγ5 cells, and presence of Vγ3 cells not seen in PBMC. Thus, aAPC are 
able to repeatedly expand γδ T cells with polyclonal TCR repertoire from both PBMC 
and UCB.   





Figure 30. Pattern of Vδ and Vγ mRNA Usage on aAPC-expanded γδ T cells. 
Quantification of mRNA species coding for (a) Vδ1*01, Vδ2*02, and Vδ3*01 alleles 
from left to right, respectively, and (b) Vγ alleles in PBMC-derived γδ T cells by DTEA 
at day 22 of co-culture on aAPC/IL2/IL21. Each circle represents an individual donor’s 
γδ T cells and lines show mean (horizontal) ± SD (vertical). Quantification of mRNA 
species coding for (c) Vδ and (d) Vγ alleles in UCB-derived γδ T cells by DTEA at day 
34-35 of co-culture on aAPC/IL2/IL21 as described for PBMC. Numbers correlate with 
identification of PBMC (1-4) and UCB (5-9) donors described further in Figure 31.  




IV.C.4.b. TCRγδ Surface Protein Expression 
After establishing Vγ and Vδ mRNA expression from a number of different isotypes, 
surface expression of TCRγ and TCRδ was investigated. However, there are only 3 
commercially available antibodies specific for individual TCRγδ isotypes, which are 
specific for TCRδ1, TCRδ2, and TCRγ9. As was seen in CAR+ γδ T cells, aAPC-
expanded γδ T cells from PBMC stained for all three Vδ populations 
(TCRδ1+TCRδ2neg, TCRδ1negTCRδ2+, and TCRδ1negTCRδ2neg), corroborating DTEA 
detection of Vδ1, Vδ2, and Vδ3 populations of γδ T cells, respectively (Figure 31a). 
Moreover, TCRδ expression frequencies followed the trend of TCRδ1>TCRδ3>TCRδ2, 
and most TCRδ2 chains paired with TCRγ9 (Figure 31b). Fewer TCRδ2 cells were 
seen in UCB-derived γδ T cells (Figure 31c) compared to PBMC-derived γδ T cells 
(Figure 31a), but UCB-derived γδ T cells followed the same TCRδ1>TCRδ3>TCRδ2, 
trend and most Vδ2 paired with Vγ9 as expected (Figure 31d). Analysis of other Vγ 
pairings with Vδ could not be performed because there are no other Vγ-specific 
commercially antibodies available. Thus, aAPC-expanded γδ T cells were polyclonal at 
both mRNA and protein levels, and this protocol therefore represents the first clinically-









Figure 31. TCRδ and TCRγ Isotype Surface Expression on aAPC-expanded γδ T 
cells. Expression by flow cytometry of (a) TCRδ2 (y-axes) and TCRδ1 (x-axes) and (b) 
TCRδ2 (y-axes) and TCRγ9 (x-axes) in PBMC-derived γδ T cells at day 22 of co-
culture on aAPC/IL2/IL21. Expression by flow cytometry of (c) TCRδ2 (y-axes) and 
TCRδ1 (x-axes) and (d) TCRδ2 (y-axes) and TCRγ9 (x-axes) in UCB-derived γδ T 
cells at day 35 of co-culture on aAPC/IL2/IL21. Numbers in lower right corners 
correlate with identification of PBMC (1-4) and UCB (5-9) donors also shown in 
Figure 30 and quadrant frequencies are displayed in upper right corners. 
  




IV.C.4.c. Validation of Vδ3 Subset and Vδ Lineage Propagation 
Little is known about the Vδ3 lineage of γδ T cells and no reports have been made to 
date about their role in anti-tumor immunity. Because this study has implications for 
showing the first ever evidence that this subset can mediate anti-tumor effects, further 
validation that the TCRδ1negTCRδ2neg cells were, in fact, Vδ3 cells was warranted. 
Complicating this matter is the fact that no commercially available antibodies for 
TCRδ3. However, an indirect means was successfully used by combining FACS and 
DTEA. As there are only three Vδ populations in humans and there are antibodies to 
two of the isoforms, a combination of DTEA and FACS was used to in two ways to 
confirm the various populations. First, γδ T cells expanded in the presence of CAR+ T 
cells (Chapter III) were sorted for TCRδ1+TCRδ2neg, TCRδ1negTCRδ2+, and 
TCRδ1negTCRδ2neg γδ T cells populations by FACS and they expressed only Vδ1*01, 
Vδ2*02, and Vδ3*01 mRNA, respectively (Figure 22a and 22b).(311) The second 
approach directly applied the same techniques to γδ T cells expanded on aAPC as 
described in Chapter IV without CAR+ T cells. Again, TCRδ1+TCRδ2neg, 
TCRδ1negTCRδ2+, and TCRδ1negTCRδ2neg populations isolated by FACS consisted 
primarily of Vδ1*01, Vδ2*02, and Vδ3*01 mRNA, respectively, and were therefore 
denoted Vδ1, Vδ2, and Vδ3, respectively (Figure 32a). It is important to note that 
Vδ1*01 only resulted in ~150 mRNA counts whereas Vδ2*02 and Vδ3*01 ranged in 
the ~1000-2000 mRNA count range (Figure 30), so the purity as measured by mRNA 
counts appeared to have contaminating Vδ1 cells in Vδ2 and Vδ3 populations but these 
populations were minor contributors in the Vδ1 population as measured by flow 




cytometry (Figures 32d and 32e). Furthermore, the FACS sorted Vδ1, Vδ2, and Vδ3 
populations were expanded on clone#4 aAPC in the presence of exogenous IL2 and 
IL21 as separate co-cultures populations and even after 15 days of isolated growth the 
same Vδ mRNA signatures were observed suggesting the cells remained pure during 
propagation (data not shown). As expected, all three Vδ populations proliferated well 
on aAPC as separate populations (Figure 32b), where fold increase capability was 
ranked as Vδ1>Vδ3=Vδ2 although there were no statistically different differences 
(Figure 32c). Indeed, there are more Vδ1 cells in polyclonal populations (Figures 30 
and 31), which may be due to a slight increase in their ability to proliferate on aAPC. 
Importantly, populations expressed the appropriate TCR alleles on the γδ T cell surface 
where Vδ1, Vδ2, and Vδ3 subsets were pure for TCRδ1+TCRδ2neg, TCRδ1negTCRδ2+, 
and TCRδ1negTCRδ2neg, respectively, after 15 days of isolated expansion on aAPC 
(Figure 32d and 32e). All separated Vδ subsets co-expressed CD3 and TCRγδ 
verifying that they were, in fact, γδ T cells (Figures 34a and 34b). Collectively, these 
results showed that (i) TCRδ1negTCRδ2neg γδ T cells contained the Vδ3 lineage, (ii) 
DTEA accurately measured Vδ mRNA, (iii) Vδ1, Vδ2, and Vδ3 lineages are stimulated 
by aAPC leading to their proliferation, and (iv) aAPC-expanded γδ T cells are truly 
polyclonal.   





Figure 32. Vδ Subset Separation, Propagation, and Resultant TCR Expression on 
Sorted T cells. PBMC were sorted for γδ T cells with paramagnetic beads and were 
expanded for 2 weeks on aAPC/IL2/IL21. They were then sorted into three populations 
(Vδ1, Vδ2, and Vδ3) by FACS. Separated populations were stimulated for 2 weeks on 
aAPC/IL2/IL21. (a) DTEA detection of Vδ1*01, Vδ2*02, and Vδ3*01 mRNA species 
in Vδ1, Vδ2, and Vδ3 subsets following FACS purification. (b) Proliferation of Vδ 
lineages on aAPC as separated populations. (c) Fold increases of each Vδ population 
where each shape represents a different donor. (d) Representative flow cytometry plots 
of TCRδ1 (x-axes) and TCRδ2 (y-axes) expression in Vδ1, Vδ2, and Vδ3 subsets (from 
left to right). Quadrant frequencies are displayed in upper right corner. (e) Frequencies 
of TCRδ1+TCRδ2neg, TCRδ1negTCRδ2+, and TCRδ1negTCRδ2neg cells in Vδ1, Vδ2, and 
Vδ3 subsets. Data are mean ± SD (n = 3-4). 
  




IV.C.5. Immunophenotype of γδ T cells Expanded on aAPC 
Functional outcomes, e.g. memory formation, homing to tissues, and effector 
mechanism, can be predicted by the expression of lymphocyte-specific proteins on the 
T cell surface. Thus, a panel of markers was used to identify the immunophenotype of 
γδ T cells cultures first as a polyclonal population to be used as therapy and then as 
sorted Vδ populations to gain insight into lineage differences. 
 
IV.C.5.a. Immunophenotype of Polyclonal γδ T cell Population 
The ultimate goal for the clinic is to use a polyclonal population of T cells for 
immunotherapy in order to have a multivariate approach to cancer immunotherapy, so 
extensive phenotyping of the γδ T cell surfaces was performed as a mixed Vδ 
population. After 22 days of co-culture on aAPC, few αβ T cells (TCRαβ) and NK cells 
(CD3negCD56+) were detected in the cultures where strong staining for γδ T cells 
(TCRγδ) was observed (Figure 33a). Most γδ T cells were CD4negCD8neg, as 
expected,(286) but some CD8 and CD4 expression was observed (Figure 33b). These T 
cells were highly activated as measured by expression of CD38 and CD95. IL2 
receptors (CD25; IL2Rα and CD122; IL2Rβ) were detected, but limited surface 
expression of IL7Rα (CD127) was identified. γδ T cells were not exhausted as 
evidenced by the absence of CD57 and PD1. Most cells expressed CD27 and CD28 co-
stimulatory ligands and had a preference towards antigen-experienced (CD45RO) over 
naïve (CD45RA) characteristics. Homing to the skin, lymph nodes, and bone marrow 




has potential as evidenced by CCR4, CXCR4/CLA, and CCR7/CD62L expression, 
respectively. In aggregate, the surface phenotypes of γδ T cells indicated that they were 
highly activated and antigen experienced with potential for memory formation and 
homing to tissues. 
  





Figure 33. Immunophenotype of Polyclonal γδ T cells Propagated on aAPC, IL2, 
and IL21. (a) Gating (one representative of four donors is shown) and (b) frequency of 
T cell surface makers by flow cytometry of T cells at Day 22 of culture. Lines show 
mean (horizontal) ± SD (vertical) and symbols represent individual donors. 
  




IV.C.5.b. Immunophenotype of Vδ1, Vδ2, and Vδ3 Subsets  
It is of interest to identify differences amongst Vδ1, Vδ2, and Vδ3 lineages that could 
enable us to predict functional responses and therapeutic efficacy. In particular, distinct 
differences were observed in TCRγδ cell surface density and memory-associated 
markers. TCRγδ often stained as a two populations with distinct MFI when co-stained 
with CD3 (Figure 27b). Separation of Vδ1, Vδ2, and Vδ3 subsets clearly identified 
Vδ2 as the low (43 ± 9; mean ± SD; n = 4), Vδ3 as the medium (168 ± 40), and Vδ1 as 
the high (236 ± 56) MFI populations in TCRγδ staining (Figure 34a). CD4 and CD8 are 
not commonly expressed on γδ T cells, but there were differences detected in limited 
surface expression of both CD4 and CD8 between the separated subsets (Figure 34b). 
Vδ1 and Vδ3 cells consistently expressed more CD4 and CD8 than did Vδ2 cells (p = 
0.001; Two-way ANOVA), and there were significantly more CD4+ Vδ1 and CD8+ Vδ3 
cells than CD4+ Vδ2 and CD8+ Vδ2 cells, respectively (Figure 34c and 34d). CCR7 
and CD62L mediate homing to the lymph nodes and other secondary lymphoid organs. 
CD8+ T cells expressing CCR7 and/or CD62L were described as TCM cells but 
CCR7negCD62Lneg were defined as TEM cells.(330, 331) Almost all Vδ1 and Vδ3 cells 
were CCR7+CD62Lneg, but larger proportions of Vδ2 cells were CCR7negCD62Lneg with 
roughly equal remaining proportions staining as single or double positive for CCR7 and 
CD62L, suggesting Vδ1 and Vδ3 were TCM and Vδ2  cells were mostly TEM (Figure 
34e). CD27 and CD28 are both memory markers for CD8+ T cells, especially in the 
absence of CD45RA, and have important roles as co-stimulatory molecules for T cell 
activation.(332) CD27 expression followed the order of Vδ1>Vδ3>Vδ2 but all were 




>80% CD27+ (Figure 34f y-axes). In contrast, there was almost no difference between 
the three Vδ populations in CD28 expression (Figure 34f x-axes). Human γδ T cell 
memory has been most extensively reported as combinations of CD27 and CD45RA 
expression where CD27+CD45RA+, CD27+CD45RAneg, CD27negCD45RAneg, and 
CD27negCD45RA+ correspond to TN, TCM, TEM, and TEMRA, respectively (Figure 
34g).(151, 333) Indeed, these were the markers that showed the most convincing 
differences between the Vδ populations although all subsets contained at least some of 
each population. More specifically, the most TN cells were Vδ1, the most TCM were 
Vδ3, the most TEM cells were Vδ2, and virtually no TEMRA were detected (Figure 34h). 
Given these differences in surface memory phenotype, different functional abilities 
were expected from the γδ T cell subsets and a polyclonal approach to adoptive T cell 
therapy could utilize these different attributes as needed. 
  





Figure 34. Immunophenotype of Vδ Lineages Propagated on aAPC, IL2, and IL21. 
After 15 days of proliferation as separated populations, Vδ1, Vδ2, and Vδ3 subsets 
were stained for lymphocyte markers. (a) Representative flow cytometry plots of CD3 
(x-axes) and TCRγδ (y-axes) expression in Vδ1, Vδ2, and Vδ3 subsets (from left to 
right). (b) Mean fluorescence intensities (MFI) of TCRγδ staining in Vδ1 (red), Vδ2 
(black), and Vδ3 (blue) subsets where each shape represents a different donor and data 
are mean ± SD (n = 4). (c) Representative flow cytometry plots of CD4 (x-axes) and 
CD8 (y-axes) expression in Vδ1, Vδ2, and Vδ3 subsets (from left to right) and (d) 
summary of frequencies in Vδ1 (red), Vδ2 (black), and Vδ3 (blue) cells where data are 
mean ± SD (n = 3) and each shape represents a different donor. Representative flow 
cytometry plots of (e) CCR7 (x-axes) and CD62L (y-axes), (f) CD28 (x-axes) and 
CD27 (y-axes), and (g) CD45RA (x-axes) and CD27 (y-axes) expression in Vδ1, Vδ2, 
and Vδ3 subsets (from left to right). Plots are representative of three normal donors. (h) 
Memory phenotypes based on CD27 and CD45RA displayed in lower right corner of 
Vδ3 in (g) where each shape represents a different donor and data are mean ± SD (n = 
3).  




IV.C.6. Polyclonal γδ T cells Secrete Pro-inflammatory Cytokines and Chemokines 
To determine whether γδ T cells would foster an inflammatory environment during 
therapy, a multiplex analysis (27-Plex Luminex) of cytokines and chemokines was 
performed on polyclonal γδ T cells following culture on aAPC. LAC and mock 
activation was used as described in Chapters II and III. There was no significant 
production of anti-inflammatory TH2 cytokines IL4, IL5, and IL13, and there was a 
small increase in IL10 production from baseline (Figure 35a). In contrast, IL1Ra, IL6, 
and IL17 were significantly secreted by γδ T cells and have roles together for TH17 
inflammatory responses (Figure 35b). Moreover, pro-inflammatory TH1 cytokines IL2, 
IL12 (p70), IFNγ, and TNFα were all significantly produced by γδ T cells when TCR 
was stimulated compared to mock stimulated controls (Figure 35c). High expression of 
chemokines CCL3 (macrophage inflammatory protein-1α; MIP1α), CCL4 (MIP1β), 
and CCL5 (regulated and normal T cell expressed and secreted; RANTES) were also 
detected (Figure 35d). CCR5 binds to all three of these chemokines,(334) but only 6% 
± 2% (mean ± SD; n = 4) of γδ T cells expressed this receptor. Nonetheless, recruitment 
of other immune cells expressing CCR5 is possible based on γδ T cell’s production of 
CCL3, CCL4, and CCL5. In aggregate, TCR stimulation in γδ T cells led to a largely 
pro-inflammatory response desired for cell-based cancer therapies. 
  





Figure 35. Cytokines and Chemokines Secreted by Polyclonal γδ T cells. At Day 22 
of culture on aAPC/IL2/21, T cells were incubated with complete media (mock) or 
leukocyte activation cocktail (LAC; PMA/Ionomycin) for 6 hours at 37oC. Conditioned 
media was interrogated on 27-Plex Luminex array to detect cytokines and chemokines. 
(a) TH2 cytokines, (b) TH17 cytokines, (c) TH1 cytokines, and (d) Chemokines. Data are 
mean ± SD from 4 healthy donors. Student’s t-test performed for statistical analysis 
between mock and LAC groups for each molecule. *p<0.05, **p<0.01, and ***p<0.001 
 
  




IV.C.7 TCRγδ Involvement in Vδ1, Vδ2, and Vδ3 Production of IFNγ 
After establishing that polyclonal γδ T cells produced pro-inflammatory cytokines upon 
non-specific TCR stimulation, it was of interest to evaluate whether they would respond 
to tumor cells through their TCRγδ. IFNγ was produced most highly of all the cytokines 
interrogated by Luminex (Figure 35c), so it was chosen as a marker for γδ T cell 
response to OvCa in a classical intracellular cytokine staining (ICS) assay. Co-cultures 
with polyclonal γδ T cells and two different OvCa cell lines were incubated at 37oC for 
6 hours in the presence of the secretory pathway inhibitor Brefeldin-A (GolgiPlug) in 
order to trap IFNγ within the T cells. Parallel co-cultures were set up with (i) normal 
mouse serum (NMS) for negative control or (ii) neutralizing TCRγδ antibody (clone 
IMMU510) for 1 hour prior to co-culture and during the duration of co-culture. Surfaces 
of T cells were stained for CD3, TCRδ1, and TCRδ2 in order to separate Vδ1, Vδ2, and 
Vδ3 populations from tumor cells (Figure 36a, 36b, and 36c). Tumor cells alone and T 
cells without tumor cells served as negative staining controls. As anticipated, each Vδ 
subset produced IFNγ in response to OvCa in the NMS (negative blocking control) 
treated cells (Figure 36d). Furthermore, the amount of IFNγ produced followed the 
order Vδ2>Vδ1>Vδ3 as evidenced by IFNγ MFI of 855 ± 475, 242 ± 178, and 194 ± 
182 (mean ± SD; n = 4), respectively. Addition of antibody neutralizing TCRγδ 
significantly inhibited IFNγ production by all three Vδ subsets where Vδ2 was most 
affected (Figure 36d, 36e, and 36f). Therefore, polyclonal γδ T cells responded to 
tumor cells indicating that they have specific anti-tumor effects through their TCRγδ.  





Figure 36. TCRγδ-specific IFNγ Production by Vδ1, Vδ2, and Vδ3 Subsets. 
Polyclonal γδ T cells were incubated for 1 hour prior to co-culture and during co-
cultures with normal mouse serum (NMS; negative control) or neutralizing TCRγδ 
antibody (αTCRγδ; clone IMMU510). Co-cultures were initiated in the presence of the 
secretory inhibitor BrefeldinA (GolgiPlug) where polyclonal γδ T cells and one of two 
OvCa cell lines (CAOV3 or OC314) and were incubated at 37oC for 6 hours. Cells were 
stained for TCRδ1, TCRδ2, CD3, and IFNγ in order to gate each T cell subset and 
assess IFNγ production. The gating strategy was (a) separation of forward and side 
scatter (FSC and SSC, respectively) in activated T cell gate, (b) isolation of CD3+ T 
cells from contaminating tumor cells in T cell gate, and (c) separation into Vδ1, Vδ2, 
and Vδ3 based on TCRδ1+TCRδ2neg, TCRδ1negTCRδ2+, and TCRδ1negTCRδ2neg, 
respectively. (d) Histogram comparisons of Vδ1, Vδ2, and Vδ3 gates (from left to 
right) co-cultured with CAOV3 and treated with NMS (open) or αTCRγδ (shaded). 
Numbers next to histograms are MFI. Flow plots are representative of 1 of 3 normal 
donors and of co-cultures with OC314 cells. Percent inhibition for each Vδ subset was 
calculated by the following equation: Inhibition (%) = 100 – 100 x [(MFITUMOR + T CELL 
– MFIT CELL ONLY)αTCRγδ / (MFITUMOR + T CELL – MFIT CELL ONLY)NMS]. Data are mean ± 
SD (n = 3). 
  




IV.C.8. Broad Anti-tumor Cytolysis by Polyclonal γδ T cells 
After establishing that γδ T cells were functional in producing pro-inflammatory 
molecules, their ability to lyse a broad range of tumor cell lines was investigated against 
healthy donor cells and established hematological and solid tumor cell lines. 
 
IV.C.8.a. Polyclonal γδ T cells Lyse Hematological Tumors 
We previously established that γδ T cells could lyse B-ALL cell lines (Daudi-β2M, 
Kasumi2, and REH) but not healthy autologous or allogeneic B cells.(311) This 
observation was confirmed again with healthy autologous and allogeneic B cells, which 
were not lysed by polyclonal γδ T cells (Figure 37a). However, the same effectors were 
able to kill allogeneic B-ALL cell lines cALL2 and RCH-ACV (Figure 37b). T-ALL 
cell lines (Kasumi3 and Jurkat) were also sensitive to γδ T cell killing suggesting that γδ 
T cells could be used to kill T cell malignancies (Figure 37c). CML cell line K562 was 
also killed by γδ T cells and has been a well-known target for γδ T cell cytolysis.(303) 
Moreover, K562-derived clone#4 aAPC were lysed by γδ T cells, as expected (Figure 
37d). Thus, polyclonal γδ T cells propagated on aAPC have anti-tumor immunity 
towards hematological malignancies. 
  





Figure 37. In vitro Cytolysis of Hematological Tumor Cells by γδ T cells. Standard 
4-hour CRA were performed with increasing effector (γδ T cells) to target (E:T) ratios 
against (a) B cells from autologous donors or from an allogeneic donor (one of four 
representative donors), (b) B-ALL cell lines cALL2 and RCH-ACV, (c) T-ALL cell 
lines Kasumi3 and Jurkat, and (d) CML cell line K562 and its derivative clone#4 aAPC. 








IV.C.8.b. Polyclonal γδ T cells Lyse Solid Tumors 
After establishing that polyclonal γδ T cells could lyse hematological tumor cells, solid 
tumor cell lines were evaluated for killing using standard 4-hour CRA. Established 
PaCa and OvCa cell lines were tested because of their high likelihood for sensitivity to 
anti-tumor immunity with a lack of current cellular therapies. Several PaCa cell lines 
(CaPan2, MiaPaCa2, Su8686, and BxPc3) cell lines were lysed by γδ T cells in a dose-
dependent manner where BxPc3 cells were killed most efficiently (Figure 38a). Next, 
eight OvCa cell lines were lysed by polyclonal γδ T cells in the following order: 
CAOV3 > EFO21 > UPN251 > IGROV1 > OC314 > Hey > A2780 > OVCAR3 
(Figure 38b). Moreover, there was an average of >60% maximum cytolysis observed 
against CAOV3 in one donor after 4 hours at an effector to target (E:T) ratio of 20:1. 
Therefore, polyclonal γδ T cells were able to kill solid tumors in vitro and other solid 
tumor cell lines may also be sensitive to cytolysis by γδ T cells. 
 
  





Figure 38. In vitro Cytolysis of Solid Tumor Cells by γδ T cells. Standard 4-hour 
CRA were performed with increasing effector (γδ T cells) to target (E:T) ratios against 
(a) PaCa cell lines CaPan2, MiaPaCa2, Su8686, and BxPc3 and (b) OvCa cell lines 
A2780, EFO21, Hey, IGROV1, OC314, OVCAR3, UPN251, and CAOV3. Each line 
represents an individual effector where data are mean ± SD (n = 3 wells per assay).  




IV.C.8.c. Mechanism of Tumor Cytolysis by γδ T cells was Multi-factorial 
We sought to determine if polyclonal γδ T cell cytolysis was directly dependent upon 
the TCRγδ by neutralizing killing with antibodies. Confounding these assays was the 
observation that γδ T cells displayed high levels of DNAM1 and NKG2D (data not 
shown), which can mediate cytolysis by both T cells and NK cells.(335, 336) Moreover, 
there was not a clear-cut choice for TCRγδ neutralizing antibody since the company 
information for TCRγδ-specific antibodies did not report on neutralization. In the end, 
the TCRγδ-specific antibody used for staining in this study (clone B1, BD Biosciences) 
and clone IMMU510 TCRγδ-specific antibody (IM) from Thermo Fisher were used for 
neutralization studies. Also, because there were many activating receptors (TCRγδ, 
DNAM1, NKG2D) on the γδ T cell surface, a pool of all antibodies was used for 
maximum inhibition and to assess if there was additivity or synergy between the 
receptors in killing. Hematological tumor cell line (Jurkat) and solid tumor cell line 
(OC314) were chosen as targets because of their reported expression of DNAM1 and 
NKG2D ligands and their sensitivity to cytolysis by polyclonal γδ T cells (Figures 37c 
and 38b).(337-339) An E:T ratio of 12:1 was chosen where effectors were pre-
incubated with the antibodies and antibodies were present during the 4-hour CRA. NMS 
was used as a negative control and parallel wells were initiated without antibodies to 
determine maximum cytolysis for normalization purposes. Antibodies targeting 
NKG2D, DNAM1, and TCRγδ (clone B1) had minimal effect on reducing cytolysis 
against Jurkat (Figure 39a) and OC314 (Figure 39b) relative to NMS. However, there 
was a statistically significant increase in killing against Jurkat with DNAM1 antibody 




and significant decrease in killing against OC314 with NKG2D antibody. In contrast, 
TCRγδ (IM) antibody significantly neutralized killing of both Jurkat and OC314 cells 
compared to NMS and reduced the killing by an average of 40% in both cell lines 
(Figures 39a and 39c second bars from right). Furthermore, a pool of all four 
antibodies (NKG2D, DNAM1, TCRγδ (B1), and TCRγδ (IM)) resulted in synergistic 
inhibition of γδ T cell cytolysis of Jurkat (65% ± 8%) and OC314 (71% ± 10%) cells 
(Figures 39a and 39c bars to far right). Moreover, dose-dependent inhibition was 
observed by both TCRγδ (IM) and pooled antibodies when concentrations were diluted 
from 3.0 µg/mL (shown in Figures 39a and 39c) to 1.0 µg/mL and 0.3 µg/mL against 
Jurkat (Figure 39b) and OC314 (Figure 39d). Similar results were seen with targeting 
IGROV1 (data not shown), which is also known to express DNAM1 and NKG2D 
ligands and was sensitive to polyclonal γδ T cell killing (Figure 38b).(337, 339, 340). 
In sum, these results suggested that killing by γδ T cells is multi-factorial with an 
emphasis on the TCRγδ to mediate cytolysis. 
  





Figure 39. Neutralization of Polyclonal γδ T cell Cytolysis. Neutralizing antibodies to 
NKG2D, DNAM1, TCRγδ (B1), TCRγδ (IM) were used to block killing of Jurkat or 
OC314 tumor targets at an E:T ratio of 12:1 in standard 4-hour CRA. Antibodies were 
pre-incubated with T cells for 1 hour and kept in the CRA at 0.3, 1.0, or 3.0 µg/mL. 
NMS was used for antibody controls and specific lysis was normalized to wells without 
antibody to yield relative cytolysis as defined by: Relative cytolysis (%) = (Specific 
Lysis)With Antibody / (Specific Lysis)Without Antibody x 100. Relative cytolysis of Jurkat cells 
by (a) all antibodies at 3.0 µg/mL and (b) NMS, TCRγδ (IM), and pooled antibodies at 
tested concentrations. Relative cytolysis of OC314 cells by (c) all antibodies at 3.0 
µg/mL and (d) NMS, TCRγδ (IM), and pooled antibodies at tested concentrations. Data 
are mean ± SD (n = 4). Two-way ANOVA with Bonferroni’s post-tests were used for 
statistical analysis.  




IV.C.8.d. Importance for TCRδ in γδ T cell Cytolysis 
Because the separated Vδ subsets displayed differences in memory phenotype and 
cytokine production, it was of interest to evaluate their ability to directly lyse solid and 
hematological tumors. Acute killing was evaluated with standard 4-hour CRA against 
Daudi-β2M, Jurkat, K562, clone#4 aAPC, and OvCa cell lines (CAOV3, IGROV1, 
OC314, and UPN251) all of which displayed high levels of susceptibility to lysis by 
polyclonal γδ T cells (Figures 37 and 38). All eight tumor cell lines were lysed by the 
separated Vδ lineages, but a distinct order of lysis was observed against all targets 
where Vδ2>>Vδ3>Vδ1 in killing capabilities (Figure 40). As the phenotype indicated 
that Vδ1 cells were mainly naïve, it was expected that they would have the most limited 
cytolytic ability, which is what was observed. Likewise, TCM have less immediate 
effector function relative to TEM cells, and these memory populations were dominated 
by Vδ3 and Vδ1, respectively. Importantly, this was the first report of anti-tumor 
activity by Vδ3 cells. It was interesting that all three Vδ lineages lysed clone#4 aAPC 
roughly equally which supports their similar proliferation (Figure 32). Long-term 
killing assays were then set up to assess whether equivalent killing could be achieved 
during 48 hours of co-culture between Vδ subsets and OvCa cell lines CAOV3, OC314, 
and UPN251 (Figure 41). Indeed, >95% of CAOV3 and UPN251 cells were eliminated 
by all three subsets in two days. Likewise, 96% ± 4% of OC314 cells were killed by 
Vδ2 cells, and Vδ1 and Vδ3 achieved 76% ± 5% and 89% ± 5% (mean ± SD; n = 3) 
killing, respectively, in 48 hours of culture. Collectively, the Vδ subset lineage was 




important for cytolysis in both acute and long-term conditions, and established that each 
Vδ lineage propagated on aAPC was capable of tumor killing.  





Figure 40. γδ T cell Subset Acute Cytolysis. Vδ subsets were tested in 4-hour CRA 
against (a) ALL cell lines Daudi-β2M and Jurkat, (b) CML cell line K562 and its 
derivative clone#4 aAPC, and (c) OvCa cell lines IGROV1, OC314, UPN251, and 
CAOV3. Vδ1 (circles), Vδ2 (squares), and Vδ3 (triangles) are displayed as mean ± SD 
from averaged triplicate measurements from four normal donors. 
  





Figure 41. γδ T cell Subset Long-term Killing. CAOV3, OC314, and UPN251 cells 
were seeded in wells of 6-well plates and incubated overnight so that they would adhere 
to the wells. T cells from Vδ1, Vδ2, or Vδ3 subsets were then added and co-cultured in 
the wells with tumor cells for 2 days. Remaining adherent cells were enzymatically 
removed from the wells and counted for viable cells. Tumor cells without T cells were 
positive control and T cells without tumor cells was the negative control. Killing (%) = 
(Viable cells)Co-culture / (Viable cells)Tumor only x 100. Data are mean ± SD (n = 3). 
  




IV.C.9. Clearance of Established Tumor Xenografts by Polyclonal γδ T cells 
As polyclonal γδ T cells are being proposed as a therapy for cancer patients, a model to 
test their efficacy in vivo was evaluated. NSG mice were used for their ability to accept 
human tumor xenografts well and were injected with CAOV3-ffLuc-mKate tumor cells 
intraperitoneally (i.p.) then randomized into treatment groups to establish a model of 
high tumor burden. This was a model for advanced OvCa disease as many women with 
OvCa do not usually develop metastases outside of the peritoneal cavity but local tumor 
growth and ascites result in disease pathology.(37) After 8 days of engraftment (denoted 
Day 0) either PBS (negative control) or γδ T cells (escalating doses) were administered 
i.p. to the mice (Figure 42). Tumor burden was monitored during the experiment with 
non-invasive BLI following D-luciferin administration. Established tumors were clearly 
visible by BLI after 8 days of engraftment at Day 0 (Figure 42a top panels), which 
continued to grow in mock (PBS) treated mice (Figure 42a bottom left panels) but 
were eliminated in mice treated with polyclonal γδ T cells (Figure 42a bottom right 
panels) at 72 days post-treatment initiation. All mice treated with PBS had increased 
BLI flux measurements (p = 0.018) whereas polyclonal γδ T cell-treated mice had 
significantly decreased (p = 0.004) BLI flux (Figure 42b). Moreover, treatment with γδ 
T cells improved overall survival (p = 0.0001) compared to mock-treated mice where 
90% of mice survived OvCa and hazard ratio for mice without treatment was 20.4 
(Figure 42c). In sum, polyclonal γδ T cells were effective in treating cancer in vivo and 
represent an attractive approach to cell-based cancer treatment.  





Figure 42. In vivo Tumor Clearance by Polyclonal γδ T cells. CAOV3-ffLuc-mKate 
tumor cells (3x106) were injected i.p. into NSG mice at Day -8 and were allowed to 
engraft until Day 0 when treatment was started with either PBS (vehicle/mock) or 
polyclonal γδ T cells. Four doses were given with 3x106, 6x106, 10x106, and 15x106 on 
days 0, 7, 14, and 21, respectively, to create a dose escalation scheme. (a) BLI flux 
images at Day 0 (top panels) or Day 72 (bottom panels) in PBS-treated (left 3 panels) or 
polyclonal γδ T cell-treated (right 3 panels) mice. Mice displayed are representative of 
10 total mice. (b) BLI flux measurements of mice at Day 0 (squares) and Day 72 
(circles) where lines are drawn between the same mouse. Student’s paired, 2-tailed t-
tests were used for statistical analysis and p values are displayed above treatment 
groups. (c) Overall survival of mice treated with PBS (open squares) or polyclonal γδ T 
cells (closed squares). Gehan-Breslow-Wilcoxon Test was used to calculate p value. H 
= hazard ratio.  





IV.D.1. Importance of Polyclonal γδ T cells for Immunotherapy  
This study establishes clone#4 aAPC as a cellular platform for the sustained 
proliferation of populations of γδ T cells that exhibit broad reactivity against 
hematologic malignancies and solid tumors. T cells expressing certain Vδ TCR usage 
have been associated with clinical responses against cancer. For example, the Vδ1 TCR 
subset correlated with complete responses observed in patients with ALL and AML 
who underwent αβ T cell-depleted allogeneic HSCT.(302, 304, 305) However, Vδ1 
cells have not been directly infused for therapy. This chapter established direct evidence 
that Vδ1 cells could mediate anti-tumor immunity and strengthens support for their use 
in adoptive T cell cancer treatments. In contrast to Vδ1 and Vδ3 cells, T cells 
expressing Vδ2 TCR have been directly infused and generated responses against solid 
and hematological tumors, but complete responses were unpredictable and sometimes 
not directly correlated to Vδ2 therapy (175, 318). Similarly, Vδ2 cells expanded in this 
chapter had the most immediate anti-tumor cytotoxicity and cytokine production, and 
aAPC-based expansions could build upon these early successes of Vδ2 T cell infusions. 
A role for T cells expressing Vδ3 TCR in targeting tumors is unknown, but these 
lymphocytes have been correlated with immunity to HIV and CMV.(165, 183) Thus 
infusion of this T-cell subset could be beneficial to immunocompromised patients. 
Importantly, these results are the first to directly show that Vδ3 cells have anti-tumor 
activity and this study could, therefore, represent a significant contribution to both 
translational research strategies and to immunologists studying γδ T cell function. In 




aggregate, the data herein lend impetus to adoptive transfer of γδ T cells that maintain 
expression of all Vδ TCR types as investigational treatment for tumors and 
opportunistic viral infections. 
 
IV.D.2. Potential Ligands for TCRγδ on aAPC 
The molecules on aAPC that stimulate TCRγδ for their numeric expansion are not 
known. K562-derived aAPC express endogenous MICA and MICB molecules (329) 
which are ligands for both Vδ1 and NKG2D.(152) NKG2D was expressed (40% ± 
16%; mean ± SD, n = 4) on aAPC-expanded γδ T cells that were also predominantly 
Vδ1 cells (Figure 31). Polyclonal γδ T cells also demonstrate expression (26% ± 7%) 
for other activating NK receptors (NKp30, NKp44, and NKp46), which may contribute 
to γδ T cell function. Two ligands described for Vδ2 TCR are surface mitochonrial F1-
ATPase and phosphoantigens, both of which are described in K562 cells.(171, 172, 297, 
299) Indeed, enhanced responses of T cells expressing Vγ9Vδ2 were observed when 
K562 cells were treated with aminobisphosphonates,(172) and a similar strategy could 
be employed upon co-culture with clone #4 to increase the frequency of Vδ2 TCR 
usage.(173) Otherwise, patients receiving polyclonal γδ T cells could be primed to 
expand Vδ2 cells in vivo through administration of aminobisphosphonates. Now that 
aAPC have been established as a means to propagate polyclonal γδ T cells, these 
molecular questions can be answered and used for future therapies. 
 




IV.D.3. Co-stimulation in Polyclonal γδ T cell Expansion 
We introduced co-stimulatory molecules to improve the ability of aAPC to propagate γδ 
T cells. CD28 and CD137 (4-1BB) expressed on γδ T cells bind CD86 and CD137L, 
respectively, expressed on aAPC. The absence of both CD86 and CD137L abrogated γδ 
T-cell proliferation and expression of single co-stimulatory molecules only partially 
restored the ability of γδ T cells to proliferate (Figure 28b). The benefit of using other 
molecules’ involvement in co-stimulation has not been evaluated to date. CD70 is 
expressed on γδ T cells (36% ± 15%) concurrently with its receptor CD27 (Figure 33), 
which may allow for trans- or cis- stimulation independent of the aAPC that does not 
express CD70. CD27 has been described as a marker for γδ T cells that produce IFNγ, 
and CD27neg γδ T cells commonly secrete IL17, a potent cytokine that has powerful, yet 
context-dependent anti-tumor activities.(127, 333, 341) Current studies are investigating 
whether other co-stimulation combinations, i.e. ICOS without CD86, can improve the 
propagation and/or change the phenotype of γδ T cells – especially in regards to 
improving production of IL17 that can have potent anti-tumor effects. It may be that a 
cocktail of cytokines and neutralizing antibodies is required to propagate IL17-
producing γδ T cells, which was required for expansion of CD4+ TH17 cells ex vivo on 
stimulating beads.(326) Indeed, the addition of IL2 and IL21 was also crucial for the 
numeric expansion of γδ T cells so the strategy will likely need addition of these two 
exogenous cytokines (Figure 28c). In the end, the aAPC co-culture system provides a 
clinically relevant methodology to tailor the type of therapeutic γδ T cell produced for 
adoptive T cell therapy. 




IV.D.4. Polyclonal γδ T cells Apparently Lack Allogeneic Responses to Healthy Tissue 
An attractive therapeutic strategy is to employ third party allogeneic γδ T cells as an 
“off-the-shelf” therapy. This may be feasible, as γδ T cells have reduced potential to 
cause graft-versus-host disease (GvHD) resulting from inappropriate TCR-mediated 
recognition of normal host tissue (305). Unlike TCRαβ that recognizes peptides in the 
context of MHC, TCRγδ is not known to be subject to MHC restriction.(141, 298, 299) 
Thus, matching recipient and donor T cell MHC may not be needed, raising the 
possibility that propagated γδ T cells from one donor can be infused into multiple 
recipients. Autologous T cells expressing Vγ9Vδ2 TCR have been adoptively 
transferred and intravenous administration of aminobisphosphonates was used for in 
vivo numeric expansion of this T-cell subset.(175, 179, 318) To date, the infusion of 
allogeneic γδ T cell has not been reported. We have evaluated aAPC-expanded γδ T 
cells for allogeneic responses and are not able to detect such reactivity. For example, γδ 
T cells proliferate (Figure 43a) and secrete IFNγ (Figure 43b) when co-cultured with 
OKT3-loaded aAPC, but not when co-cultured with autologous or allogeneic B cells. 
Allogeneic tumor cell lines were lysed by our γδ T cells, but healthy B cell donors were 
spared (Figures 24a and 37a). Further, formation of colonies from hematopoietic stem 
cells was inhibited by allogeneic NK cells, but not by allogeneic γδ T cells (Figure 
43c). Autologous EBV-transformed LCL stimulated γδ T cells suggesting they may 
react with EBV antigens (data not shown) as indicated by previous studies.(342, 343) 
Bi-specific αβ T cells expressing CARs specific for GD2 or CD19 and grown on LCL 
have shown excellent anti-tumor immunity and could be applicable for the γδ T cell 




population using aAPC.(236, 344) The ability to infuse donor-derived γδ T cells when 
needed, rather than wait the availability of an autologous product raises the therapeutic 
potential of this T-cell subset. This adds to our development of “off-the-shelf” cells as 
we previously reported that zinc finger nucleases can be used to eliminate expression of 
TCRαβ to help generate “universal” CAR+ T cells.(345) 
  





Figure 43. Absence of Allogeneic Responses by Polyclonal γδ T cells to Partially 
Mis-matched Donors’ Healthy Cells. (a) Polyclonal γδ T cells were labeled with red 
fluorescent dye (PKH-26) and co-cultured with (i) media only (mock), (ii) autologous B 
cells, (iii) allogeneic B cells from normal donors (n = 5), or (iv) OKT3-loaded clone#4 
aAPC (positive control) for 3 days at 37oC without exogenous cytokines. Proliferation 
was measured by dilution of PKH-26 dye MFI and each group was normalized to mock 
treated T cells after gating for CD3+TCRγδ+ cells. Each shape represents a polyclonal γδ 
T cell effector (n = 3). Representative flow cytometry plot is displayed to the right. (b) 
The same co-cultures set up in (a) were initiated overnight in an IFNγ ELISpot assay 
plate, except that cells were not labeled with PKH-26. Spots were enumerated and 
normalized to mock-treated cells for each donor, which is represented by an individual 
shape. (c) Hematopoietic stem cell (HSC) colony forming unit assays were set up with 
co-cultures of donor-matched NK cells or γδ T cells and PBMC containing a fixed 
number of HSC and co-cultures were added to semi-solid media supplemented with 
cytokines for colony formation. HSC cultures without co-cultured lymphocytes were 
used as negative controls for inhibition of colony formation and to normalize co-culture 
colony formation. Student’s paired, 1-tailed t-tests were used for statistical analysis. 
*p<0.05 and **p<0.001. 
  
  




IV.D.5. Application of Polyclonal γδ T cells for Immunotherapy  
These data demonstrate that our aAPC can be used to generate large numbers of γδ T 
cells that maintain polyclonal TCR repertoire and have an ability to kill tumor cells. 
Clone#4 has been produced as a master cell bank and thus there is a clear path to 
generating clinical-grade γδ T cells for human application. A polyclonal approach to γδ 
T cell immunotherapy is supported by the ability to of aAPC generate TN, TCM, and TEM 
γδ T cells from Vδ1, Vδ2, and Vδ3 lineages (Figure 34) that could then produce a 
range of effector functions including production of pro-inflammatory cytokines 
(Figures 35 and 36), exerting direct cytotoxicity against tumors (Figures 37, 38, 39, 40 
and 41), and eliminating solid tumor xenografts (Figure 42). Thus, immediate tumor 
cytotoxicity can be achieved mainly through effector and TEM cells and long-lived anti-
tumor immunity could be repopulated in patients with TN and TCM γδ T cells. Clinical 
trials can now, for the first time, test the efficacy of polyclonal γδ T cell transfers in 
cancer treatments of both solid and hematological tumors.  
 
  





General Discussion and Future Directions 
 
V.A. Dissertation Summary 
The central aim of this dissertation was to develop and test novel cellular 
immunotherapies for cancer treatment. This was tested in three independent specific 
aims. First, ROR1-specific CARs were able to re-direct αβ T cells towards leukemia 
without affecting normal B cells, and this represented an improvement from current 
CD19-specific CAR strategies that result in normal B cell aplasia (Chapter II). Current 
CD19-specific CAR and CD19+ aAPC are currently in clinical trials at MD Anderson 
and were the fastest way to translate a strategy to use CAR+ γδ T cells for 
immunotherapy. Therefore, the second approach used polyclonal γδ T cells expressing 
TCRγδ with anti-tumor reactivity as sentinels of CD19-specific CAR anti-tumor 
immunity. These CAR+ γδ T cells may have clinical bi-specific anti-leukemia efficacy 
due to targeting the tumor through both TCR and CAR (Chapter III). The last aim 
evaluated the broad anti-tumor activity of polyclonal γδ T cells expanded on aAPC, and 
established that they can be an effective option for leukemia, PaCa, and OvCa (Chapter 
IV). The translation of these pre-clinical methods into the clinical trials will give people 
facing cancer treatment new, safe, and effective options. 
 
 




V.B. Combinational Cellular Immunotherapies 
Using more than one cell immunotherapy product in therapy may lead to therapeutic 
additivity, or better yet, synergy. Indeed, clinical trials have already combined HSCT 
with CD19-specific CARs to target B-cell leukemia.(263, 346) The trials are still in the 
enrolling stages, so it will take time to determine whether they are better than historical 
controls. Similar to HSCT and CD19-specific CAR+ T cells, CARs can be paired to 
other cellular products to increase anti-tumor efficacy. For instance, polyclonal γδ T 
cells had inherent anti-tumor immunity towards ovarian and pancreatic cancers 
(Chapter V) and ROR1 is a TAA expressed on both PaCa and OvCa where ROR1+ 
OvCa cells were lysed by ROR1-specific CAR+ T cells (Figure 16c),(67) so a 
combinational immunotherapy of ROR1-specific αβ T cells and polyclonal γδ T cells 
could be used. In fact, the 4A5 mAb specific for ROR1 and from which the CAR was 
derived detected ROR1 at some level in 11 of 12 OvCa cell lines (Figure 6c and data 
not shown). Given the potent anti-tumor activity of polyclonal γδ T cells towards OvCa 
(Figure 38b), the two approaches could be done together to increase tumor clearance. 
Moreover, patients with low ROR1 antigen expression and resistance to γδ T cell-
mediated cytolysis may be sensitive to synergistic killing by ROR1-specific CAR+ αβ T 
cells and polyclonal γδ T cells. Also, γδ T cells are unlikely to participate in GvHD in 
allogeneic transplantation, so a universal bank of polyclonal γδ T cells could be 
established that was known to have high anti-tumor immunity or containing a particular 
set frequency of Vδ1, Vδ2, and Vδ3 populations with maximum efficacy.(305) 
Polyclonal γδ T cells could also be used as front-line therapy before addition of HSCT, 
CAR+ T cells, TILs, etc. in order to prime the tumor microenvironment for adaptive 




immune cells with broader tumor specificity or to reveal neo-tumor antigens. 
Furthermore, the bystander effects of γδ T cells in the microenvironment are largely 
unknown, and tumor lysis could lead to other resident cell types, e.g. NK cells, 
macrophages, DCs, etc. to have renewed reactivity to the tumor.(347) Indeed, B-ALL 
cell lines coated with mAb were lysed by CD16+ Vγ9Vδ2 cells via antibody-dependent 
cell-mediated cytotoxicity (ADCC), and subsequently the Vγ9Vδ2 had APC function to 
generate antigen-specific CD8+ αβ T cell responses to known B-ALL peptides, e.g. 
PAX5.(348, 349) The advantage of polyclonal γδ T cells expanded on aAPC is that 
there may be sufficient direct tumor lysis that ADCC would not be necessary. However, 
the APC function of aAPC-expanded polyclonal γδ T cells has not yet been studied. 
Lastly, melanoma may be an ideal target for combinational cellular immunotherapy 
because it is one of the most responsive tumors to immunotherapy and many T cells 
specific to melanoma peptides, e.g. MART1 and gp100, have been well characterized 
for rapid detection of antigen-specific responses. As aAPC have already been adapted 
for melanoma TIL studies (Forget MA, unpublished observation),(274) it is a logical 
next step to evaluate whether polyclonal γδ T cells can induce antigen-specific CD8+ T 
cell responses to melanoma. If successful, this approach could impact the TIL 
expansion protocols to adapt them to a wider range of patients. In aggregate, there are 








V.C. Generation of IL17-producing T cells for Adoptive Immunotherapy 
IL17 has been shown to have potent anti-tumor effects when used in the tumor 
microenvironment, and therefore secretion of IL17 by transferred T cells homing to the 
tumor may have potent anti-tumor immunity.(321, 323, 350) T cells that produce IL17 
can be mutually exclusive from those who produce IFNγ. Indeed, most of the T cells 
expanded on aAPC in this dissertation, with or without CARs, produced IFNγ, and the 
expanded γδ T cells secreted IL17 in diminished quantities compared to IFNγ (Figures 
23 and 35). CD27 has been a marker for these cytokines in γδ T cells where CD27neg 
and CD27+ are associated with IL17 and IFNγ, respectively.(333, 351, 352) It holds 
then that ~80% of polyclonal γδ T cells stain positive for CD27 (Figures 33 and 34). 
CD28 co-stimulation was shown to inhibit TH17 polarization in CD4+ T cells through 
ICOS co-stimulation,(326) and so it may be that CD86 co-stimulation by aAPC and/or 
CD28 endodomains in the CAR lead to polarization towards IFNγ in polyclonal γδ T 
cells, CAR+ γδ T cells, and CAR+ αβ T cells. Replacement of CD28 for ICOS in the 
CAR(s) and CD86 for ICOSL in the aAPC can be tested to see if these can generate T 
cells that secrete IL17. Another strategy comes out of the observation that ROR1-
specific CAR+ T cells signaling through CD137 produce less IFNγ than do those 
signaling through CD28 (Figure 15). This may be due to (i) CD137 signaling yielding 
less inflammatory cells or (ii) CAR-CD137 cells expressed other cytokines that have yet 
to be detected. Clinical trials out of The University of Pennsylvania (PI: June, CH) 
using CD19-specific CAR+ T cells for ALL and CLL treatment have shown that 
responders had high serum IL6.(4, 7) This cytokine has importance for macrophages, 
inflammatory response (of particular interest in his trials as patients underwent massive 




fevers from T cells attacking their leukemia), and polarization of CD4+ T cells from 
TREG to TH17.(127) In regards to the latter, release of immunosuppression by TREG and 
production of IL17 could explain these impressive complete responses. Chapter II did 
not directly evaluate the influence of TREG cells on CAR+ T cell function or IL6 and 
IL17 production, but experiments using intracellular cytokine staining or multiplex 
arrays can be used to pursue this line of questioning.  Development of an aAPC-based 
expansion of IL17 secreting T cells would allow for direct testing of their benefit 
relative to IFNγ-producing cells, and may lead to rationales to use one or both of them 
in the clinic for cancer therapies. 
 
V.D. Importance of Polyclonal γδ T cells to Immunology 
One of the major accomplishments of this dissertation was creating a method for 
expanding polyclonal γδ T cells (Chapter IV), which has broader applications outside 
of immunotherapy to the immunology and cancer biology fields. For example, few mAb 
exist that are specific for TCRγδ isotypes, which limits their detection in correlative 
studies and other assays.(165) Given the ability of aAPC to expand large numbers of 
polyclonal γδ T cells, mice can be immunized to generate mAb specific for desired 
TCRγδ isotypes, e.g. Vδ3 and Vγ isotypes outside of Vγ9. Commercial and academic 
use of these detection antibodies have tangible outcomes, including diagnostic and/or 
prognostic profiling of γδ T cell TIL within tumors. Other major unknowns are the 
ligands for many TCRγδ heterodimers. Generation of γδ T cell clones could be used to 
determine the specific ligands of Vδ/Vγ combinations and therefore lead to future 




studies on γδ T cell affinity towards a particular disease. Moreover, the ligands on the 
K562-derived aAPC that TCRγδ binds are unknown. Likely candidates include IPP 
(Vδ2) and MICA/B (Vδ1) but their exact roles have not been determined.(155, 172) 
Elucidation of these interactions could assist attempts to tailor the aAPC for total γδ T 
cell expansion, expansion of a particular γδ T cell lineage, or polarization towards a 
certain γδ T cell phenotype. Thus, aAPC could be an excellent source for the study of 
fundamental γδ T cell immunobiology and could yield answers not currently accessible 
because of limited starting cell numbers and ineffective polyclonal expansion protocols. 
 
V.E. Potential Benefits and Issues with Cellular Immunotherapy 
Although promising, there may be some limitations to the immunotherapies created in 
this dissertation. First, patients with advanced B-cell leukemia disease often have few T 
cells in their peripheral blood, and have even fewer γδ T cells.(6) In some cases, the 
residual autologous T cells are functionally unresponsive and difficult to expand to 
clinically-relevant doses.(353) Preliminary studies using CD19-specific CAR have 
indicated that CAR+ T cells can be generated from CLL patients with <5% T cells at the 
start of culture (Huls MH, unpublished observation). Other options would be to use 
haplo-identical or MHC-matched T cells. However, this is not always feasible, so 
allogeneic γδ T cells could be an ideal choice because of they are generally thought to 
recognize antigens outside of MHC-restriction.(304, 342) Of course, if normal 
hematopoiesis resumes in the patients then the γδ T cell graft may be rejected, but there 
may still be a therapeutic window. Another unknown is whether γδ T cells will be 




subjected to the same regulation by TREG cells or other immunosuppressive forces. 
Some γδ T cells have been reported to have immunosuppressive function, and it would 
be of interest to identify these cells and eliminate them from the adoptive T cell product 
prior to infusion.(354) The tumor microenvironment is also of interest because it often 
contains hypoxic areas containing malignant cells resistant to conventional 
treatments.(355, 356) In preliminary experiments, the co-culture system was adapted to 
assess γδ T cell proliferation as a function of oxygen tension. No difference in 
proliferative capacity (p = 0.404) was observed when the cultures were in hypoxia (1% 
O2) or normoxia (20% O2) and stimulated with clone#4 aAPC, IL2, and IL21, indicating 
that γδ T cells have potential to operate within the bone marrow or hypoxic tumor 
milieu (Figure 44). Thus, administration of graded doses of autologous and allogeneic 
γδ T cells in humans will test the ability of γδ T cells to home and recycle effector 
function in the tumor microenvironment. In the end, clinical trials will be the ultimate 
test of whether these potential pitfalls out weight the anti-tumor benefits to cancer 
patients.  
  





Figure 44. Proliferation of γδ T cells in Hypoxia Compared to Normoxia. Co-
cultures were initiated in parallel with γδ T cells and aAPC in the presence of 
exogenous IL2 and IL21 in incubators set with either 1% O2 (hypoxia) or 20% O2 
(normoxia) and were normalized to starting quantities 10 days after culture initiation. 
Student’s paired, 2-tailed t-test was used for statistical analysis. 
 
  




V.F. Clinical Applications of Dissertation Immunotherapies 
As of June, 2013 there are immediate plans to use immunotherapies detailed in 
Chapters II and IV in the clinic. A Phase I clinical trial was written to co-administer 
autologous ROR1RCD28 and ROR1RCD137 T cell populations into CLL patients after 
lymphodepletive (Cytoxan and Fludarabine) chemotherapy. Proof-of-principle studies 
have established protocols for expanding CAR+ T cells from patient samples by using 
an “electroporation-then-sort” strategy used for growing CAR+ γδ T cells (Chapter 
III). Patient PBMC will be electroporated with SB transposase and SB transposase 
plasmids and sorted on paramagnetic beads the following day to deplete CD19+ T cells. 
Co-culture on aAPC led to CAR+ T cell growth in the translation research lab (TRL) 
built to translate lab protocols to the current good manufacturing practices (cGMP) 
facility. As more data has arrived, the support for utilizing only ROR1RCD137 in the 
clinical trial has gained momentum and may be the treatment modality tested instead of 
a competitive re-population experiment of both CAR+ T cell populations. This 
investigational new drug (IND) application passed rigorous examination by the National 
Institutes of Health (NIH) Recombinant DNA Advisory Committee (RAC) with 
approval in December 2012. Review at the MD Anderson IRB is underway before 
sending the trial for final IND approval by the Food and Drug Administration (FDA). A 
second CAR trial has been proposed for treatment of leukemia with both ROR1-specific 
T cells and the chemotherapy dasatinib, which leads to increased surface expression of 
ROR1 in t(1;19) B-ALL cells and could minimize the risk for ROR1 antigen 
escape.(13) In regards to Chapter IV translation, a compassionate IND (CIND) has 
been written to treat a late stage CLL patient with autologous or allogeneic polyclonal 




γδ T cells in the case that the autologous γδ T cells do not proliferate or respond to the 
tumor. If allogeneic γδ T cells are infused into this patient, this will represent the first 
time that purified polyclonal γδ T cells from an allogeneic host were ever infused into a 
human. There is great optimism that the polyclonal γδ T cells can home to secondary 
lymphoid tissues harboring CLL and that they can eliminate the leukemia. These two 
trials are, hopefully, the beginning of the trials to come that will apply ROR1-specific T 
cells, CAR+ γδ T cells, and polyclonal γδ T cells for human cancer immunotherapies. 
  





MATERIALS AND METHODS 
 
VI.A. DNA Plasmids and Construct Cloning 
All plasmids in this study were propagated in dam-/- bacteria (C2925, Invitrogen, Grand 
Island, NY) and purified as single cell bacteria clones with EndoFree Plasmid Maxi Kit 
(Qiagen, Valencia, CA). Plasmids were cleared for transfection when (i) identity was 
confirmed by analytical digestion, (ii) samples were negative for endotoxin, and (iii) 
had spectrophotometer readings of 1.80 < A260/A280 < 2.00. 
 
VI.A.1. Tumor Antigens 
VI.A.1.a. ROR1 
The extracellular and transmembrane domains of ROR1 (Accession: NM_005012), 
termed dROR1, were cloned into a SB vector (pSBSO). The open reading frame (ORF) 
was codon optimized for expression in human cells and cloned into a shuttle vector 
(pMK-RQ) by GeneArt (Invitrogen). Codon-optimized dROR1/pMK-RQ and GlySer-
EGFP-mIgG1(CooP)/pSBSO plasmids were digested with NheI and XhoI restriction 
enzymes and were purified from pMK-RQ and GlySer-EGFP-mIgG1 fragments, 
respectively, by gel electrophoresis. Purified dROR1 and pSBSO fragments were 
ligated with T4 DNA Ligase (Promega, Madison, WI) to create dROR1/pSBSO 
plasmid, which was then amplified in the presence of kanamycin for large-scale 




purification. Identity of the purified plasmid was confirmed with digestions of (i) ClaI, 
(ii) ClaI and SmaI, (iii) PvuII, and (iv) PvuI and SmaI enzymes to distinguish between 
parental plasmids and dROR1/pSBSO. 
 
VI.A.1.b. CD19 
The extracellular and transmembrane domains of human CD19 (Accession: M84371), 
termed Delta-CD19, were cloned into a pSBSO with linked F2A cleavage site and 
neomycin resistance (NeoR) for enforced dCD19 expression (performed by Olivares S). 
As with dROR1, the ORF was codon optimized for expression in human cells and 
cloned into a shuttle vector by GeneArt. In order to create the final vector, codon-
optimized dCD19 from plasmid vector Delta-CD19(CoOp)-F2A-SStomato/pSBSO and 
Neomycin resistance from plasmid vector Myc-FFLuc(CoOp)-Neo/pSBSO, were 
digested with ZraI/SpeI and EcoRV/SpeI restriction enzymes respectively.  The 
fragments (Neo-insert and Delta-CD19(CoOp)-F2A-X/pSBSO-vector) were purified by 
gel electrophoresis. Purified fragments were ligated with T4 DNA Ligase to create 
Delta-CD19(CoOp)-F2A-Neo/pSBSO plasmid, which was then amplified in the 
presence of kanamycin for large-scale purification. Identity of the purified plasmid was 
confirmed with digestions of SacI restriction enzyme to distinguish between parental 
plasmids and Delta-CD19-F2A-NeoR/pSBSO. 
 
 




VI.A.2. Co-stimulatory Molecules 
VI.A.2.a. CD86 and CD137L 
The entire ORF for CD86 (Accession: EF064748.1) and CD137L (Accession: 
NM_003811.3) were codon optimized and synthesized by GeneArt and were then 
cloned into pSBSO (performed by Ang S). 
 
VI.A.2.b. IL15-IL15Rα Fusion Construct 
This construct will produce an IL15 that is membrane-bound, but also presented in the 
context of IL15Rα. A fusion of IL15 (NM_000585.4) to the full length IL15Rα 
(NM_002189.3) was constructed with a serine-glycine linker and a C-terminal Flag (x3) 
motif attached to generate membrane bound IL15 (mIL15). The signal peptides for IL15 
and IL15Rα were omitted and the IgE signal peptide (gb|AAB59424.1) was used for the 
mIL15 fusion protein. As with dROR1, mIL15 was codon optimized and synthesized by 
GeneArt and was then subcloned into GlySer-EGFP-mIgG1(CooP)/pSBSO using NheI 
and XhoI restriction sites. 
 
VI.A.3. Chimeric Antigen Receptors 
Cloning of second generation CD19-specific CAR signaling through CD28 and CD3ζ 
(CD19RCD28) has been previously described.(57, 272, 281) The CAR was modified to 
replace CD28 endodomain for CD137 endodomain as a synthetic cDNA sequence 




(GeneArt) that was cloned back into the original plasmid with SmaI and SpeI restriction 
endonucleases to create another second generation CD19-specific CAR signaling 
though CD137 and CD3ζ (CD19RCD137). These plasmids were further manipulated to 
contain “SIM” and “FRA” oligonucleotides at the 3’ end of the CD19RCD28 and 
CD19RCD137 transposons, respectively, by shuttling the entire CARs into new pSBSO 
backbones with NheI and XhoI enzymes (CD19-specific CAR work performed by 
Olivares S). Heavy and light chain immunoglobulin sequences from the 4A5 mAb 
hybridoma were provided by Dr. Thomas J Kipps (UCSD) and were used to assemble 
the following ROR1R sequence de novo (GeneArt) from 5’ to 3’ (i) murine IgGκ signal 
peptide, (ii) VL, (iii) Whitlow linker, (iv) VH, and (v) the first 73 amino acids of the 
IgG4 stalk, and ROR1R sequence was shipped to MD Anderson as 
ROR1R(CoOp)/pMK-RQ plasmid. Amplification of ROR1R fragment from 
ROR1R(CoOp)/pMK-RQ was done by PCR with the following primers: 
ROR1RCoOpF (GCTAGCCGCCACCATGGGCTGGTCCTGCATC) and ROR1Rrev 
(GCTCCTCCC GGGGCTTTGTCTTGGC). The PCR product was cloned into pCR4-
TOPO with TOPO TA Cloning Kit (Invitrogen) to generate ROR1R(CoOp)/pCR4-
TOPO and the sequence was verified with T7 and T13-0 primers by Sanger sequencing 
(DNA Sequencing Core, MDACC). Then NheI and SmaI were used to digest 
ROR1R(CoOp)/pCR4-TOPO and CD19RCD28mZ(CoOp)/pEK plasmids and 
appropriate bands were purified by gel electrophoresis and ligated with T4 DNA Ligase 
to generate ROR1RCD28mZ(CoOp)/pEK. The ROR1-specific CAR was then 
transferred into a SB transposon by digestion of CD19RCD28mZ(CoOp)/pSBSO-MCS 
and ROR1RCD28mZ(CoOp)/pEK with NheI and SpeI, removal of phosphates by 




Antarctic Phosphatase from pSBSO-MCS digestion, isolation of ROR1RCD28mZ and 
pSBSO-MCS bands by gel electrophoresis, and ligation with T4 DNA Ligase to 
generate ROR1RCD28mZ(CoOp)/pSBSO-MCS. The final ROR1RCD28 transposon 
plasmid was constructed by digesting CD19RCD28mZ(CoOp)/pSBSO-SIM with NheI, 
XmaI, and Antarctic Phosphatase and ROR1RCD28mZ(CoOp)/pSBSO-MCS with 
NheI, XmnI, and XmaI, purifying appropriate bands by gel electrophoresis, and ligating 
them together with T4 DNA Ligase to generate ROR1RCD28CD3z/pSBSO-SIM 
plasmid. Similarly, the final ROR1RCD137 transposon plasmid was constructed by 
digesting CD19R-CD28Tm-41BBCyt-Z(CoOp)/pSBSO-FRA with NheI, XmaI, and 
Antarctic Phosphatase and ROR1RCD28mZ(CoOp)/pSBSO-MCS with NheI, XmnI, 
and XmaI, purifying appropriate bands by gel electrophoresis, and ligating them 
together with T4 DNA Ligase to generate ROR1RCD137CD3z/pSBSO-FRA plasmid. 
Identities of final ROR1R plasmids were distinguished from CD19R plamids by PmlI 
enzyme and pSBSO-SIM and pSBSO-FRA plasmids were distinguished by BsrGI 
enzyme (Figure 7). 
 
VI.B. Cell Culture 
Three media formulations were used herein for tissue culture. First, RPMI-CM was 
composed of RPMI (Gibco, Grand Island, NY), 10% heat-inactivated fetal bovine 
serum (FBS; Hyclone, Logan, UT), and 1% Glutamax-100 (Gibco). Similarly, RPMI-
NaPyr-CM was RPMI, 10% FBS, 1% sodium pyruvate solution (Gibco), and 1% 
Glutamax-100. Last, DMEM-CM was made with DMEM (Sigma, St. Louis, MO), 10% 




FBS, 1% sodium pyruvate solution, and 1% Glutamax-100. All tissue culture work was 
performed with 5% CO2 at 37oC in humidified conditions unless otherwise stated. 
 
VI.B.1. Established Tumor Cell Lines 
Jurkat, HCT-116, Kasumi3, and K562 cell lines were acquired from American Type 
Culture Collection (ATCC; Manassas, VA). K562-derived aAPC (clone #4 and 
clone#9) were acquired as previously described from the University of Pennslyvania 
courtesy of Dr. Carl June.(57, 275, 278, 279) B-cell acute lymphoblastic leukemia (B-
ALL) cell lines cALL2, Kasumi2, REH, and RCH-ACV cell lines were gifts from Dr. 
Jeff Tyner (OHSU), pancreatic cancer cell lines (BxPC3, CaPan2, MiaPaCa2, and 
Su8686) were donated by Dr. Viji Ramachandran (MDACC), and ovarian cancer cell 
lines (A2780, CAOV3, EFO21, Hey, IGROV1, OC314, OVCAR3, and UPN251) were 
provided by Dr. Robert Bast (MDACC). Cell cultures were maintained in (i) RPMI-
CM: K562 parental cells, clone#1 aAPC, clone#4 aAPC, clone A6 aAPC, clone A3 
aAPC, clone D4 aAPC, Jurkat, cALL2, Kasumi2, REH, RCH-ACV, and Kasumi3, (ii) 
RPMI-NaPyr-CM: A2780, EFO21, EFO27, Hey, IGROV1, OC314, OVCAR3, 
SKOV3, and UPN251, or (iii) DMEM-CM: CAOV3, BxPC3, CaPan2, MiaPaCa2, and 
Su8686. UPN251 cells were supplemented with insulin-transferrin-selenium solution 
(Gibco). Identities of all cell lines were confirmed by STR DNA Fingerprinting at 
MDACC’s Cancer Center Support Grant (CCGS) supported facility “Characterized Cell 
Line Core.” 
 




VI.B.2. Genetic Modification of Cell Lines 
VI.B.2.a. ROR1 aAPC (clone#1) 
Clone#9 aAPC was generated though enforced expression of CD19, CD64, CD86, and 
CD137L on K562 cells (June CH, UPenn). This aAPC was further modified to express 
IL15/IL15Rα fusion protein (Chapter VI.A.2.b) on their surfaces and was sub-cloned 
to generate clone#27. Then clone#27 was made to express dROR1 (Chapter VI.A.1.a), 
and single cell clones were isolated based on expression of ROR1, CD137L, and IL15. 
The clone#1 aAPC uniformly expressed CD19, CD32, CD64, CD86, CD137L, IL15, 
and ROR1 and was cleared for co-culture following negative testing for mycoplasma 
and other microbial pathogens. 
 
VI.B.2.b. HLA-/- aAPC 
Zinc-finger nuclease (ZFN) specific for HLA-C was used to remove all MHC Class I 
expression from K562 cell surface (Torakai H, Lee DA, Rosoff H, and Cooper LJN). 
Clone#4 aAPC expresses IL15, CD86, and CD137L, so in order to investigate the roles 
of these molecules on γδ T cell proliferation new aAPC were constructed on K562 
background (Figure 28). SB transposon containing IL15/IL15Rα fusion protein and 
SB11 transposase were electro-transferred into K562 cells (CD86neg and CD137Lneg) 
using Amaxa nucleofection and Kit V (cat#VCA-1003, Lonza, Basel, Switzerland). 
FACS was used to isolate IL15+ cells, which were electroporated with SB11 and SB 
transposons containing either CD86 or CD137L. Cells were sorted again by FACS to 




obtain IL15+CD86+ or IL15+CD137L+ as single cell clones A3 
(IL15+CD86+CD137Lneg) and D4 (IL15+CD86negCD137L+), respectively. Single cell 
sorting FACS was also used to make a single cell clone (A6; IL15+CD86negCD137Lneg) 
of cells electroporated once. Each cell line was negative for mycoplasma and microbial 
pathogens. 
 
VI.B.2.c. Lenitviral Packaging and Gene Transduction 
Lentivirus particles were packaged according to a modified version of a protocol 
described elsewhere.(357) Briefly, packaging cells (293-METR) were plated on flasks 
and transfected the following day with pCMV R8.2, VSV-G, and pLVU3G-effLuc-
T2A-mKateS158A (Figure 45) plasmids in conjunction with Lipofectamine 2000 
transfection reagent according to manufacturer’s instructions (Invitrogen). Virus-like 
particles were harvested 48 and 72 hours post-transfection and were concentrated on 
100 kDa NMWL filters (cat#UFC810096, MilliPore, Billerica, MA). CAOV3 cells 
were plated on wells of a 6 well plate, and the following day ffluc-mKate virus particles 
were added with 8 µg/ml polybrene then plate was spun at 1,800 rpm for 1.5 hours. The 
same was done for Kasumi2, except that polybrene was not added. Six hours later, the 
viral-conditioned supernatant was removed and the tissue culture media was 
immediately changed and changed the following day. Transduced CAOV3 were sub-
cultured and single-cell clones were derived from limiting dilution that displayed the 
same morphology as the parental cell line and had uniform mKate fluorescence with 
high (>106 signal to noise ratio) ffLuc activity. CAOV3 clone 1C2 was used for mouse 




experiments. Kasumi2 were sorted for mKate and were used as a bulk population for 
mouse experiments (Figure 17a and 17b). 
  





Figure 45. DNA Plasmid Map for pLVU3G-effLuc-T2A-mKateS158A. Annotations 
are, LTR: long terminal repeat; HIV cPPT: HIV central polypurine tract; B1: Gateway 
donor site B1; effLuc: enhanced firefly Luciferase; T2A: T2A ribosomal slip site; 
mKate S158A: enhanced mKate red fluorescence protein; B2: Gateway donor site B2; 
HBV PRE: Hepatitis B post-translational regulatory element; HIV SIN LTR: HIV self-
inactivating long terminal repeat; ampR: ampicillin resistance (β-Lactamase). 
  




VI.B.3. Primary Tumor Cells 
PBMC were isolated by Ficoll-Hypaque (GE Healthcare) from patients with CLL 
diagnosis after informed consent was granted. Samples were cryopreserved and were 
thawed and used the day of the experiments. All cells frozen at the Cooper Lab were 
cryopreserved in 50% FBS, 40% RPMI, 10% dimethylsulfoxide (DMSO) termed “free 
media.” All patient samples were maintained in RPMI-CM. 
 
VI.B.4. Lymphocyte Cultures 
All PBMC from adult donor blood or UCB used in this dissertation were obtained after 
informed consent and were isolated from whole blood by Ficoll-Hypaque or steady-
state apheresis. PBMC were cryopreserved and thawed for experimental use whereas 
UCB were freshly isolated and immediately used. All aAPC were γ-irradiated (100 Gy) 
prior to co-culture and were then used immediately or were cryopreserved then thawed 
at the time of the co-culture. Validation of co-expression of cell surface markers (for 
example CD19, CD64, CD86, CD137L, and IL15 (co-expressed with eGFP) for clone 
#4) were performed before addition to T-cell cultures. All lymphocyte cultures were 
maintained in RPMI-CM. 
 
VI.B.4.a. CARneg αβ T cells 
γ-irradiated clone#4 aAPC were loaded with OKT3 antibody, which is agonistic for 
CD3 thereby leading to T cell proliferation independent of the TCR specificity, by 




OKT3 antibody docking on CD64 (high-affinity Fc Receptor) expressed on aAPC. 
CD3+ T cells were stimulated with an equal number of OKT3-loaded clone#4 cells in 
the presence of exogenous IL2 (50 U/mL; Aldeleukin; Novartis, Switzerland) and IL21 
(30 ng/mL; cat#AF20021; Peprotech, Rocky Hill, NJ) unless otherwise stated. 
Exogenous IL2 and IL21 were added back to cultures every 2-3 days along with at least 
half of the current volume of RPMI-CM. 
 
VI.B.4.b. CAR+ αβ T cells 
CAR+ T cells were propagated based on modified standard operating protocols as 
previously described.(57, 273) Cryopreserved PBMC were thawed the day of the 
electroporation (designated day 0) and rested for 2 hours in RPMI-CM at 37oC. Cells 
for electroporation were spun at 200g for 10 minutes, enumerated, and 2x107 cells were 
mixed with DNA (5 µg SB11 transposase and 15 µg SB transposon) in Human T cell 
Nucleofector Solution (cat#VPA-1002, Lonza) then added to a cuvette, which was then 
electroporated on the U-014 program of Amaxa Nucleofector II (Lonza). Transfected 
cells were then added to wells of a 6-well plate containing phenol-free RPMI, 20% 
FBS, and 1x Glutamax-100. The following day, electroporated T cells were phenotyped 
and stimulated with aAPC according to their CAR expression. A ratio of 2:1 of clone#4 
to CD19-specific CAR+ T cells was used and a 1:1 ratio of clone#1 to ROR1-specific 
CAR+ T cells was used. Each co-culture was supplemented with IL21 during the first 
week (given every 2-3 days) and with both IL2 and IL21 for the subsequent weeks. 
CAR expression was evaluated each week in order to do the stimulation according to 




CAR+ T cells. If NK cells reached >10% of the total populations, they were depleted 
from co-cultures with paramagnetic CD56 microbeads (cat#130-050-401, Miltenyi 
Biotec, Auburn, CA) and LS columns (cat#130-042-401, Miltenyi Biotec). Stocks were 
made of CAR+ T cells at days 14, 21, 28, and 35 (where applicable), and inferred cell 
numbers were calculated by the number of cells that were generated multiplied by the 
fold change from the previous week relative to the number of cells that were carried 
forward. Phenotyping and functional analyses were performed between days 21 – 28 
unless otherwise stated. For ROR1-specific CAR+ T cell studies, 3 normal donors were 
tested in 3 independent experiments. 
 
VI.B.4.c. CAR+ γδ T cells 
CAR+ γδ T cells were generated as previously described.(311) Briefly, 108 PBMC were 
electroporated as described above for CAR+ αβ T cells (Chapter VI.B.4.b.), and were 
then sorted for γδ T cells using TCRγ/δ+ Isolation Kit (cat#130-092-892, Miltenyi 
Biotec). Co-cultures were established with clone#4 along with IL2 and IL21 from the 
start of the cultures where cytokines were added every 2-3 days and clone#4 aAPC was 
added every 7 days at a 2:1 ratio with CAR+ γδ T cells. NK cells were depleted from co-
cultures when they reached >10% of total cells as described above. T cells were 
phenotyped for CD3, Fc (CAR), CD56, and TCRγδ every week to monitor the co-
cultures. Cells were cryopreserved at days 21, 28, and 35 and inferred cell numbers 
were calculated as described above. Functional assays were performed between the 




third and fifth weeks of stimulation. Six donors were tested in 3 independent 
experiments. 
 
VI.B.4.d. Polyclonal γδ T cells 
Experiments were initiated to expand γδ T cells on aAPC that did not express a CAR. 
Thawed PBMC (108) were depleted of NK cells as described above and were then 
labeled with TCRγ/δ+ T-cell isolation kit and placed on LS columns to separate γδ T 
cells in the unlabeled fraction from other cells attached to magnet. γδ T cells were 
stimulated at a ratio of one T cell to two aAPC (clone #4) in presence of exogenous IL2 
and IL21. Cells were serially re-stimulated with addition of aAPC every 7 days for three 
weeks. FACS was used to isolate Vδ1 (TCRδ1+ TCRδ2neg), Vδ2 (TCRδ1neg TCRδ2+), 
and Vδ3 (TCRδ1neg TCRδ2neg) populations, which were stimulated as above with 
clone#4 aAPC twice and then phenotyped and used for functional assays. UCB-derived 
mononuclear cells were isolated from fresh Ficoll-Hypaque gradients by FACS 
following staining for TCRγδ and CD3, and were stimulated for five weeks on aAPC as 
per PBMC. Ten PBMC donors were tested in six independent experiments and five 
UCB donors were tested in four independent experiments. Four donors were tested in 2 








VI.B.4.e. NK cells 
As controls for killing and allogeneic reactivity, NK cells autologous to γδ T cells were 
separated from healthy donor PBMC with CD56 microbeads and LS columns and were 
then stimulated at a 1:2 ratio with clone#4 aAPC in cultures that were supplemented at 
the initiation of culture and every 2-3 days later with IL2 and IL21. 
 
VI.B.4.f. γδ T cell Proliferation in Hypoxia 
A dedicated incubator set to 1% O2, 5% CO2, and 37oC under humidified conditions 
was used to assess proliferation in hypoxia in parallel to “normal” tissue culture 
incubators set at 20% O2, 5% CO2, and 37oC under humidified conditions. Parallel co-
cultures were added to the incubators and were analyzed after the reported times. 
 
VI.B.5 γδ T cell Co-culture Deconstruction  
Experiments were implemented to assess the relative contribution of co-culture 
molecules to γδ T cell proliferation. This was dissected by cytokine dependence and 
dependence upon molecules on the aAPC using new aAPC described in Chapter 








VI.B.5.a. Effects of Cytokines on γδ T cell Proliferation 
In order to assess the dependence of γδ T cells on cytokines for proliferation, co-
cultures were initiated with 105 γδ T cells and 2x105 clone#4 aAPC and then were 
added to an equal volume of (i) complete media (CM), (ii) CM and 100 U/mL IL2, (iii) 
CM and 60 ng/mL IL21, or (iv) CM, 100 U/mL IL2, and 60 ng/mL IL21. Co-cultures 
were counted 9 days after initiation to determine yields. Three donors were tested in 
two independent experiments. 
 
VI.B.5.b. Effects of Co-Stimulation on γδ T cell Proliferation 
HLA-/- aAPC (Chapter VI.B.2.b) were used to assess effects of co-stimulation on γδ T 
cell growth. Co-cultures were then initiated with 105 γδ T cells in CM, 100 U/mL IL2, 
and 60 ng/mL IL21 and were added to 2x105 γ-irradiated (i) parental K562 cells, (ii) 
clone A6, (iii) clone A3, (iv) clone D4, (v) clone#4 aAPC, or (vi) no aAPC. Co-cultures 
were counted 9 days as above with cytokine experiments. Three donors were tested in 
two independent experiments. 
 
VI.C. Multiplex Gene Expression Analysis 
At Day 22 of co-culture on aAPC, >105 T cells were lysed at a ratio of 5 µL RLT Buffer 
(Qiagen) per 3x104 cells and frozen at -80oC in replicate vials for one time use. RNA 
lysates were thawed and immediately analyzed using nCounter Analysis System 




(NanoString Technologies, Seattle, WA) with “designer TCR expression array” 
(DTEA) as previously described or with “lymphocyte codeset array” (LCA; Appendix 
A).(290, 311) DTEA data was normalized to both spike positive control RNA and 
housekeeping genes (ACTB, G6PD, OAZ1, POLR1B, POLR2A, RPL27, Rps13, and 
TBP) where 2 normalization factors were calculated and applied to the raw coutns. Each 
normalization factor was calculated from the average of sums for all samples divided by 
the sum of counts for an individual sample. Reported expression of TCR frequencies for 
ROR1-specific T cells (Figure 14) was calculated as counts for each TCRα or TCRβ 
allele over the total sum of TCRα or TCRβ counts, respectively. Total counts for LCA 
genes described in ROR1-specific CAR+ T cells (Figures 12 and 13) and for TCRδ and 
TCRγ alleles in polyclonal γδ T cells were directly reported as normalized counts 
(Figure 30). For Vδ sorted γδ T cells, the normalized counts were reported at 
frequencies of each Vδ population per donor for each TCRδ or TCRγ allele (Figure 




Antibodies directly conjugated to FITC, PerCP/Cy5.5, PE, and APC were used at 1:20, 
1:33, 1:40, and 1:40 dilutions, respectively, in 100 µL FACS buffer (PBS, 0.1% FBS, 
0.1% sodium azide) unless otherwise stated. A complete list of antibodies, clonotypes, 
and vendors can be found in Appendix B. CAR detection was primarily performed with 
anti-human Fc antibody (Invitrogen). CD19-specific CAR was stained with an idiotypic 




antibody conjugated to AlexFluor-647 in some instances.(259) BD FACS CAlibur was 
used for most flow cytometry. Samples were analyzed with FlowJo software (version 
7.6.5). BD FACS Aria Ilu II was used to sort cells where appropriate and was used to 
isolate single cell clones in 96 well plates for aAPC cloning strategies. Tumor cells 
transduced with ffLuc-mKate lentivirus particles were sorted for mKate expression on 
BD Influx for bulk populations or as single cell clones as appropriate. 
 
VI.E. Cytokine Production 
Expression of cytokines was assessed by intracellular cytokine staining (ICS) and 
secretion of cytokines into tissue culture supernatants was evaluated by Luminex 
multiplex analysis. Co-cultures were set up with T cells and targets as described for 
each experiment and were incubated at 37oC. For ICS, Brefeldin-A (GolgiPlug; BD 
Biosciences) was added to co-cultures to block exocytosis and secretion of cytokines 
produced in response to agonists. All ICS experiments were incubated for 6 hours and 
were then (i) stained for surface markers, e.g. CD3 and CAR, (ii) fixed and 
permeabilized with BD Cytofix/Cytoperm (BD Biosciences), (iii) stained for 
intracellular proteins, e.g. IFNγ and TNFα, and (iv) analyzed by flow cytometry. Co-
cultures to assess cytokine secretion were incubated for 24 hours and supernatants from 
triplicate wells were pooled and analyzed by Bio-Plex Human Cytokine Group I 27-
plex Assay (#L50-0KCAF0Y, BioRad Technologies, Hercules, CA) using Luminex100 
(xMap Technologies, Austin, TX). 
 




VI.F. In Vitro Killing Assays 
VI.F.1. Chromium Release Assay 
In vitro specific lysis was assessed using a standard 4-hour CRA, as previously 
described.(57) Purified antibodies specific for NKG2D (clone 1D11; BD Biosciences), 
DNAM1 (clone DX11; BD Biosciences), TCRγδ (clone B1; BD Biosciences), and 
TCRγδ (clone IMMU510; Thermo Fisher, Pittsburg, PA) were used for neutralization 
experiments at 0.3, 1.0, and 3.0 µg/mL final concentrations in CRA at E:T ratios of 
12:1. Normal mouse serum was used as a negative control at the same concentrations. 
 
VI.F.2. Long-term Killing Assay 
Tumor cells were seeded in wells of 12-well plates at a density of 4x104 cells/well. The 
following day, 5x105 γδ T cells were added to each well of the plate and an equal 
number was added to a well without tumor cells (media only). One well of tumor cells 
had an equal volume of RPMI-CM added as a positive control for growth. After 2 days, 
supernatants were harvested, wells were washed in PBS, and remaining tumor cells 
were harvested with trypsin-EDTA and were then enumerated. The frequencies of cells 








VI.G. Mixed Lymphocyte Reactions 
B cells from healthy donors were isolated with CD19 microbeads (cat#130-050-301, 
Miltenyi Biotec) the day of each assay and were used as target cells in proliferation, 
IFNγ production (ELISpot), and cytolysis assays. Standard 4-hour CRA were used for 
the latter as described above. For proliferation assays, effector cells were labeled with 
PKH26 red fluorescent dye according to manufacturer’s instructions (Sigma) and were 
co-cultured with target cells for 4 days at 37oC at an E:T ratio of 5:1. Co-cultures were 
stained for CD3, CD19, and CD56 then were analyzed by flow cytometry. Similarly, 
IFNγ ELISpot plate (Mabtech, Mariemont, OH) was set up with effector (γδ T cells) 
and target (B cells) at an E:T ratio of 0.3:1 and plate was incubated for 24 hours at 37oC 
then stained according to manufacturer’s instructions, and spots were counted on 
Immunospot (CTL, Shaker Heights, OH). OKT3-loaded aAPC were used as positive 
controls and mock treated were used as negative controls along with autologous B cells. 
Co-cultures of effectors and allogeneic PBMC (normalized to equal CD34+ cells) at a 
4:1 ratio of effectors to CD34+ HSC were incubated at 37oC for 4 hours and were then 
plated in wells of 6-well plates in semi-solid HSC-CFU Complete without EPO 
(Miltenyi Biotec). After 12 days, individual colonies were counted under inverted 
microscope. Colonies formed with effectors alone or targets alone were used to 








VI.H. In Vivo Anti-tumor Activity 
In vivo anti-tumor efficacy was assessed in NSG mice (NOD.Cg-Prkdcscid 
Il2rγtm1Wjl/SzJ; Jackson Laboratories). Non-invasive BLI was performed during the 
course of the experiments to measure tumor burden of cell lines expressing ffLuc 
following subcutaneous D-Luciferin (cat#122796, Caliper, Hopkinton, MA) 
administration with IVIS-100 Imager (Caliper). BLI was analyzed using Living Image 
software (version 2.50, Xenogen, Caliper). 
 
VI.H.1. ROR1-specific Anti-leukemia Effects 
Kasumi-2-ffLuc-mKate cells (4x104 per mouse) were engrafted into NSG mice (n = 15) 
intravenously (i.v.) the day before the first T cell dose (designated Day -1). The 
following day (Day 0), treatment groups for mice with tumors were set up with (i) no 
treatment (n = 5), (ii) ROR1RCD28 T cells (n = 5), and (iii) ROR1RCD137 T cells (n = 
5). Mice were injected with T cells only as controls for xenogeneic reactivity (one 
mouse per T cell type). T cell doses (107 total cells per mouse) were given on days 0, 7, 
and 14. Frequencies for CAR expression for ROR1RCD28 were 96%, 91%, and 90% 
and for ROR1RCD137 were 94%, 62%, and 46% on days 0, 7, and 14, respectively. 
Survival was the primary endpoint for the study and BLI from tumor ffLuc was 
monitored twice per week as above. 
 
 




VI.H.2. CD19-specific Anti-leukemia Activity 
The anti-tumor effects of CD19-specific CAR+ γδ T cells were evaluated as previously 
described.(311) 
 
VI.H.3. γδ T cells Clearance of Ovarian Cancer 
CAOV3-ffLuc-mkate (clone 1C2; 3x106 cells/mouse) tumors were established by 
intraperitoneal (i.p.) injection and mice were randomly distributed into treatment 
groups. Eight days later (designated Day 0), a dose escalation regimen was initiated 
with polyclonal γδ T cells administered i.p. and PBS administered i.p. as a negative 
control. T cell doses infused were 3x106, 6x106, 107, and 1.5x107 on days 0, 7, 14, and 
21, respectively. BLI was monitored during the course of the experiment by weekly 
monitoring of tumor ffLuc activity as above. Survival was the primary endpoint for the 
experiment.  





Appendix A. Lymphocyte CodeSet Array 
GENE ID Access-ion 
Target 



























































































































BAD NM_004 195-295 CAGCTGTGCCTTGACTACGTAACATCTTGTCCTCACAGCCCAGAGCATGTTCC







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix B. Antibodies Used in Dissertation 
Antibody specificity Clone Vendor 
Fc* H10104 Invitrogen 
anti-CD19scFv mAb** 136.20.1 Cooper Lab 
ROR1 4A5 Kipps, TJ Lab (UCSD) 
CD3 SK7 BD Biosciences 
CD4 RPA-T4 BD Biosciences 
CD8 RPA-T8 BD Biosciences 
CD19 HIB19 BD Biosciences 
CD25 M-A251 BD Biosciences 
CD27 M-T271 BD Biosciences 
CD28 L293 BD Biosciences 
CD32 FLI8.26 (2003) BD Biosciences 
CD38 HB7 BD Biosciences 
CD45RA HI100 BD Biosciences 
CD45RO UCHL1 BD Biosciences 
CD56 B159 BD Biosciences 
CD57 NK-1 BD Biosciences 
CD62L Dreg 56 BD Biosciences 




CD64 10.1 BD Biosciences 
CD86 2331 FUN-1 BD Biosciences 
CD95 DX2 BD Biosciences 
CD122 TM-Beta 1 BD Biosciences 
CD127 HIL-7R-M21 BD Biosciences 
CD137 4B4-1 BD Biosciences 
CD137L C65-485 BD Biosciences 
CCR7*** TG8 eBiosciences 
CXCR4 12G5 BD Biosciences 
CLA HECA-452 BD Biosciences 
CCR4 1G1 BD Biosciences 
ICOS ISA-3 eBiosciences 
ICOS-L MIH12 eBiosciences 
OX40 ACT35 BD Biosciences 
PD-1 MIH4 BD Biosciences 
TCRαβ WT31 BD Biosciences 
TCRγδ B1 BD Biosciences 
TCRγδ IMMU510 Thermo Fisher 
TCRδ1 TS-1 Thermo/Pierce 




TCRδ2 B6 BD Biosciences 
TCRγ9 B3 BD Biosciences 
invariant NKT 6B11 BD Biosciences 
NMS 015-000-120 Jackson ImmunoResearch 
DNAM1 DX11 BD Biosciences 
NKG2D 1D11 BD Biosciences 
IL15 34559 R&D Systems 
IFNγ 4S.B3 BD Biosciences 
TNFα MAb11 BD Biosciences 
 
* To detect CAR expression 
** To detect CD19-specific CAR expression 
*** Used at 1:67 dilution 
  





1. http://www.cdc.gov/nchs/fastats/lcod.htm. 2010. Leading Causes of Death. In 
FastStats Homepage. National Center for Health Statistics, Centers for Disease 
Control and Prevention. 
2. Siegel, R., C. DeSantis, K. Virgo, K. Stein, A. Mariotto, T. Smith, D. Cooper, T. 
Gansler, C. Lerro, S. Fedewa, C. Lin, C. Leach, R. S. Cannady, H. Cho, S. 
Scoppa, M. Hachey, R. Kirch, A. Jemal, and E. Ward. 2012. Cancer treatment 
and survivorship statistics, 2012. CA Cancer J Clin 62:220-241. 
3. Matasar, M. J., E. K. Ritchie, N. Consedine, C. Magai, and A. I. Neugut. 2006. 
Incidence rates of the major leukemia subtypes among US Hispanics, Blacks, 
and non-Hispanic Whites. Leukemia & Lymphoma 47:2365-2370. 
4. Grupp, S. A., M. Kalos, D. Barrett, R. Aplenc, D. L. Porter, S. R. Rheingold, D. 
T. Teachey, A. Chew, B. Hauck, J. F. Wright, M. C. Milone, B. L. Levine, and 
C. H. June. 2013. Chimeric antigen receptor-modified T cells for acute 
lymphoid leukemia. The New England Journal of Medicine 368:1509-1518. 
5. Kochenderfer, J. N., M. E. Dudley, S. A. Feldman, W. H. Wilson, D. E. Spaner, 
I. Maric, M. Stetler-Stevenson, G. Q. Phan, M. S. Hughes, R. M. Sherry, J. C. 
Yang, U. S. Kammula, L. Devillier, R. Carpenter, D. A. Nathan, R. A. Morgan, 
C. Laurencot, and S. A. Rosenberg. 2012. B-cell depletion and remissions of 
malignancy along with cytokine-associated toxicity in a clinical trial of anti-
CD19 chimeric-antigen-receptor-transduced T cells. Blood 119:2709-2720. 
6. Brentjens, R. J., I. Riviere, J. H. Park, M. L. Davila, X. Wang, J. Stefanski, C. 
Taylor, R. Yeh, S. Bartido, O. Borquez-Ojeda, M. Olszewska, Y. Bernal, H. 




Pegram, M. Przybylowski, D. Hollyman, Y. Usachenko, D. Pirraglia, J. Hosey, 
E. Santos, E. Halton, P. Maslak, D. Scheinberg, J. Jurcic, M. Heaney, G. Heller, 
M. Frattini, and M. Sadelain. 2011. Safety and persistence of adoptively 
transferred autologous CD19-targeted T cells in patients with relapsed or 
chemotherapy refractory B-cell leukemias. Blood 118:4817-4828. 
7. Porter, D. L., B. L. Levine, M. Kalos, A. Bagg, and C. H. June. 2011. Chimeric 
antigen receptor-modified T cells in chronic lymphoid leukemia. The New 
England Journal of Medicine 365:725-733. 
8. McNeer, J. L., and E. A. Raetz. 2012. Acute lymphoblastic leukemia in young 
adults: which treatment? Current Opinion in Oncology 24:487-494. 
9. Lo Nigro, L. 2013. Biology of childhood acute lymphoblastic leukemia. Journal 
of Pediatric Hematology/Oncology 35:245-252. 
10. Belson, M., B. Kingsley, and A. Holmes. 2007. Risk factors for acute leukemia 
in children: a review. Environmental Health Perspectives 115:138-145. 
11. Cobaleda, C., and I. Sanchez-Garcia. 2009. B-cell acute lymphoblastic 
leukaemia: towards understanding its cellular origin. BioEssays : news and 
reviews in molecular, cellular and developmental biology 31:600-609. 
12. Aspland, S. E., H. H. Bendall, and C. Murre. 2001. The role of E2A-PBX1 in 
leukemogenesis. Oncogene 20:5708-5717. 
13. Bicocca, V. T., B. H. Chang, B. K. Masouleh, M. Muschen, M. M. Loriaux, B. 
J. Druker, and J. W. Tyner. 2012. Crosstalk between ROR1 and the Pre-B cell 
receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell 
22:656-667. 




14. Onciu, M. 2009. Acute lymphoblastic leukemia. Hematology/Oncology Clinics 
of North America 23:655-674. 
15. Faderl, S., S. O'Brien, C. H. Pui, W. Stock, M. Wetzler, D. Hoelzer, and H. M. 
Kantarjian. 2010. Adult acute lymphoblastic leukemia: concepts and strategies. 
Cancer 116:1165-1176. 
16. Oliansky, D. M., B. Camitta, P. Gaynon, M. L. Nieder, S. K. Parsons, M. A. 
Pulsipher, H. Dillon, T. A. Ratko, D. Wall, P. L. McCarthy, Jr., T. Hahn, B. 
American Society for, and T. Marrow. 2012. Role of cytotoxic therapy with 
hematopoietic stem cell transplantation in the treatment of pediatric acute 
lymphoblastic leukemia: update of the 2005 evidence-based review. Biology of 
Blood and Marrow Transplantation : Journal of the American Society for Blood 
and Marrow Transplantation 18:505-522. 
17. Pulsipher, M. A., C. Peters, and C. H. Pui. 2011. High-risk pediatric acute 
lymphoblastic leukemia: to transplant or not to transplant? Biology of Blood and 
Marrow Transplantation : Journal of the American Society for Blood and 
Marrow Transplantation 17:S137-148. 
18. Forman, S. J., and J. M. Rowe. 2013. The myth of the second remission of acute 
leukemia in the adult. Blood 121:1077-1082. 
19. Borowitz, M. J., M. Devidas, S. P. Hunger, W. P. Bowman, A. J. Carroll, W. L. 
Carroll, S. Linda, P. L. Martin, D. J. Pullen, D. Viswanatha, C. L. Willman, N. 
Winick, B. M. Camitta, and G. Children's Oncology. 2008. Clinical significance 
of minimal residual disease in childhood acute lymphoblastic leukemia and its 




relationship to other prognostic factors: a Children's Oncology Group study. 
Blood 111:5477-5485. 
20. Pullen, J., J. J. Shuster, M. Link, M. Borowitz, M. Amylon, A. J. Carroll, V. 
Land, A. T. Look, B. McIntyre, and B. Camitta. 1999. Significance of 
commonly used prognostic factors differs for children with T cell acute 
lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A 
Pediatric Oncology Group (POG) study. Leukemia 13:1696-1707. 
21. Shimizu, H., H. Handa, N. Hatsumi, S. Takada, T. Saitoh, T. Sakura, S. 
Miyawaki, and Y. Nojima. 2013. Distinctive disease subgroups according to 
differentiation stages in adult patients with T-cell acute lymphoblastic leukemia. 
European Journal of Haematology 90:301-307. 
22. Fielding, A. K., L. Banerjee, and D. I. Marks. 2012. Recent developments in the 
management of T-cell precursor acute lymphoblastic leukemia/lymphoma. 
Current Hematologic Malignancy Reports 7:160-169. 
23. Szczepanski, T., V. H. van der Velden, E. Waanders, R. P. Kuiper, P. Van 
Vlierberghe, B. Gruhn, C. Eckert, R. Panzer-Grumayer, G. Basso, H. Cave, U. 
Z. Stadt, D. Campana, A. Schrauder, R. Sutton, E. van Wering, J. P. Meijerink, 
and J. J. van Dongen. 2011. Late recurrence of childhood T-cell acute 
lymphoblastic leukemia frequently represents a second leukemia rather than a 
relapse: first evidence for genetic predisposition. Journal of Clinical Oncology : 
Official Journal of the American Society of Clinical Oncology 29:1643-1649. 
24. Van Vlierberghe, P., and A. Ferrando. 2012. The molecular basis of T cell acute 
lymphoblastic leukemia. The Journal of clinical investigation 122:3398-3406. 




25. McGregor, S., J. McNeer, and S. Gurbuxani. 2012. Beyond the 2008 World 
Health Organization classification: the role of the hematopathology laboratory in 
the diagnosis and management of acute lymphoblastic leukemia. Seminars in 
Diagnostic Pathology 29:2-11. 
26. Tam, C. S., and M. J. Keating. 2010. Chemoimmunotherapy of chronic 
lymphocytic leukemia. Nature reviews. Clinical Oncology 7:521-532. 
27. Chiorazzi, N., K. R. Rai, and M. Ferrarini. 2005. Chronic lymphocytic leukemia. 
The New England Journal of Medicine 352:804-815. 
28. Binet, J. L., F. Caligaris-Cappio, D. Catovsky, B. Cheson, T. Davis, G. 
Dighiero, H. Dohner, M. Hallek, P. Hillmen, M. Keating, E. Montserrat, T. J. 
Kipps, K. Rai, and L. International Workshop on Chronic Lymphocytic. 2006. 
Perspectives on the use of new diagnostic tools in the treatment of chronic 
lymphocytic leukemia. Blood 107:859-861. 
29. Yee, K. W., and S. M. O'Brien. 2006. Chronic lymphocytic leukemia: diagnosis 
and treatment. Mayo Clinic proceedings. Mayo Clinic 81:1105-1129. 
30. Wierda, W. G., T. J. Kipps, and M. J. Keating. 2005. Novel immune-based 
treatment strategies for chronic lymphocytic leukemia. Journal of Clinical 
Oncology : Official Journal of the American Society of Clinical Oncology 
23:6325-6332. 
31. Cooper, L. J., Z. Al-Kadhimi, D. DiGiusto, M. Kalos, D. Colcher, A. 
Raubitschek, S. J. Forman, and M. C. Jensen. 2004. Development and 
application of CD19-specific T cells for adoptive immunotherapy of B cell 
malignancies. Blood Cells Mol Dis 33:83-89. 




32. Kalos, M., B. L. Levine, D. L. Porter, S. Katz, S. A. Grupp, A. Bagg, and C. H. 
June. 2011. T cells with chimeric antigen receptors have potent antitumor effects 
and can establish memory in patients with advanced leukemia. Science 
Translational Medicine 3:95ra73. 
33. Rauh-Hain, J. A., T. C. Krivak, M. G. Del Carmen, and A. B. Olawaiye. 2011. 
Ovarian cancer screening and early detection in the general population. Rev 
Obstet Gynecol 4:15-21. 
34. Lowe, K. A., V. M. Chia, A. Taylor, C. O'Malley, M. Kelsh, M. Mohamed, F. S. 
Mowat, and B. Goff. 2013. An international assessment of ovarian cancer 
incidence and mortality. Gynecologic Oncology. 
35. Baldwin, L. A., B. Huang, R. W. Miller, T. Tucker, S. T. Goodrich, I. 
Podzielinski, C. P. DeSimone, F. R. Ueland, J. R. van Nagell, and L. G. 
Seamon. 2012. Ten-year relative survival for epithelial ovarian cancer. 
Obstetrics and Gynecology 120:612-618. 
36. Pignata, S., L. Cannella, D. Leopardo, C. Pisano, G. S. Bruni, and G. Facchini. 
2011. Chemotherapy in epithelial ovarian cancer. Cancer Letters 303:73-83. 
37. Lengyel, E. 2010. Ovarian cancer development and metastasis. The American 
journal of pathology 177:1053-1064. 
38. Moore, R. G., S. MacLaughlan, and R. C. Bast, Jr. 2010. Current state of 
biomarker development for clinical application in epithelial ovarian cancer. 
Gynecologic Oncology 116:240-245. 




39. Mould, T. 2012. An overview of current diagnosis and treatment in ovarian 
cancer. International Journal of Gynecological Cancer : Official Journal of the 
International Gynecological Cancer Society 22 Suppl 1:S2-4. 
40. Le, X. F., and R. C. Bast, Jr. 2011. Src family kinases and paclitaxel sensitivity. 
Cancer Biology & Therapy 12:260-269. 
41. Brahmer, J. R., S. S. Tykodi, L. Q. Chow, W. J. Hwu, S. L. Topalian, P. Hwu, 
C. G. Drake, L. H. Camacho, J. Kauh, K. Odunsi, H. C. Pitot, O. Hamid, S. 
Bhatia, R. Martins, K. Eaton, S. Chen, T. M. Salay, S. Alaparthy, J. F. Grosso, 
A. J. Korman, S. M. Parker, S. Agrawal, S. M. Goldberg, D. M. Pardoll, A. 
Gupta, and J. M. Wigginton. 2012. Safety and activity of anti-PD-L1 antibody in 
patients with advanced cancer. The New England Journal of Medicine 
366:2455-2465. 
42. Kershaw, M. H., J. A. Westwood, L. L. Parker, G. Wang, Z. Eshhar, S. A. 
Mavroukakis, D. E. White, J. R. Wunderlich, S. Canevari, L. Rogers-Freezer, C. 
C. Chen, J. C. Yang, S. A. Rosenberg, and P. Hwu. 2006. A phase I study on 
adoptive immunotherapy using gene-modified T cells for ovarian cancer. 
Clinical Cancer Research : An Official Journal of the American Association for 
Cancer Research 12:6106-6115. 
43. Fujita, K., H. Ikarashi, K. Takakuwa, S. Kodama, A. Tokunaga, T. Takahashi, 
and K. Tanaka. 1995. Prolonged disease-free period in patients with advanced 
epithelial ovarian cancer after adoptive transfer of tumor-infiltrating 
lymphocytes. Clinical Cancer Research : An Official Journal of the American 
Association for Cancer Research 1:501-507. 




44. Hung, C. F., T. C. Wu, A. Monie, and R. Roden. 2008. Antigen-specific 
immunotherapy of cervical and ovarian cancer. Immunological Reviews 222:43-
69. 
45. Saif, M. W. 2013. Advancements in the management of pancreatic cancer: 2013. 
JOP : Journal of the Pancreas 14:112-118. 
46. Sharma, C., K. M. Eltawil, P. D. Renfrew, M. J. Walsh, and M. Molinari. 2011. 
Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-
2010. World Journal of Gastroenterology : WJG 17:867-897. 
47. DiMagno, E. P. 1999. Pancreatic cancer: clinical presentation, pitfalls and early 
clues. Annals of Oncology : Official Journal of the European Society for 
Medical Oncology / ESMO 10 Suppl 4:140-142. 
48. Paulson, A. S., H. S. Tran Cao, M. A. Tempero, and A. M. Lowy. 2013. 
Therapeutic advances in pancreatic cancer. Gastroenterology 144:1316-1326. 
49. Di Marco, M., R. Di Cicilia, M. Macchini, E. Nobili, S. Vecchiarelli, G. Brandi, 
and G. Biasco. 2010. Metastatic pancreatic cancer: is gemcitabine still the best 
standard treatment? (Review). Oncology Reports 23:1183-1192. 
50. el-Kamar, F. G., M. L. Grossbard, and P. S. Kozuch. 2003. Metastatic pancreatic 
cancer: emerging strategies in chemotherapy and palliative care. Oncologist 
8:18-34. 
51. Koido, S., S. Homma, A. Takahara, Y. Namiki, S. Tsukinaga, J. Mitobe, S. 
Odahara, T. Yukawa, H. Matsudaira, K. Nagatsuma, K. Uchiyama, K. Satoh, M. 
Ito, H. Komita, H. Arakawa, T. Ohkusa, J. Gong, and H. Tajiri. 2011. Current 




immunotherapeutic approaches in pancreatic cancer. Clinical & Developmental 
Immunology 2011:267539. 
52. Plate, J. M. 2012. Advances in therapeutic vaccines for pancreatic cancer. 
Discovery Medicine 14:89-94. 
53. Gordan, J. D., and R. H. Vonderheide. 2002. Universal tumor antigens as targets 
for immunotherapy. Cytotherapy 4:317-327. 
54. Offringa, R. 2009. Antigen choice in adoptive T-cell therapy of cancer. Current 
Opinion in Immunology 21:190-199. 
55. Zhou, G., and H. Levitsky. 2012. Towards curative cancer immunotherapy: 
overcoming posttherapy tumor escape. Clinical & Developmental Immunology 
2012:124187. 
56. Kochenderfer, J. N., W. H. Wilson, J. E. Janik, M. E. Dudley, M. Stetler-
Stevenson, S. A. Feldman, I. Maric, M. Raffeld, D. A. Nathan, B. J. Lanier, R. 
A. Morgan, and S. A. Rosenberg. 2010. Eradication of B-lineage cells and 
regression of lymphoma in a patient treated with autologous T cells genetically 
engineered to recognize CD19. Blood 116:4099-4102. 
57. Singh, H., M. J. Figliola, M. J. Dawson, H. Huls, S. Olivares, K. Switzer, T. Mi, 
S. Maiti, P. Kebriaei, D. A. Lee, R. E. Champlin, and L. J. Cooper. 2011. 
Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve 
Adoptive Immunotherapy of B-Lineage Malignancies. Cancer Research 
71:3516-3527. 
58. Chaplin, D. D. 2010. Overview of the immune response. J Allergy Clin 
Immunol 125:S3-23. 




59. Boackle, S. A., M. A. Morris, V. M. Holers, and D. R. Karp. 1998. Complement 
opsonization is required for presentation of immune complexes by resting 
peripheral blood B cells. Journal of Immunology 161:6537-6543. 
60. Rickert, R. C. 2005. Regulation of B lymphocyte activation by complement C3 
and the B cell coreceptor complex. Current Opinion in Immunology 17:237-243. 
61. Cherukuri, A., T. Shoham, H. W. Sohn, S. Levy, S. Brooks, R. Carter, and S. K. 
Pierce. 2004. The tetraspanin CD81 is necessary for partitioning of coligated 
CD19/CD21-B cell antigen receptor complexes into signaling-active lipid rafts. 
Journal of Immunology 172:370-380. 
62. Carter, R. H., Y. Wang, and S. Brooks. 2002. Role of CD19 signal transduction 
in B cell biology. Immunologic Research 26:45-54. 
63. Jolles, S., W. A. Sewell, and S. A. Misbah. 2005. Clinical uses of intravenous 
immunoglobulin. Clin Exp Immunol 142:1-11. 
64. Rebagay, G., S. Yan, C. Liu, and N. K. Cheung. 2012. ROR1 and ROR2 in 
Human Malignancies: Potentials for Targeted Therapy. Frontiers in Oncology 
2:34. 
65. Baskar, S., K. Y. Kwong, T. Hofer, J. M. Levy, M. G. Kennedy, E. Lee, L. M. 
Staudt, W. H. Wilson, A. Wiestner, and C. Rader. 2008. Unique cell surface 
expression of receptor tyrosine kinase ROR1 in human B-cell chronic 
lymphocytic leukemia. Clinical Cancer Research : An Official Journal of the 
American Association for Cancer Research 14:396-404. 
66. Broome, H. E., L. Z. Rassenti, H. Y. Wang, L. M. Meyer, and T. J. Kipps. 2011. 
ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte 




precursors) and a minority of precursor-B acute lymphoblastic leukemia. 
Leukemia Research 35:1390-1394. 
67. Zhang, S., L. Chen, J. Wang-Rodriguez, L. Zhang, B. Cui, W. Frankel, R. Wu, 
and T. J. Kipps. 2012. The onco-embryonic antigen ROR1 is expressed by a 
variety of human cancers. The American Journal of Pathology 181:1903-1910. 
68. Masiakowski, P., and R. D. Carroll. 1992. A novel family of cell surface 
receptors with tyrosine kinase-like domain. The Journal of Biological Chemistry 
267:26181-26190. 
69. Nomi, M., I. Oishi, S. Kani, H. Suzuki, T. Matsuda, A. Yoda, M. Kitamura, K. 
Itoh, S. Takeuchi, K. Takeda, S. Akira, M. Ikeya, S. Takada, and Y. Minami. 
2001. Loss of mRor1 enhances the heart and skeletal abnormalities in mRor2-
deficient mice: redundant and pleiotropic functions of mRor1 and mRor2 
receptor tyrosine kinases. Molecular and Cellular Biology 21:8329-8335. 
70. Takeuchi, S., K. Takeda, I. Oishi, M. Nomi, M. Ikeya, K. Itoh, S. Tamura, T. 
Ueda, T. Hatta, H. Otani, T. Terashima, S. Takada, H. Yamamura, S. Akira, and 
Y. Minami. 2000. Mouse Ror2 receptor tyrosine kinase is required for the heart 
development and limb formation. Genes to Cells : Devoted to Molecular & 
Cellular Mechanisms 5:71-78. 
71. Reddy, U. R., S. Phatak, C. Allen, L. M. Nycum, E. P. Sulman, P. S. White, and 
J. A. Biegel. 1997. Localization of the human Ror1 gene (NTRKR1) to 
chromosome 1p31-p32 by fluorescence in situ hybridization and somatic cell 
hybrid analysis. Genomics 41:283-285. 




72. Schwabe, G. C., B. Trepczik, K. Suring, N. Brieske, A. S. Tucker, P. T. Sharpe, 
Y. Minami, and S. Mundlos. 2004. Ror2 knockout mouse as a model for the 
developmental pathology of autosomal recessive Robinow syndrome. 
Developmental Dynamics : An Official Publication of the American Association 
of Anatomists 229:400-410. 
73. van Bokhoven, H., J. Celli, H. Kayserili, E. van Beusekom, S. Balci, W. Brussel, 
F. Skovby, B. Kerr, E. F. Percin, N. Akarsu, and H. G. Brunner. 2000. Mutation 
of the gene encoding the ROR2 tyrosine kinase causes autosomal recessive 
Robinow syndrome. Nature Genetics 25:423-426. 
74. Oldridge, M., A. M. Fortuna, M. Maringa, P. Propping, S. Mansour, C. Pollitt, 
T. M. DeChiara, R. B. Kimble, D. M. Valenzuela, G. D. Yancopoulos, and A. O. 
Wilkie. 2000. Dominant mutations in ROR2, encoding an orphan receptor 
tyrosine kinase, cause brachydactyly type B. Nature Genetics 24:275-278. 
75. Fukuda, T., L. Chen, T. Endo, L. Tang, D. Lu, J. E. Castro, G. F. Widhopf, 2nd, 
L. Z. Rassenti, M. J. Cantwell, C. E. Prussak, D. A. Carson, and T. J. Kipps. 
2008. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells 
identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proceedings of 
the National Academy of Sciences of the United States of America 105:3047-
3052. 
76. Daneshmanesh, A. H., E. Mikaelsson, M. Jeddi-Tehrani, A. A. Bayat, R. Ghods, 
M. Ostadkarampour, M. Akhondi, S. Lagercrantz, C. Larsson, A. Osterborg, F. 
Shokri, H. Mellstedt, and H. Rabbani. 2008. Ror1, a cell surface receptor 




tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a 
putative target for therapy. International Journal of Cancer 123:1190-1195. 
77. Hudecek, M., T. M. Schmitt, S. Baskar, M. T. Lupo-Stanghellini, T. Nishida, T. 
N. Yamamoto, M. Bleakley, C. J. Turtle, W. C. Chang, H. A. Greisman, B. 
Wood, D. G. Maloney, M. C. Jensen, C. Rader, and S. R. Riddell. 2010. The B-
cell tumor-associated antigen ROR1 can be targeted with T cells modified to 
express a ROR1-specific chimeric antigen receptor. Blood 116:4532-4541. 
78. Gentile, A., L. Lazzari, S. Benvenuti, L. Trusolino, and P. M. Comoglio. 2011. 
Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer 
Research 71:3132-3141. 
79. Zhang, S., L. Chen, B. Cui, H. Y. Chuang, J. Yu, J. Wang-Rodriguez, L. Tang, 
G. Chen, G. W. Basak, and T. J. Kipps. 2012. ROR1 is expressed in human 
breast cancer and associated with enhanced tumor-cell growth. PloS One 
7:e31127. 
80. Hojjat-Farsangi, M., F. Ghaemimanesh, A. H. Daneshmanesh, A. A. Bayat, J. 
Mahmoudian, M. Jeddi-Tehrani, H. Rabbani, and H. Mellstedt. 2013. Inhibition 
of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies 
and siRNA Induced Apoptosis of Melanoma Cells. PloS One 8:e61167. 
81. Dave, H., M. R. Anver, D. O. Butcher, P. Brown, J. Khan, A. S. Wayne, S. 
Baskar, and C. Rader. 2012. Restricted cell surface expression of receptor 
tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia 
suggests targetability with therapeutic monoclonal antibodies. PloS One 
7:e52655. 




82. Li, P., D. Harris, Z. Liu, J. Liu, M. Keating, and Z. Estrov. 2010. Stat3 activates 
the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic 
leukemia cells. PloS One 5:e11859. 
83. Medzhitov, R., and C. Janeway, Jr. 2000. Innate immunity. The New England 
Journal of Medicine 343:338-344. 
84. Hoebe, K., E. Janssen, and B. Beutler. 2004. The interface between innate and 
adaptive immunity. Nature Immunology 5:971-974. 
85. Schenten, D., and R. Medzhitov. 2011. The control of adaptive immune 
responses by the innate immune system. Advances in Immunology 109:87-124. 
86. Vesely, M. D., M. H. Kershaw, R. D. Schreiber, and M. J. Smyth. 2011. Natural 
innate and adaptive immunity to cancer. Annual Review of Immunology 
29:235-271. 
87. Janeway, C. A., Jr., and R. Medzhitov. 2002. Innate immune recognition. 
Annual review of Immunology 20:197-216. 
88. Clem, A. S. 2011. Fundamentals of vaccine immunology. Journal of Global 
Infectious Diseases 3:73-78. 
89. Elgueta, R., V. C. de Vries, and R. J. Noelle. 2010. The immortality of humoral 
immunity. Immunological Reviews 236:139-150. 
90. Koretzky, G. A. 2010. Multiple roles of CD4 and CD8 in T cell activation. 
Journal of Immunology 185:2643-2644. 
91. Nishana, M., and S. C. Raghavan. 2012. Role of recombination activating genes 
in the generation of antigen receptor diversity and beyond. Immunology 
137:271-281. 




92. Kreslavsky, T., M. Gleimer, A. I. Garbe, and H. von Boehmer. 2010. alphabeta 
versus gammadelta fate choice: counting the T-cell lineages at the branch point. 
Immunological Reviews 238:169-181. 
93. Mackelprang, R., C. S. Carlson, L. Subrahmanyan, R. J. Livingston, M. A. 
Eberle, and D. A. Nickerson. 2002. Sequence variation in the human T-cell 
receptor loci. Immunological Reviews 190:26-39. 
94. Marrack, P., J. P. Scott-Browne, S. Dai, L. Gapin, and J. W. Kappler. 2008. 
Evolutionarily conserved amino acids that control TCR-MHC interaction. 
Annual review of Immunology 26:171-203. 
95. Bednarski, J. J., and B. P. Sleckman. 2012. Lymphocyte development: 
integration of DNA damage response signaling. Advances in Immunology 
116:175-204. 
96. Ramsden, D. A., B. D. Weed, and Y. V. Reddy. 2010. V(D)J recombination: 
Born to be wild. Seminars in Cancer Biology 20:254-260. 
97. Spits, H. 2002. Development of alphabeta T cells in the human thymus. Nature 
Reviews. Immunology 2:760-772. 
98. Robins, H. S., P. V. Campregher, S. K. Srivastava, A. Wacher, C. J. Turtle, O. 
Kahsai, S. R. Riddell, E. H. Warren, and C. S. Carlson. 2009. Comprehensive 
assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 
114:4099-4107. 
99. Stritesky, G. L., S. C. Jameson, and K. A. Hogquist. 2012. Selection of self-
reactive T cells in the thymus. Annual Review of Immunology 30:95-114. 




100. Halkias, J., H. J. Melichar, K. T. Taylor, J. O. Ross, B. Yen, S. B. Cooper, A. 
Winoto, and E. A. Robey. 2013. Opposing chemokine gradients control human 
thymocyte migration in situ. The Journal of Clinical Investigation. 
101. Stefanski, H. E., D. Mayerova, S. C. Jameson, and K. A. Hogquist. 2001. A low 
affinity TCR ligand restores positive selection of CD8+ T cells in vivo. Journal 
of Immunology 166:6602-6607. 
102. Yin, L., J. Scott-Browne, J. W. Kappler, L. Gapin, and P. Marrack. 2012. T cells 
and their eons-old obsession with MHC. Immunological Reviews 250:49-60. 
103. Capone, M., P. Romagnoli, F. Beermann, H. R. MacDonald, and J. P. van 
Meerwijk. 2001. Dissociation of thymic positive and negative selection in 
transgenic mice expressing major histocompatibility complex class I molecules 
exclusively on thymic cortical epithelial cells. Blood 97:1336-1342. 
104. Akirav, E. M., N. H. Ruddle, and K. C. Herold. 2011. The role of AIRE in 
human autoimmune disease. Nature Reviews. Endocrinology 7:25-33. 
105. Germain, R. N. 2002. T-cell development and the CD4-CD8 lineage decision. 
Nature reviews. Immunology 2:309-322. 
106. Van Laethem, F., A. N. Tikhonova, and A. Singer. 2012. MHC restriction is 
imposed on a diverse T cell receptor repertoire by CD4 and CD8 co-receptors 
during thymic selection. Trends in Immunology 33:437-441. 
107. Bretscher, P. A. 1999. A two-step, two-signal model for the primary activation 
of precursor helper T cells. Proceedings of the National Academy of Sciences of 
the United States of America 96:185-190. 




108. Groux, H., M. Bigler, J. E. de Vries, and M. G. Roncarolo. 1996. Interleukin-10 
induces a long-term antigen-specific anergic state in human CD4+ T cells. The 
Journal of Experimental Medicine 184:19-29. 
109. Appleman, L. J., and V. A. Boussiotis. 2003. T cell anergy and costimulation. 
Immunological Reviews 192:161-180. 
110. Gascoigne, N. R., T. Zal, P. P. Yachi, and J. A. Hoerter. 2010. Co-receptors and 
recognition of self at the immunological synapse. Current Topics in 
Microbiology and Immunology 340:171-189. 
111. Kuhns, M. S., and H. B. Badgandi. 2012. Piecing together the family portrait of 
TCR-CD3 complexes. Immunological Reviews 250:120-143. 
112. Love, P. E., and S. M. Hayes. 2010. ITAM-mediated signaling by the T-cell 
antigen receptor. Cold Spring Harbor Perspectives in Biology 2:a002485. 
113. Smith-Garvin, J. E., G. A. Koretzky, and M. S. Jordan. 2009. T cell activation. 
Annual Review of Immunology 27:591-619. 
114. Vigano, S., M. Perreau, G. Pantaleo, and A. Harari. 2012. Positive and negative 
regulation of cellular immune responses in physiologic conditions and diseases. 
Clinical & Developmental Immunology 2012:485781. 
115. Kinnear, G., N. D. Jones, and K. J. Wood. 2013. Costimulation blockade: 
current perspectives and implications for therapy. Transplantation 95:527-535. 
116. Bertram, E. M., W. Dawicki, and T. H. Watts. 2004. Role of T cell 
costimulation in anti-viral immunity. Seminars in Immunology 16:185-196. 
117. Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of 
T cell costimulation. Annual Review of Immunology 14:233-258. 




118. Croft, M. 2003. Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine 
& Growth Factor Reviews 14:265-273. 
119. Quezada, S. A., and K. S. Peggs. 2013. Exploiting CTLA-4, PD-1 and PD-L1 to 
reactivate the host immune response against cancer. British Journal of Cancer 
108:1560-1565. 
120. Janeway, C. A., Jr. 2001. How the immune system protects the host from 
infection. Microbes and Infection / Institut Pasteur 3:1167-1171. 
121. Martin-Fontecha, A., A. Lanzavecchia, and F. Sallusto. 2009. Dendritic cell 
migration to peripheral lymph nodes. Handbook of Experimental 
Pharmacology:31-49. 
122. Alvarez, D., E. H. Vollmann, and U. H. von Andrian. 2008. Mechanisms and 
consequences of dendritic cell migration. Immunity 29:325-342. 
123. Curtsinger, J. M., and M. F. Mescher. 2010. Inflammatory cytokines as a third 
signal for T cell activation. Current Opinion in Immunology 22:333-340. 
124. Zou, W., and N. P. Restifo. 2010. T(H)17 cells in tumour immunity and 
immunotherapy. Nature Reviews. Immunology 10:248-256. 
125. Zhu, J., and W. E. Paul. 2010. Peripheral CD4+ T-cell differentiation regulated 
by networks of cytokines and transcription factors. Immunological Reviews 
238:247-262. 
126. Zhu, J., and W. E. Paul. 2008. CD4 T cells: fates, functions, and faults. Blood 
112:1557-1569. 
127. Muranski, P., and N. P. Restifo. 2013. Essentials of Th17 cell commitment and 
plasticity. Blood 121:2402-2414. 




128. Taylor, A., J. Verhagen, K. Blaser, M. Akdis, and C. A. Akdis. 2006. 
Mechanisms of immune suppression by interleukin-10 and transforming growth 
factor-beta: the role of T regulatory cells. Immunology 117:433-442. 
129. Bendelac, A., P. B. Savage, and L. Teyton. 2007. The biology of NKT cells. 
Annual Review of Immunology 25:297-336. 
130. Brennan, P. J., M. Brigl, and M. B. Brenner. 2013. Invariant natural killer T 
cells: an innate activation scheme linked to diverse effector functions. Nature 
reviews. Immunology 13:101-117. 
131. Klebanoff, C. A., L. Gattinoni, and N. P. Restifo. 2006. CD8+ T-cell memory in 
tumor immunology and immunotherapy. Immunological Reviews 211:214-224. 
132. Wherry, E. J., and R. Ahmed. 2004. Memory CD8 T-cell differentiation during 
viral infection. Journal of Virology 78:5535-5545. 
133. Harty, J. T., and V. P. Badovinac. 2008. Shaping and reshaping CD8+ T-cell 
memory. Nature reviews. Immunology 8:107-119. 
134. Gattinoni, L., E. Lugli, Y. Ji, Z. Pos, C. M. Paulos, M. F. Quigley, J. R. 
Almeida, E. Gostick, Z. Yu, C. Carpenito, E. Wang, D. C. Douek, D. A. Price, 
C. H. June, F. M. Marincola, M. Roederer, and N. P. Restifo. 2011. A human 
memory T cell subset with stem cell-like properties. Nature Medicine 17:1290-
1297. 
135. Geginat, J., A. Lanzavecchia, and F. Sallusto. 2003. Proliferation and 
differentiation potential of human CD8+ memory T-cell subsets in response to 
antigen or homeostatic cytokines. Blood 101:4260-4266. 




136. Butcher, E. C., and L. J. Picker. 1996. Lymphocyte homing and homeostasis. 
Science 272:60-66. 
137. Harrington, L. E., K. M. Janowski, J. R. Oliver, A. J. Zajac, and C. T. Weaver. 
2008. Memory CD4 T cells emerge from effector T-cell progenitors. Nature 
452:356-360. 
138. MacLeod, M. K., J. W. Kappler, and P. Marrack. 2010. Memory CD4 T cells: 
generation, reactivation and re-assignment. Immunology 130:10-15. 
139. Shedlock, D. J., and H. Shen. 2003. Requirement for CD4 T cell help in 
generating functional CD8 T cell memory. Science 300:337-339. 
140. Vantourout, P., and A. Hayday. 2013. Six-of-the-best: unique contributions of 
gammadelta T cells to immunology. Nature reviews. Immunology 13:88-100. 
141. Kabelitz, D., D. Wesch, and W. He. 2007. Perspectives of gammadelta T cells in 
tumor immunology. Cancer Research 67:5-8. 
142. Roden, A. C., W. G. Morice, and C. A. Hanson. 2008. Immunophenotypic 
attributes of benign peripheral blood gammadelta T cells and conditions 
associated with their increase. Archives of Pathology & Laboratory Medicine 
132:1774-1780. 
143. Lopez, R. D. 2002. Human gammadelta-T cells in adoptive immunotherapy of 
malignant and infectious diseases. Immunologic Research 26:207-221. 
144. Carding, S. R., and P. J. Egan. 2002. Gammadelta T cells: functional plasticity 
and heterogeneity. Nature Reviews. Immunology 2:336-345. 
145. Poggi, A., S. Catellani, A. Musso, and M. R. Zocchi. 2009. Gammadelta T 
lymphocytes producing IFNgamma and IL-17 in response to Candida albicans 




or mycobacterial antigens: possible implications for acute and chronic 
inflammation. Current Medicinal Chemistry 16:4743-4749. 
146. Bonneville, M., R. L. O'Brien, and W. K. Born. 2010. Gammadelta T cell 
effector functions: a blend of innate programming and acquired plasticity. 
Nature Reviews. Immunology 10:467-478. 
147. Xiong, N., and D. H. Raulet. 2007. Development and selection of gammadelta T 
cells. Immunological Reviews 215:15-31. 
148. Hayday, A. C. 2009. Gammadelta T cells and the lymphoid stress-surveillance 
response. Immunity 31:184-196. 
149. Hao, J., X. Wu, S. Xia, Z. Li, T. Wen, N. Zhao, Z. Wu, P. Wang, L. Zhao, and 
Z. Yin. 2010. Current progress in gammadelta T-cell biology. Cellular & 
Molecular Immunology 7:409-413. 
150. Ishikawa, H., T. Naito, T. Iwanaga, H. Takahashi-Iwanaga, M. Suematsu, T. 
Hibi, and M. Nanno. 2007. Curriculum vitae of intestinal intraepithelial T cells: 
their developmental and behavioral characteristics. Immunological Reviews 
215:154-165. 
151. Pang, D. J., J. F. Neves, N. Sumaria, and D. J. Pennington. 2012. Understanding 
the complexity of gammadelta T-cell subsets in mouse and human. Immunology 
136:283-290. 
152. Xu, B., J. C. Pizarro, M. A. Holmes, C. McBeth, V. Groh, T. Spies, and R. K. 
Strong. 2011. Crystal structure of a gammadelta T-cell receptor specific for the 
human MHC class I homolog MICA. Proceedings of the National Academy of 
Sciences of the United States of America 108:2414-2419. 




153. Steinle, A., V. Groh, and T. Spies. 1998. Diversification, expression, and 
gamma delta T cell recognition of evolutionarily distant members of the MIC 
family of major histocompatibility complex class I-related molecules. 
Proceedings of the National Academy of Sciences of the United States of 
America 95:12510-12515. 
154. Groh, V., R. Rhinehart, H. Secrist, S. Bauer, K. H. Grabstein, and T. Spies. 
1999. Broad tumor-associated expression and recognition by tumor-derived 
gamma delta T cells of MICA and MICB. Proceedings of the National Academy 
of Sciences of the United States of America 96:6879-6884. 
155. Li, J., L. Cui, and W. He. 2005. Distinct pattern of human Vdelta1 gammadelta 
T cells recognizing MICA. Cellular & Molecular Immunology 2:253-258. 
156. Spada, F. M., E. P. Grant, P. J. Peters, M. Sugita, A. Melian, D. S. Leslie, H. K. 
Lee, E. van Donselaar, D. A. Hanson, A. M. Krensky, O. Majdic, S. A. Porcelli, 
C. T. Morita, and M. B. Brenner. 2000. Self-recognition of CD1 by gamma/delta 
T cells: implications for innate immunity. The Journal of Experimental 
Medicine 191:937-948. 
157. Ciocca, D. R., and S. K. Calderwood. 2005. Heat shock proteins in cancer: 
diagnostic, prognostic, predictive, and treatment implications. Cell Stress & 
Chaperones 10:86-103. 
158. Borg, N. A., K. S. Wun, L. Kjer-Nielsen, M. C. Wilce, D. G. Pellicci, R. Koh, 
G. S. Besra, M. Bharadwaj, D. I. Godfrey, J. McCluskey, and J. Rossjohn. 2007. 
CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. 
Nature 448:44-49. 




159. Paget, C., M. T. Chow, H. Duret, S. R. Mattarollo, and M. J. Smyth. 2012. Role 
of gammadelta T cells in alpha-galactosylceramide-mediated immunity. Journal 
of Immunology 188:3928-3939. 
160. Dieude, M., H. Striegl, A. J. Tyznik, J. Wang, S. M. Behar, C. A. Piccirillo, J. S. 
Levine, D. M. Zajonc, and J. Rauch. 2011. Cardiolipin binds to CD1d and 
stimulates CD1d-restricted gammadelta T cells in the normal murine repertoire. 
Journal of Immunology 186:4771-4781. 
161. Nanno, M., T. Shiohara, H. Yamamoto, K. Kawakami, and H. Ishikawa. 2007. 
gammadelta T cells: firefighters or fire boosters in the front lines of 
inflammatory responses. Immunological Reviews 215:103-113. 
162. Chodaczek, G., V. Papanna, M. A. Zal, and T. Zal. 2012. Body-barrier 
surveillance by epidermal gammadelta TCRs. Nature Immunology 13:272-282. 
163. Xiong, N., C. Kang, and D. H. Raulet. 2004. Positive selection of dendritic 
epidermal gammadelta T cell precursors in the fetal thymus determines 
expression of skin-homing receptors. Immunity 21:121-131. 
164. Wesch, D., T. Hinz, and D. Kabelitz. 1998. Analysis of the TCR Vgamma 
repertoire in healthy donors and HIV-1-infected individuals. International 
Immunology 10:1067-1075. 
165. Knight, A., A. J. Madrigal, S. Grace, J. Sivakumaran, P. Kottaridis, S. 
Mackinnon, P. J. Travers, and M. W. Lowdell. 2010. The role of Vdelta2-
negative gammadelta T cells during cytomegalovirus reactivation in recipients 
of allogeneic stem cell transplantation. Blood 116:2164-2172. 




166. Brandes, M., K. Willimann, and B. Moser. 2005. Professional antigen-
presentation function by human gammadelta T Cells. Science 309:264-268. 
167. Bukowski, J. F., C. T. Morita, and M. B. Brenner. 1999. Human gamma delta T 
cells recognize alkylamines derived from microbes, edible plants, and tea: 
implications for innate immunity. Immunity 11:57-65. 
168. Wang, L., A. Kamath, H. Das, L. Li, and J. F. Bukowski. 2001. Antibacterial 
effect of human V gamma 2V delta 2 T cells in vivo. The Journal of Clinical 
Investigation 108:1349-1357. 
169. Munk, M. E., C. Elser, and S. H. Kaufmann. 1996. Human gamma/delta T-cell 
response to Listeria monocytogenes protein components in vitro. Immunology 
87:230-235. 
170. Green, A. E., A. Lissina, S. L. Hutchinson, R. E. Hewitt, B. Temple, D. James, 
J. M. Boulter, D. A. Price, and A. K. Sewell. 2004. Recognition of nonpeptide 
antigens by human V gamma 9V delta 2 T cells requires contact with cells of 
human origin. Clin Exp Immunol 136:472-482. 
171. Mookerjee-Basu, J., P. Vantourout, L. O. Martinez, B. Perret, X. Collet, C. 
Perigaud, S. Peyrottes, and E. Champagne. 2010. F1-adenosine triphosphatase 
displays properties characteristic of an antigen presentation molecule for 
Vgamma9Vdelta2 T cells. Journal of Immunology 184:6920-6928. 
172. Vantourout, P., J. Mookerjee-Basu, C. Rolland, F. Pont, H. Martin, C. 
Davrinche, L. O. Martinez, B. Perret, X. Collet, C. Perigaud, S. Peyrottes, and E. 
Champagne. 2009. Specific requirements for Vgamma9Vdelta2 T cell 




stimulation by a natural adenylated phosphoantigen. Journal of Immunology 
183:3848-3857. 
173. D'Asaro, M., C. La Mendola, D. Di Liberto, V. Orlando, M. Todaro, M. Spina, 
G. Guggino, S. Meraviglia, N. Caccamo, A. Messina, A. Salerno, F. Di 
Raimondo, P. Vigneri, G. Stassi, J. J. Fournie, and F. Dieli. 2010. V gamma 9V 
delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, 
imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. 
Journal of Immunology 184:3260-3268. 
174. Thedrez, A., C. Harly, A. Morice, S. Salot, M. Bonneville, and E. Scotet. 2009. 
IL-21-mediated potentiation of antitumor cytolytic and proinflammatory 
responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy. 
Journal of Immunology 182:3423-3431. 
175. Chiplunkar, S., S. Dhar, D. Wesch, and D. Kabelitz. 2009. gammadelta T cells 
in cancer immunotherapy: current status and future prospects. Immunotherapy 
1:663-678. 
176. Thompson, K., A. J. Roelofs, M. Jauhiainen, H. Monkkonen, J. Monkkonen, and 
M. J. Rogers. 2010. Activation of gammadelta T cells by bisphosphonates. 
Advances in Experimental Medicine and Biology 658:11-20. 
177. Gomes, A. Q., D. S. Martins, and B. Silva-Santos. 2010. Targeting gammadelta 
T lymphocytes for cancer immunotherapy: from novel mechanistic insight to 
clinical application. Cancer Research 70:10024-10027. 




178. Nagamine, I., Y. Yamaguchi, M. Ohara, T. Ikeda, and M. Okada. 2009. 
Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients 
with metastatic cancer. Hiroshima J Med Sci 58:37-44. 
179. Wilhelm, M., V. Kunzmann, S. Eckstein, P. Reimer, F. Weissinger, T. Ruediger, 
and H. P. Tony. 2003. Gammadelta T cells for immune therapy of patients with 
lymphoid malignancies. Blood 102:200-206. 
180. Nicol, A. J., H. Tokuyama, S. R. Mattarollo, T. Hagi, K. Suzuki, K. Yokokawa, 
and M. Nieda. 2011. Clinical evaluation of autologous gamma delta T cell-based 
immunotherapy for metastatic solid tumours. British Journal of Cancer 105:778-
786. 
181. Lang, J. M., M. R. Kaikobad, M. Wallace, M. J. Staab, D. L. Horvath, G. 
Wilding, G. Liu, J. C. Eickhoff, D. G. McNeel, and M. Malkovsky. 2011. Pilot 
trial of interleukin-2 and zoledronic acid to augment gammadelta T cells as 
treatment for patients with refractory renal cell carcinoma. Cancer Immunology, 
Immunotherapy : CII 60:1447-1460. 
182. Kobayashi, H., Y. Tanaka, J. Yagi, N. Minato, and K. Tanabe. 2011. Phase I/II 
study of adoptive transfer of gammadelta T cells in combination with zoledronic 
acid and IL-2 to patients with advanced renal cell carcinoma. Cancer 
Immunology, Immunotherapy : CII 60:1075-1084. 
183. Kabelitz, D., T. Hinz, T. Dobmeyer, U. Mentzel, S. Marx, A. Bohme, B. Arden, 
R. Rossol, and D. Hoelzer. 1997. Clonal expansion of Vgamma3/Vdelta3-
expressing gammadelta T cells in an HIV-1/2-negative patient with CD4 T-cell 
deficiency. British Journal of Haematology 96:266-271. 




184. Cooper, L. J. 2008. Test-driving CARs. Blood 112:2172-2173. 
185. June, C. H. 2007. Principles of adoptive T cell cancer therapy. The Journal of 
Clinical Investigation 117:1204-1212. 
186. Jena, B., G. Dotti, and L. J. Cooper. 2010. Redirecting T-cell specificity by 
introducing a tumor-specific chimeric antigen receptor. Blood 116:1035-1044. 
187. Sadelain, M., R. Brentjens, and I. Riviere. 2009. The promise and potential 
pitfalls of chimeric antigen receptors. Current Opinion in Immunology 21:215-
223. 
188. Gross, G., T. Waks, and Z. Eshhar. 1989. Expression of immunoglobulin-T-cell 
receptor chimeric molecules as functional receptors with antibody-type 
specificity. Proceedings of the National Academy of Sciences of the United 
States of America 86:10024-10028. 
189. Kowolik, C. M., M. S. Topp, S. Gonzalez, T. Pfeiffer, S. Olivares, N. Gonzalez, 
D. D. Smith, S. J. Forman, M. C. Jensen, and L. J. Cooper. 2006. CD28 
costimulation provided through a CD19-specific chimeric antigen receptor 
enhances in vivo persistence and antitumor efficacy of adoptively transferred T 
cells. Cancer Research 66:10995-11004. 
190. Milone, M. C., J. D. Fish, C. Carpenito, R. G. Carroll, G. K. Binder, D. Teachey, 
M. Samanta, M. Lakhal, B. Gloss, G. Danet-Desnoyers, D. Campana, J. L. 
Riley, S. A. Grupp, and C. H. June. 2009. Chimeric receptors containing CD137 
signal transduction domains mediate enhanced survival of T cells and increased 
antileukemic efficacy in vivo. Molecular Therapy : The Journal of the American 
Society of Gene Therapy 17:1453-1464. 




191. Cartellieri, M., M. Bachmann, A. Feldmann, C. Bippes, S. Stamova, R. Wehner, 
A. Temme, and M. Schmitz. 2010. Chimeric antigen receptor-engineered T cells 
for immunotherapy of cancer. Journal of Biomedicine & Biotechnology 
2010:956304. 
192. Brentjens, R. J., E. Santos, Y. Nikhamin, R. Yeh, M. Matsushita, K. La Perle, A. 
Quintas-Cardama, S. M. Larson, and M. Sadelain. 2007. Genetically targeted T 
cells eradicate systemic acute lymphoblastic leukemia xenografts. Clinical 
Cancer Research : An Official Journal of the American Association for Cancer 
Research 13:5426-5435. 
193. Imai, C., K. Mihara, M. Andreansky, I. C. Nicholson, C. H. Pui, T. L. Geiger, 
and D. Campana. 2004. Chimeric receptors with 4-1BB signaling capacity 
provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 
18:676-684. 
194. Zhao, Y., Q. J. Wang, S. Yang, J. N. Kochenderfer, Z. Zheng, X. Zhong, M. 
Sadelain, Z. Eshhar, S. A. Rosenberg, and R. A. Morgan. 2009. A herceptin-
based chimeric antigen receptor with modified signaling domains leads to 
enhanced survival of transduced T lymphocytes and antitumor activity. Journal 
of Immunology 183:5563-5574. 
195. Wang, J., M. Jensen, Y. Lin, X. Sui, E. Chen, C. G. Lindgren, B. Till, A. 
Raubitschek, S. J. Forman, X. Qian, S. James, P. Greenberg, S. Riddell, and O. 
W. Press. 2007. Optimizing adoptive polyclonal T cell immunotherapy of 
lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 
costimulatory domains. Human Gene Therapy 18:712-725. 




196. Carpenito, C., M. C. Milone, R. Hassan, J. C. Simonet, M. Lakhal, M. M. 
Suhoski, A. Varela-Rohena, K. M. Haines, D. F. Heitjan, S. M. Albelda, R. G. 
Carroll, J. L. Riley, I. Pastan, and C. H. June. 2009. Control of large, established 
tumor xenografts with genetically retargeted human T cells containing CD28 
and CD137 domains. Proceedings of the National Academy of Sciences of the 
United States of America 106:3360-3365. 
197. Finney, H. M., A. D. Lawson, C. R. Bebbington, and A. N. Weir. 1998. 
Chimeric receptors providing both primary and costimulatory signaling in T 
cells from a single gene product. Journal of Immunology 161:2791-2797. 
198. James, S. E., P. D. Greenberg, M. C. Jensen, Y. Lin, J. Wang, B. G. Till, A. A. 
Raubitschek, S. J. Forman, and O. W. Press. 2008. Antigen sensitivity of CD22-
specific chimeric TCR is modulated by target epitope distance from the cell 
membrane. Journal of Immunology 180:7028-7038. 
199. Hudecek, M., M. T. Lupo Stanghellini, P. L. Kosasih, D. Sommermeyer, M. 
Jensen, C. Rader, and S. Riddell. 2013. Receptor affinity and extracellular 
domain modifications affect tumor recognition by ROR1-specific chimeric 
antigen receptor T-cells. Clinical Cancer Research : An Official Journal of the 
American Association for Cancer Research. 
200. Till, B. G., M. C. Jensen, J. Wang, X. Qian, A. K. Gopal, D. G. Maloney, C. G. 
Lindgren, Y. Lin, J. M. Pagel, L. E. Budde, A. Raubitschek, S. J. Forman, P. D. 
Greenberg, S. R. Riddell, and O. W. Press. 2012. CD20-specific adoptive 
immunotherapy for lymphoma using a chimeric antigen receptor with both 
CD28 and 4-1BB domains: pilot clinical trial results. Blood 119:3940-3950. 




201. Giordano Attianese, G. M., V. Marin, V. Hoyos, B. Savoldo, I. Pizzitola, S. 
Tettamanti, V. Agostoni, M. Parma, M. Ponzoni, M. T. Bertilaccio, P. Ghia, A. 
Biondi, G. Dotti, and E. Biagi. 2011. In vitro and in vivo model of a novel 
immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 
chimeric antigen receptor. Blood 117:4736-4745. 
202. Park, J. H., and R. J. Brentjens. 2010. Adoptive immunotherapy for B-cell 
malignancies with autologous chimeric antigen receptor modified tumor targeted 
T cells. Discovery Medicine 9:277-288. 
203. Jensen, M. C., L. J. Cooper, A. M. Wu, S. J. Forman, and A. Raubitschek. 2003. 
Engineered CD20-specific primary human cytotoxic T lymphocytes for 
targeting B-cell malignancy. Cytotherapy 5:131-138. 
204. Vera, J., B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, J. Wu, H. E. 
Heslop, C. M. Rooney, M. K. Brenner, and G. Dotti. 2006. T lymphocytes 
redirected against the kappa light chain of human immunoglobulin efficiently 
kill mature B lymphocyte-derived malignant cells. Blood 108:3890-3897. 
205. Di Stasi, A., B. De Angelis, C. M. Rooney, L. Zhang, A. Mahendravada, A. E. 
Foster, H. E. Heslop, M. K. Brenner, G. Dotti, and B. Savoldo. 2009. T 
lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting 
CD30 have improved homing and antitumor activity in a Hodgkin tumor model. 
Blood 113:6392-6402. 
206. Savoldo, B., C. M. Rooney, A. Di Stasi, H. Abken, A. Hombach, A. E. Foster, 
L. Zhang, H. E. Heslop, M. K. Brenner, and G. Dotti. 2007. Epstein Barr virus 
specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial 




chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 
110:2620-2630. 
207. Hombach, A., C. Heuser, R. Sircar, T. Tillmann, V. Diehl, C. Pohl, and H. 
Abken. 1998. An anti-CD30 chimeric receptor that mediates CD3-zeta-
independent T-cell activation against Hodgkin's lymphoma cells in the presence 
of soluble CD30. Cancer Research 58:1116-1119. 
208. Haso, W., D. W. Lee, N. N. Shah, M. Stetler-Stevenson, C. M. Yuan, I. H. 
Pastan, D. S. Dimitrov, R. A. Morgan, D. J. FitzGerald, D. M. Barrett, A. S. 
Wayne, C. L. Mackall, and R. J. Orentas. 2013. Anti-CD22-chimeric antigen 
receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 
121:1165-1174. 
209. Wang, D., L. Zhang, Y. Li, H. Wang, Q. Xiao, W. Cao, and W. Feng. 2012. 
Construction and expression of humanized chimeric T cell receptor specific for 
chronic myeloid leukemia cells. Biotechnology Letters 34:1193-1201. 
210. Tettamanti, S., V. Marin, I. Pizzitola, C. F. Magnani, G. M. Giordano Attianese, 
E. Cribioli, F. Maltese, S. Galimberti, A. F. Lopez, A. Biondi, D. Bonnet, and E. 
Biagi. 2013. Targeting of acute myeloid leukaemia by cytokine-induced killer 
cells redirected with a novel CD123-specific chimeric antigen receptor. British 
Journal of Haematology 161:389-401. 
211. Dutour, A., V. Marin, I. Pizzitola, S. Valsesia-Wittmann, D. Lee, E. Yvon, H. 
Finney, A. Lawson, M. Brenner, A. Biondi, E. Biagi, and R. Rousseau. 2012. In 
Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-




Expressing EBV-CTL against CD33 Acute Myeloid Leukemia. Advances in 
Hematology 2012:683065. 
212. Pizzitola, I., V. Agostoni, E. Cribioli, M. Pule, R. Rousseau, H. Finney, A. 
Lawson, A. Biondi, E. Biagi, and V. Marin. 2011. In vitro comparison of three 
different chimeric receptor-modified effector T-cell populations for leukemia 
cell therapy. Journal of Immunotherapy 34:469-479. 
213. Schmitt, N., M. C. Cumont, M. T. Nugeyre, B. Hurtrel, F. Barre-Sinoussi, D. 
Scott-Algara, and N. Israel. 2007. Ex vivo characterization of human thymic 
dendritic cell subsets. Immunobiology 212:167-177. 
214. Garnache-Ottou, F., L. Chaperot, S. Biichle, C. Ferrand, J. P. Remy-Martin, E. 
Deconinck, P. D. de Tailly, B. Bulabois, J. Poulet, E. Kuhlein, M. C. Jacob, V. 
Salaun, M. Arock, B. Drenou, F. Schillinger, E. Seilles, P. Tiberghien, J. C. 
Bensa, J. Plumas, and P. Saas. 2005. Expression of the myeloid-associated 
marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic 
cells. Blood 105:1256-1264. 
215. Song, D. G., Q. Ye, C. Carpenito, M. Poussin, L. P. Wang, C. Ji, M. Figini, C. 
H. June, G. Coukos, and D. J. Powell, Jr. 2011. In vivo persistence, tumor 
localization, and antitumor activity of CAR-engineered T cells is enhanced by 
costimulatory signaling through CD137 (4-1BB). Cancer Research 71:4617-
4627. 
216. Kandalaft, L. E., D. J. Powell, Jr., and G. Coukos. 2012. A phase I clinical trial 
of adoptive transfer of folate receptor-alpha redirected autologous T cells for 
recurrent ovarian cancer. Journal of Translational Medicine 10:157. 




217. Parker, L. L., M. T. Do, J. A. Westwood, J. R. Wunderlich, M. E. Dudley, S. A. 
Rosenberg, and P. Hwu. 2000. Expansion and characterization of T cells 
transduced with a chimeric receptor against ovarian cancer. Human Gene 
Therapy 11:2377-2387. 
218. Tchou, J., L. C. Wang, B. Selven, H. Zhang, J. Conejo-Garcia, H. Borghaei, M. 
Kalos, R. H. Vondeheide, S. M. Albelda, C. H. June, and P. J. Zhang. 2012. 
Mesothelin, a novel immunotherapy target for triple negative breast cancer. 
Breast Cancer Research and Treatment 133:799-804. 
219. Lanitis, E., M. Poussin, I. S. Hagemann, G. Coukos, R. Sandaltzopoulos, N. 
Scholler, and D. J. Powell, Jr. 2012. Redirected antitumor activity of primary 
human lymphocytes transduced with a fully human anti-mesothelin chimeric 
receptor. Molecular Therapy : The Journal of the American Society of Gene 
Therapy 20:633-643. 
220. Lamers, C. H., S. Sleijfer, S. van Steenbergen, P. van Elzakker, B. van Krimpen, 
C. Groot, A. Vulto, M. den Bakker, E. Oosterwijk, R. Debets, and J. W. 
Gratama. 2013. Treatment of metastatic renal cell carcinoma with CAIX CAR-
engineered T cells: clinical evaluation and management of on-target toxicity. 
Molecular Therapy : The Journal of the American Society of Gene Therapy 
21:904-912. 
221. Lamers, C. H., R. Willemsen, P. van Elzakker, S. van Steenbergen-Langeveld, 
M. Broertjes, J. Oosterwijk-Wakka, E. Oosterwijk, S. Sleijfer, R. Debets, and J. 
W. Gratama. 2011. Immune responses to transgene and retroviral vector in 
patients treated with ex vivo-engineered T cells. Blood 117:72-82. 




222. Genega, E. M., M. Ghebremichael, R. Najarian, Y. Fu, Y. Wang, P. Argani, C. 
Grisanzio, and S. Signoretti. 2010. Carbonic anhydrase IX expression in renal 
neoplasms: correlation with tumor type and grade. American Journal of Clinical 
Pathology 134:873-879. 
223. Chmielewski, M., O. Hahn, G. Rappl, M. Nowak, I. H. Schmidt-Wolf, A. A. 
Hombach, and H. Abken. 2012. T cells that target carcinoembryonic antigen 
eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis 
in mice. Gastroenterology 143:1095-1107 e1092. 
224. Schlimper, C., A. A. Hombach, H. Abken, and I. G. Schmidt-Wolf. 2012. 
Improved activation toward primary colorectal cancer cells by antigen-specific 
targeting autologous cytokine-induced killer cells. Clinical & Developmental 
Immunology 2012:238924. 
225. Nakazawa, Y., L. E. Huye, V. S. Salsman, A. M. Leen, N. Ahmed, L. Rollins, 
G. Dotti, S. M. Gottschalk, M. H. Wilson, and C. M. Rooney. 2011. PiggyBac-
mediated cancer immunotherapy using EBV-specific cytotoxic T-cells 
expressing HER2-specific chimeric antigen receptor. Molecular Therapy : The 
Journal of the American Society of Gene Therapy 19:2133-2143. 
226. Li, S., J. Yang, F. A. Urban, J. N. MacGregor, D. P. Hughes, A. E. Chang, K. T. 
McDonagh, and Q. Li. 2008. Genetically engineered T cells expressing a HER2-
specific chimeric receptor mediate antigen-specific tumor regression. Cancer 
Gene Therapy 15:382-392. 
227. Ahmed, N., M. Ratnayake, B. Savoldo, L. Perlaky, G. Dotti, W. S. Wels, M. B. 
Bhattacharjee, R. J. Gilbertson, H. D. Shine, H. L. Weiss, C. M. Rooney, H. E. 




Heslop, and S. Gottschalk. 2007. Regression of experimental medulloblastoma 
following transfer of HER2-specific T cells. Cancer Research 67:5957-5964. 
228. Stancovski, I., D. G. Schindler, T. Waks, Y. Yarden, M. Sela, and Z. Eshhar. 
1993. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric 
single chain Fv receptors. Journal of Immunology 151:6577-6582. 
229. Morgan, R. A., J. C. Yang, M. Kitano, M. E. Dudley, C. M. Laurencot, and S. 
A. Rosenberg. 2010. Case report of a serious adverse event following the 
administration of T cells transduced with a chimeric antigen receptor 
recognizing ERBB2. Molecular Therapy : The Journal of the American Society 
of Gene Therapy 18:843-851. 
230. Zhou, X., J. Li, Z. Wang, Z. Chen, J. Qiu, Y. Zhang, W. Wang, Y. Ma, N. 
Huang, K. Cui, J. Li, and Y. Q. Wei. 2013. Cellular Immunotherapy for 
Carcinoma Using Genetically Modified EGFR-Specific T Lymphocytes. 
Neoplasia 15:544-553. 
231. Ohno, M., A. Natsume, K. Ichiro Iwami, H. Iwamizu, K. Noritake, D. Ito, Y. 
Toi, M. Ito, K. Motomura, J. Yoshida, K. Yoshikawa, and T. Wakabayashi. 
2010. Retrovirally engineered T-cell-based immunotherapy targeting type III 
variant epidermal growth factor receptor, a glioma-associated antigen. Cancer 
Science 101:2518-2524. 
232. Morgan, R. A., L. A. Johnson, J. L. Davis, Z. Zheng, K. D. Woolard, E. A. 
Reap, S. A. Feldman, N. Chinnasamy, C. T. Kuan, H. Song, W. Zhang, H. A. 
Fine, and S. A. Rosenberg. 2012. Recognition of glioma stem cells by 




genetically modified T cells targeting EGFRvIII and development of adoptive 
cell therapy for glioma. Human Gene Therapy 23:1043-1053. 
233. Westwood, J. A., M. J. Smyth, M. W. Teng, M. Moeller, J. A. Trapani, A. M. 
Scott, F. E. Smyth, G. A. Cartwright, B. E. Power, D. Honemann, H. M. Prince, 
P. K. Darcy, and M. H. Kershaw. 2005. Adoptive transfer of T cells modified 
with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing 
tumors in mice. Proceedings of the National Academy of Sciences of the United 
States of America 102:19051-19056. 
234. Orentas, R. J., D. W. Lee, and C. Mackall. 2012. Immunotherapy targets in 
pediatric cancer. Frontiers in Oncology 2:3. 
235. Park, J. R., D. L. Digiusto, M. Slovak, C. Wright, A. Naranjo, J. Wagner, H. B. 
Meechoovet, C. Bautista, W. C. Chang, J. R. Ostberg, and M. C. Jensen. 2007. 
Adoptive transfer of chimeric antigen receptor re-directed cytolytic T 
lymphocyte clones in patients with neuroblastoma. Molecular Therapy : The 
Journal of the American Society of Gene Therapy 15:825-833. 
236. Pule, M. A., B. Savoldo, G. D. Myers, C. Rossig, H. V. Russell, G. Dotti, M. H. 
Huls, E. Liu, A. P. Gee, Z. Mei, E. Yvon, H. L. Weiss, H. Liu, C. M. Rooney, H. 
E. Heslop, and M. K. Brenner. 2008. Virus-specific T cells engineered to 
coexpress tumor-specific receptors: persistence and antitumor activity in 
individuals with neuroblastoma. Nature Medicine 14:1264-1270. 
237. Louis, C. U., B. Savoldo, G. Dotti, M. Pule, E. Yvon, G. D. Myers, C. Rossig, 
H. V. Russell, O. Diouf, E. Liu, H. Liu, M. F. Wu, A. P. Gee, Z. Mei, C. M. 
Rooney, H. E. Heslop, and M. K. Brenner. 2011. Antitumor activity and long-




term fate of chimeric antigen receptor-positive T cells in patients with 
neuroblastoma. Blood 118:6050-6056. 
238. Kailayangiri, S., B. Altvater, J. Meltzer, S. Pscherer, A. Luecke, C. Dierkes, U. 
Titze, K. Leuchte, S. Landmeier, M. Hotfilder, U. Dirksen, J. Hardes, G. 
Gosheger, H. Juergens, and C. Rossig. 2012. The ganglioside antigen G(D2) is 
surface-expressed in Ewing sarcoma and allows for MHC-independent immune 
targeting. British Journal of Cancer 106:1123-1133. 
239. Yvon, E., M. Del Vecchio, B. Savoldo, V. Hoyos, A. Dutour, A. Anichini, G. 
Dotti, and M. K. Brenner. 2009. Immunotherapy of metastatic melanoma using 
genetically engineered GD2-specific T cells. Clinical Cancer Research : An 
Official Journal of the American Association for Cancer Research 15:5852-
5860. 
240. Burns, W. R., Y. Zhao, T. L. Frankel, C. S. Hinrichs, Z. Zheng, H. Xu, S. A. 
Feldman, S. Ferrone, S. A. Rosenberg, and R. A. Morgan. 2010. A high 
molecular weight melanoma-associated antigen-specific chimeric antigen 
receptor redirects lymphocytes to target human melanomas. Cancer Research 
70:3027-3033. 
241. Morgan, R. A., M. E. Dudley, and S. A. Rosenberg. 2010. Adoptive cell 
therapy: genetic modification to redirect effector cell specificity. Cancer Journal 
16:336-341. 
242. Rosenberg, S. A. 2012. Raising the bar: the curative potential of human cancer 
immunotherapy. Science Translational Medicine 4:127ps128. 




243. Zhong, X. S., M. Matsushita, J. Plotkin, I. Riviere, and M. Sadelain. 2010. 
Chimeric antigen receptors combining 4-1BB and CD28 signaling domains 
augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor 
eradication. Molecular Therapy : The Journal of the American Society of Gene 
Therapy 18:413-420. 
244. Morgenroth, A., M. Cartellieri, M. Schmitz, S. Gunes, B. Weigle, M. 
Bachmann, H. Abken, E. P. Rieber, and A. Temme. 2007. Targeting of tumor 
cells expressing the prostate stem cell antigen (PSCA) using genetically 
engineered T-cells. The Prostate 67:1121-1131. 
245. Gade, T. P., W. Hassen, E. Santos, G. Gunset, A. Saudemont, M. C. Gong, R. 
Brentjens, X. S. Zhong, M. Stephan, J. Stefanski, C. Lyddane, J. R. Osborne, I. 
M. Buchanan, S. J. Hall, W. D. Heston, I. Riviere, S. M. Larson, J. A. Koutcher, 
and M. Sadelain. 2005. Targeted elimination of prostate cancer by genetically 
directed human T lymphocytes. Cancer Research 65:9080-9088. 
246. Sanchez, C., R. Chan, P. Bajgain, S. Rambally, G. Palapattu, M. Mims, C. M. 
Rooney, A. M. Leen, M. K. Brenner, and J. F. Vera. 2013. Combining T-cell 
immunotherapy and anti-androgen therapy for prostate cancer. Prostate Cancer 
and Prostatic Diseases. 
247. Wilkie, S., G. Picco, J. Foster, D. M. Davies, S. Julien, L. Cooper, S. Arif, S. J. 
Mather, J. Taylor-Papadimitriou, J. M. Burchell, and J. Maher. 2008. 
Retargeting of human T cells to tumor-associated MUC1: the evolution of a 
chimeric antigen receptor. Journal of Immunology 180:4901-4909. 




248. Sharifzadeh, Z., F. Rahbarizadeh, M. A. Shokrgozar, D. Ahmadvand, F. 
Mahboudi, F. R. Jamnani, and S. M. Moghimi. 2012. Genetically engineered T 
cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific 
camelid single domain antibodies as targeting agents. Cancer Letters. 
249. Ren-Heidenreich, L., G. T. Hayman, and K. T. Trevor. 2000. Specific targeting 
of EGP-2+ tumor cells by primary lymphocytes modified with chimeric T cell 
receptors. Human Gene Therapy 11:9-19. 
250. Chinnasamy, D., Z. Yu, S. P. Kerkar, L. Zhang, R. A. Morgan, N. P. Restifo, 
and S. A. Rosenberg. 2012. Local delivery of interleukin-12 using T cells 
targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. 
Clinical Cancer Research : An Official Journal of the American Association for 
Cancer Research 18:1672-1683. 
251. Chinnasamy, D., Z. Yu, M. R. Theoret, Y. Zhao, R. K. Shrimali, R. A. Morgan, 
S. A. Feldman, N. P. Restifo, and S. A. Rosenberg. 2010. Gene therapy using 
genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of 
vascularized syngenic tumors in mice. The Journal of Clinical Investigation 
120:3953-3968. 
252. Kahlon, K. S., C. Brown, L. J. Cooper, A. Raubitschek, S. J. Forman, and M. C. 
Jensen. 2004. Specific recognition and killing of glioblastoma multiforme by 
interleukin 13-zetakine redirected cytolytic T cells. Cancer Research 64:9160-
9166. 




253. Stastny, M. J., C. E. Brown, C. Ruel, and M. C. Jensen. 2007. Medulloblastomas 
expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells. Journal 
of Pediatric Hematology/Oncology 29:669-677. 
254. Brown, C. E., R. Starr, B. Aguilar, A. F. Shami, C. Martinez, M. D'Apuzzo, M. 
E. Barish, S. J. Forman, and M. C. Jensen. 2012. Stem-like tumor-initiating cells 
isolated from IL13Ralpha2 expressing gliomas are targeted and killed by IL13-
zetakine-redirected T Cells. Clinical Cancer Research : An Official Journal of 
the American Association for Cancer Research 18:2199-2209. 
255. Kong, S., S. Sengupta, B. Tyler, A. J. Bais, Q. Ma, S. Doucette, J. Zhou, A. 
Sahin, B. S. Carter, H. Brem, R. P. Junghans, and P. Sampath. 2012. 
Suppression of human glioma xenografts with second-generation IL13R-specific 
chimeric antigen receptor-modified T cells. Clinical Cancer Research : An 
Official Journal of the American Association for Cancer Research 18:5949-
5960. 
256. June, C. H. 2007. Adoptive T cell therapy for cancer in the clinic. The Journal of 
Clinical Investigation 117:1466-1476. 
257. Lipowska-Bhalla, G., D. E. Gilham, R. E. Hawkins, and D. G. Rothwell. 2012. 
Targeted immunotherapy of cancer with CAR T cells: achievements and 
challenges. Cancer Immunology, Immunotherapy : CII 61:953-962. 
258. Hosing, C., P. Kebriaei, W. Wierda, B. Jena, L. J. Cooper, and E. Shpall. 2013. 
CARs in chronic lymphocytic leukemia -- ready to drive. Current Hematologic 
Malignancy Reports 8:60-70. 




259. Jena, B., S. Maiti, H. Huls, H. Singh, D. A. Lee, R. E. Champlin, and L. J. 
Cooper. 2013. Chimeric antigen receptor (CAR)-specific monoclonal antibody 
to detect CD19-specific T cells in clinical trials. PloS One 8:e57838. 
260. Kochenderfer, J. N., and S. A. Rosenberg. 2013. Treating B-cell cancer with T 
cells expressing anti-CD19 chimeric antigen receptors. Nature reviews. Clinical 
Oncology 10:267-276. 
261. Brentjens, R., R. Yeh, Y. Bernal, I. Riviere, and M. Sadelain. 2010. Treatment 
of chronic lymphocytic leukemia with genetically targeted autologous T cells: 
case report of an unforeseen adverse event in a phase I clinical trial. Molecular 
Therapy : The Journal of the American Society of Gene Therapy 18:666-668. 
262. Ertl, H. C., J. Zaia, S. A. Rosenberg, C. H. June, G. Dotti, J. Kahn, L. J. Cooper, 
J. Corrigan-Curay, and S. E. Strome. 2011. Considerations for the clinical 
application of chimeric antigen receptor T cells: observations from a 
recombinant DNA Advisory Committee Symposium held June 15, 2010. Cancer 
Research 71:3175-3181. 
263. Maiti, S. N., H. Huls, H. Singh, M. Dawson, M. Figliola, S. Olivares, P. Rao, Y. 
J. Zhao, A. Multani, G. Yang, L. Zhang, D. Crossland, S. Ang, H. Torikai, B. 
Rabinovich, D. A. Lee, P. Kebriaei, P. Hackett, R. E. Champlin, and L. J. 
Cooper. 2013. Sleeping beauty system to redirect T-cell specificity for human 
applications. Journal of Immunotherapy 36:112-123. 
264. Hackett, P. B., D. A. Largaespada, and L. J. Cooper. 2010. A transposon and 
transposase system for human application. Molecular Therapy : The Journal of 
the American Society of Gene Therapy 18:674-683. 




265. Wadman, S. A., K. J. Clark, and P. B. Hackett. 2005. Fishing for answers with 
transposons. Marine Biotechnology 7:135-141. 
266. Liu, G., E. L. Aronovich, Z. Cui, C. B. Whitley, and P. B. Hackett. 2004. 
Excision of Sleeping Beauty transposons: parameters and applications to gene 
therapy. The Journal of Gene Medicine 6:574-583. 
267. Hackett, P. B., D. A. Largaespada, K. C. Switzer, and L. J. Cooper. 2013. 
Evaluating risks of insertional mutagenesis by DNA transposons in gene 
therapy. Translational Research : The Journal of Laboratory and Clinical 
Medicine 161:265-283. 
268. Hackett, P. B., Jr., E. L. Aronovich, D. Hunter, M. Urness, J. B. Bell, S. J. Kass, 
L. J. Cooper, and S. McIvor. 2011. Efficacy and safety of Sleeping Beauty 
transposon-mediated gene transfer in preclinical animal studies. Current Gene 
Therapy 11:341-349. 
269. Liu, G., A. M. Geurts, K. Yae, A. R. Srinivasan, S. C. Fahrenkrug, D. A. 
Largaespada, J. Takeda, K. Horie, W. K. Olson, and P. B. Hackett. 2005. 
Target-site preferences of Sleeping Beauty transposons. Journal of Molecular 
Biology 346:161-173. 
270. Howe, S. J., M. R. Mansour, K. Schwarzwaelder, C. Bartholomae, M. Hubank, 
H. Kempski, M. H. Brugman, K. Pike-Overzet, S. J. Chatters, D. de Ridder, K. 
C. Gilmour, S. Adams, S. I. Thornhill, K. L. Parsley, F. J. Staal, R. E. Gale, D. 
C. Linch, J. Bayford, L. Brown, M. Quaye, C. Kinnon, P. Ancliff, D. K. Webb, 
M. Schmidt, C. von Kalle, H. B. Gaspar, and A. J. Thrasher. 2008. Insertional 
mutagenesis combined with acquired somatic mutations causes leukemogenesis 




following gene therapy of SCID-X1 patients. The Journal of Clinical 
Investigation 118:3143-3150. 
271. Hacein-Bey-Abina, S., A. Garrigue, G. P. Wang, J. Soulier, A. Lim, E. Morillon, 
E. Clappier, L. Caccavelli, E. Delabesse, K. Beldjord, V. Asnafi, E. MacIntyre, 
L. Dal Cortivo, I. Radford, N. Brousse, F. Sigaux, D. Moshous, J. Hauer, A. 
Borkhardt, B. H. Belohradsky, U. Wintergerst, M. C. Velez, L. Leiva, R. 
Sorensen, N. Wulffraat, S. Blanche, F. D. Bushman, A. Fischer, and M. 
Cavazzana-Calvo. 2008. Insertional oncogenesis in 4 patients after retrovirus-
mediated gene therapy of SCID-X1. The Journal of Clinical Investigation 
118:3132-3142. 
272. Singh, H., P. R. Manuri, S. Olivares, N. Dara, M. J. Dawson, H. Huls, P. B. 
Hackett, D. B. Kohn, E. J. Shpall, R. E. Champlin, and L. J. Cooper. 2008. 
Redirecting specificity of T-cell populations for CD19 using the Sleeping 
Beauty system. Cancer Research 68:2961-2971. 
273. Huls, M. H., M. J. Figliola, M. J. Dawson, S. Olivares, P. Kebriaei, E. J. Shpall, 
R. E. Champlin, H. Singh, and L. J. Cooper. 2013. Clinical application of 
Sleeping Beauty and artificial antigen presenting cells to genetically modify T 
cells from peripheral and umbilical cord blood. Journal of Visualized 
Experiments : JoVE:e50070. 
274. Ye, Q., M. Loisiou, B. L. Levine, M. M. Suhoski, J. L. Riley, C. H. June, G. 
Coukos, and D. J. Powell, Jr. 2011. Engineered artificial antigen presenting cells 
facilitate direct and efficient expansion of tumor infiltrating lymphocytes. 
Journal of Translational Medicine 9:131. 




275. Denman, C. J., V. V. Senyukov, S. S. Somanchi, P. V. Phatarpekar, L. M. Kopp, 
J. L. Johnson, H. Singh, L. Hurton, S. N. Maiti, M. H. Huls, R. E. Champlin, L. 
J. Cooper, and D. A. Lee. 2012. Membrane-bound IL-21 promotes sustained ex 
vivo proliferation of human natural killer cells. PloS One 7:e30264. 
276. Butler, M. O., S. Ansen, M. Tanaka, O. Imataki, A. Berezovskaya, M. M. 
Mooney, G. Metzler, M. I. Milstein, L. M. Nadler, and N. Hirano. 2010. A panel 
of human cell-based artificial APC enables the expansion of long-lived antigen-
specific CD4+ T cells restricted by prevalent HLA-DR alleles. International 
Immunology 22:863-873. 
277. Suhoski, M. M., T. N. Golovina, N. A. Aqui, V. C. Tai, A. Varela-Rohena, M. 
C. Milone, R. G. Carroll, J. L. Riley, and C. H. June. 2007. Engineering artificial 
antigen-presenting cells to express a diverse array of co-stimulatory molecules. 
Molecular Therapy : The Journal of the American Society of Gene Therapy 
15:981-988. 
278. Maus, M. V., A. K. Thomas, D. G. Leonard, D. Allman, K. Addya, K. 
Schlienger, J. L. Riley, and C. H. June. 2002. Ex vivo expansion of polyclonal 
and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing 
ligands for the T-cell receptor, CD28 and 4-1BB. Nature Biotechnology 20:143-
148. 
279. Manuri, P. V., M. H. Wilson, S. N. Maiti, T. Mi, H. Singh, S. Olivares, M. J. 
Dawson, H. Huls, D. A. Lee, P. H. Rao, J. M. Kaminski, Y. Nakazawa, S. 
Gottschalk, P. Kebriaei, E. J. Shpall, R. E. Champlin, and L. J. Cooper. 2010. 




piggyBac transposon/transposase system to generate CD19-specific T cells for 
the treatment of B-lineage malignancies. Human Gene Therapy 21:427-437. 
280. Numbenjapon, T., L. M. Serrano, H. Singh, C. M. Kowolik, S. Olivares, N. 
Gonzalez, W. C. Chang, S. J. Forman, M. C. Jensen, and L. J. Cooper. 2006. 
Characterization of an artificial antigen-presenting cell to propagate cytolytic 
CD19-specific T cells. Leukemia 20:1889-1892. 
281. Singh, H., L. M. Serrano, T. Pfeiffer, S. Olivares, G. McNamara, D. D. Smith, 
Z. Al-Kadhimi, S. J. Forman, S. D. Gillies, M. C. Jensen, D. Colcher, A. 
Raubitschek, and L. J. Cooper. 2007. Combining adoptive cellular and 
immunocytokine therapies to improve treatment of B-lineage malignancy. 
Cancer Research 67:2872-2880. 
282. Choudhury, A., K. Derkow, A. H. Daneshmanesh, E. Mikaelsson, S. Kiaii, P. 
Kokhaei, A. Osterborg, and H. Mellstedt. 2010. Silencing of ROR1 and FMOD 
with siRNA results in apoptosis of CLL cells. British Journal of Haematology 
151:327-335. 
283. Baskar, S., A. Wiestner, W. H. Wilson, I. Pastan, and C. Rader. 2012. Targeting 
malignant B cells with an immunotoxin against ROR1. mAbs 4:349-361. 
284. Stonier, S. W., and K. S. Schluns. 2010. Trans-presentation: a novel mechanism 
regulating IL-15 delivery and responses. Immunology Letters 127:85-92. 
285. Stonier, S. W., L. J. Ma, E. F. Castillo, and K. S. Schluns. 2008. Dendritic cells 
drive memory CD8 T-cell homeostasis via IL-15 transpresentation. Blood 
112:4546-4554. 




286. Smetak, M., B. Kimmel, J. Birkmann, K. Schaefer-Eckart, H. Einsele, M. 
Wilhelm, and V. Kunzmann. 2008. Clinical-scale single-step CD4(+) and 
CD8(+) cell depletion for donor innate lymphocyte infusion (DILI). Bone 
Marrow Transplant 41:643-650. 
287. Kelly-Rogers, J., L. Madrigal-Estebas, T. O'Connor, and D. G. Doherty. 2006. 
Activation-induced expression of CD56 by T cells is associated with a 
reprogramming of cytolytic activity and cytokine secretion profile in vitro. 
Human Immunology 67:863-873. 
288. Gattinoni, L., X. S. Zhong, D. C. Palmer, Y. Ji, C. S. Hinrichs, Z. Yu, C. 
Wrzesinski, A. Boni, L. Cassard, L. M. Garvin, C. M. Paulos, P. Muranski, and 
N. P. Restifo. 2009. Wnt signaling arrests effector T cell differentiation and 
generates CD8+ memory stem cells. Nature Medicine 15:808-813. 
289. Di Mitri, D., R. I. Azevedo, S. M. Henson, V. Libri, N. E. Riddell, R. Macaulay, 
D. Kipling, M. V. Soares, L. Battistini, and A. N. Akbar. 2011. Reversible 
senescence in human CD4+CD45RA+CD27- memory T cells. Journal of 
Immunology 187:2093-2100. 
290. Zhang, M., S. Maiti, C. Bernatchez, H. Huls, B. Rabinovich, R. E. Champlin, L. 
M. Vence, P. Hwu, L. Radvanyi, and L. J. Cooper. 2012. A New Approach to 
Simultaneously Quantify Both TCR alpha- and beta-Chain Diversity after 
Adoptive Immunotherapy. Clinical Cancer Research : An Official Journal of the 
American Association for Cancer Research. 




291. Chatila, T., L. Silverman, R. Miller, and R. Geha. 1989. Mechanisms of T cell 
activation by the calcium ionophore ionomycin. Journal of Immunology 
143:1283-1289. 
292. Iwata, M., Y. Ohoka, T. Kuwata, and A. Asada. 1996. Regulation of T cell 
apoptosis via T cell receptors and steroid receptors. Stem Cells 14:632-641. 
293. Yang, J., S. Baskar, K. Y. Kwong, M. G. Kennedy, A. Wiestner, and C. Rader. 
2011. Therapeutic potential and challenges of targeting receptor tyrosine kinase 
ROR1 with monoclonal antibodies in B-cell malignancies. PloS One 6:e21018. 
294. Straathof, K. C., M. A. Pule, P. Yotnda, G. Dotti, E. F. Vanin, M. K. Brenner, H. 
E. Heslop, D. M. Spencer, and C. M. Rooney. 2005. An inducible caspase 9 
safety switch for T-cell therapy. Blood 105:4247-4254. 
295. Gattinoni, L., C. A. Klebanoff, D. C. Palmer, C. Wrzesinski, K. Kerstann, Z. Yu, 
S. E. Finkelstein, M. R. Theoret, S. A. Rosenberg, and N. P. Restifo. 2005. 
Acquisition of full effector function in vitro paradoxically impairs the in vivo 
antitumor efficacy of adoptively transferred CD8+ T cells. The Journal of 
Clinical Investigation 115:1616-1626. 
296. Cooper, L. J., M. S. Topp, L. M. Serrano, S. Gonzalez, W. C. Chang, A. 
Naranjo, C. Wright, L. Popplewell, A. Raubitschek, S. J. Forman, and M. C. 
Jensen. 2003. T-cell clones can be rendered specific for CD19: toward the 
selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 
101:1637-1644. 




297. Castella, B., C. Vitale, M. Coscia, and M. Massaia. 2011. Vgamma9Vdelta2 T 
cell-based immunotherapy in hematological malignancies: from bench to 
bedside. Cell Mol Life Sci 68:2419-2432. 
298. Brandes, M., K. Willimann, G. Bioley, N. Levy, M. Eberl, M. Luo, R. Tampe, F. 
Levy, P. Romero, and B. Moser. 2009. Cross-presenting human gammadelta T 
cells induce robust CD8+ alphabeta T cell responses. Proceedings of the 
National Academy of Sciences of the United States of America 106:2307-2312. 
299. Scotet, E., L. O. Martinez, E. Grant, R. Barbaras, P. Jeno, M. Guiraud, B. 
Monsarrat, X. Saulquin, S. Maillet, J. P. Esteve, F. Lopez, B. Perret, X. Collet, 
M. Bonneville, and E. Champagne. 2005. Tumor recognition following 
Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related 
structure and apolipoprotein A-I. Immunity 22:71-80. 
300. Hayday, A. C. 2000. [gamma][delta] cells: a right time and a right place for a 
conserved third way of protection. Annual Review of Immunology 18:975-1026. 
301. Kondo, M., K. Sakuta, A. Noguchi, N. Ariyoshi, K. Sato, S. Sato, A. Hosoi, J. 
Nakajima, Y. Yoshida, K. Shiraishi, K. Nakagawa, and K. Kakimi. 2008. 
Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta 
T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 
10:842-856. 
302. Lamb, L. S., Jr., P. J. Henslee-Downey, R. S. Parrish, K. Godder, J. Thompson, 
C. Lee, and A. P. Gee. 1996. Increased frequency of TCR gamma delta + T cells 
in disease-free survivors following T cell-depleted, partially mismatched, related 
donor bone marrow transplantation for leukemia. J Hematother 5:503-509. 




303. Lamb, L. S., Jr., A. P. Gee, L. J. Hazlett, P. Musk, R. S. Parrish, T. P. O'Hanlon, 
S. S. Geier, R. S. Folk, W. G. Harris, K. McPherson, C. Lee, and P. J. Henslee-
Downey. 1999. Influence of T cell depletion method on circulating gammadelta 
T cell reconstitution and potential role in the graft-versus-leukemia effect. 
Cytotherapy 1:7-19. 
304. Lamb, L. S., Jr., P. Musk, Z. Ye, F. van Rhee, S. S. Geier, J. J. Tong, K. M. 
King, and P. J. Henslee-Downey. 2001. Human gammadelta(+) T lymphocytes 
have in vitro graft vs leukemia activity in the absence of an allogeneic response. 
Bone Marrow Transplant 27:601-606. 
305. Godder, K. T., P. J. Henslee-Downey, J. Mehta, B. S. Park, K. Y. Chiang, S. 
Abhyankar, and L. S. Lamb. 2007. Long term disease-free survival in acute 
leukemia patients recovering with increased gammadelta T cells after partially 
mismatched related donor bone marrow transplantation. Bone Marrow 
Transplant 39:751-757. 
306. Rischer, M., S. Pscherer, S. Duwe, J. Vormoor, H. Jurgens, and C. Rossig. 2004. 
Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-
tumour immunity. British Journal of Haematology 126:583-592. 
307. Hanrahan, C. F., W. G. Kimpton, C. J. Howard, K. R. Parsons, M. R. Brandon, 
A. E. Andrews, and A. D. Nash. 1997. Cellular requirements for the activation 
and proliferation of ruminant gammadelta T cells. Journal of Immunology 
159:4287-4294. 
308. Garcia, V. E., D. Jullien, M. Song, K. Uyemura, K. Shuai, C. T. Morita, and R. 
L. Modlin. 1998. IL-15 enhances the response of human gamma delta T cells to 




nonpeptide [correction of nonpetide] microbial antigens. Journal of Immunology 
160:4322-4329. 
309. Do, J. S., and B. Min. 2009. IL-15 produced and trans-presented by DCs 
underlies homeostatic competition between CD8 and {gamma}{delta} T cells in 
vivo. Blood 113:6361-6371. 
310. O'Connor, C. M., S. Sheppard, C. A. Hartline, H. Huls, M. Johnson, S. L. Palla, 
S. Maiti, W. Ma, R. E. Davis, S. Craig, D. A. Lee, R. Champlin, H. Wilson, and 
L. J. Cooper. 2012. Adoptive T-cell therapy improves treatment of canine non-
Hodgkin lymphoma post chemotherapy. Sci Rep 2:249. 
311. Deniger, D. C., K. Switzer, T. Mi, S. Maiti, L. Hurton, H. Singh, H. Huls, S. 
Olivares, D. A. Lee, R. E. Champlin, and L. J. Cooper. 2013. Bispecific T-cells 
expressing polyclonal repertoire of endogenous gammadelta T-cell receptors and 
introduced CD19-specific chimeric antigen receptor. Molecular Therapy : The 
Journal of the American Society of Gene Therapy 21:638-647. 
312. Kulkarni, M. M. 2011. Digital multiplexed gene expression analysis using the 
NanoString nCounter system. Curr Protoc Mol Biol Chapter 25:Unit25B 10. 
313. Kang, N., J. Zhou, T. Zhang, L. Wang, F. Lu, Y. Cui, L. Cui, and W. He. 2009. 
Adoptive immunotherapy of lung cancer with immobilized anti-
TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral 
blood. Cancer Biology & Therapy 8:1540-1549. 
314. Dokouhaki, P., M. Han, B. Joe, M. Li, M. R. Johnston, M. S. Tsao, and L. 
Zhang. 2010. Adoptive immunotherapy of cancer using ex vivo expanded 
human gammadelta T cells: A new approach. Cancer Letters 297:126-136. 




315. Lopez, R. D., S. Xu, B. Guo, R. S. Negrin, and E. K. Waller. 2000. CD2-
mediated IL-12-dependent signals render human gamma delta-T cells resistant 
to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of 
functionally distinct lymphocytes: implications for the development of adoptive 
immunotherapy strategies. Blood 96:3827-3837. 
316. Newton, D. J., E. M. Andrew, J. E. Dalton, R. Mears, and S. R. Carding. 2006. 
Identification of novel gammadelta T-cell subsets following bacterial infection 
in the absence of Vgamma1+ T cells: homeostatic control of gammadelta T-cell 
responses to pathogen infection by Vgamma1+ T cells. Infect Immun 74:1097-
1105. 
317. Olofsson, K., S. Hellstrom, and M. L. Hammarstrom. 1998. The surface 
epithelium of recurrent infected palatine tonsils is rich in gammadelta T cells. 
Clin Exp Immunol 111:36-47. 
318. Stresing, V., F. Daubine, I. Benzaid, H. Monkkonen, and P. Clezardin. 2007. 
Bisphosphonates in cancer therapy. Cancer Letters 257:16-35. 
319. Angelini, D. F., G. Borsellino, M. Poupot, A. Diamantini, R. Poupot, G. 
Bernardi, F. Poccia, J. J. Fournie, and L. Battistini. 2004. FcgammaRIII 
discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with 
different responses and activation pathways. Blood 104:1801-1807. 
320. Haas, J. D., K. Nistala, F. Petermann, N. Saran, V. Chennupati, S. Schmitz, T. 
Korn, L. R. Wedderburn, R. Forster, A. Krueger, and I. Prinz. 2011. Expression 
of miRNAs miR-133b and miR-206 in the Il17a/f locus is co-regulated with IL-
17 production in alphabeta and gammadelta T cells. PloS One 6:e20171. 




321. Kryczek, I., S. Wei, L. Zou, S. Altuwaijri, W. Szeliga, J. Kolls, A. Chang, and 
W. Zou. 2007. Cutting edge: Th17 and regulatory T cell dynamics and the 
regulation by IL-2 in the tumor microenvironment. Journal of Immunology 
178:6730-6733. 
322. Lai, D., F. Wang, Y. Chen, C. Wang, S. Liu, B. Lu, X. Ge, and L. Guo. 2011. 
Human ovarian cancer stem-like cells can be efficiently killed by gammadelta T 
lymphocytes. Cancer Immunology, Immunotherapy : CII. 
323. Middleton, G. W., N. E. Annels, and H. S. Pandha. 2011. Are we ready to start 
studies of Th17 cell manipulation as a therapy for cancer? Cancer Immunology, 
Immunotherapy : CII. 
324. Cua, D. J., and C. M. Tato. 2010. Innate IL-17-producing cells: the sentinels of 
the immune system. Nature Reviews. Immunology 10:479-489. 
325. Haas, J. D., F. H. Gonzalez, S. Schmitz, V. Chennupati, L. Fohse, E. Kremmer, 
R. Forster, and I. Prinz. 2009. CCR6 and NK1.1 distinguish between IL-17A 
and IFN-gamma-producing gammadelta effector T cells. European Journal of 
Immunology 39:3488-3497. 
326. Paulos, C. M., C. Carpenito, G. Plesa, M. M. Suhoski, A. Varela-Rohena, T. N. 
Golovina, R. G. Carroll, J. L. Riley, and C. H. June. 2010. The inducible 
costimulator (ICOS) is critical for the development of human T(H)17 cells. 
Science translational medicine 2:55ra78. 
327. Turchinovich, G., and D. J. Pennington. 2011. T cell receptor signalling in 
gammadelta cell development: strength isn't everything. Trends in Immunology 
32:567-573. 




328. Janssen, O., S. Wesselborg, B. Heckl-Ostreicher, K. Pechhold, A. Bender, S. 
Schondelmaier, G. Moldenhauer, and D. Kabelitz. 1991. T cell receptor/CD3-
signaling induces death by apoptosis in human T cell receptor gamma delta + T 
cells. Journal of Immunology 146:35-39. 
329. Numbenjapon, T., L. M. Serrano, W. C. Chang, S. J. Forman, M. C. Jensen, and 
L. J. Cooper. 2007. Antigen-independent and antigen-dependent methods to 
numerically expand CD19-specific CD8+ T cells. Exp Hematol 35:1083-1090. 
330. Sallusto, F., D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Two 
subsets of memory T lymphocytes with distinct homing potentials and effector 
functions. Nature 401:708-712. 
331. Unsoeld, H., and H. Pircher. 2005. Complex memory T-cell phenotypes 
revealed by coexpression of CD62L and CCR7. Journal of Virology 79:4510-
4513. 
332. Tomiyama, H., T. Matsuda, and M. Takiguchi. 2002. Differentiation of human 
CD8(+) T cells from a memory to memory/effector phenotype. Journal of 
Immunology 168:5538-5550. 
333. Caccamo, N., C. La Mendola, V. Orlando, S. Meraviglia, M. Todaro, G. Stassi, 
G. Sireci, J. J. Fournie, and F. Dieli. 2011. Differentiation, phenotype, and 
function of interleukin-17-producing human Vgamma9Vdelta2 T cells. Blood 
118:129-138. 
334. Rostene, W., P. Kitabgi, and S. M. Parsadaniantz. 2007. Chemokines: a new 
class of neuromodulator? Nat Rev Neurosci 8:895-903. 




335. Gilfillan, S., C. J. Chan, M. Cella, N. M. Haynes, A. S. Rapaport, K. S. Boles, 
D. M. Andrews, M. J. Smyth, and M. Colonna. 2008. DNAM-1 promotes 
activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells 
and tumors. The Journal of Experimental Medicine 205:2965-2973. 
336. Bauer, S., V. Groh, J. Wu, A. Steinle, J. H. Phillips, L. L. Lanier, and T. Spies. 
1999. Activation of NK cells and T cells by NKG2D, a receptor for stress-
inducible MICA. Science 285:727-729. 
337. Bottino, C., R. Castriconi, D. Pende, P. Rivera, M. Nanni, B. Carnemolla, C. 
Cantoni, J. Grassi, S. Marcenaro, N. Reymond, M. Vitale, L. Moretta, M. Lopez, 
and A. Moretta. 2003. Identification of PVR (CD155) and Nectin-2 (CD112) as 
cell surface ligands for the human DNAM-1 (CD226) activating molecule. The 
Journal of Experimental Medicine 198:557-567. 
338. Jensen, H., M. Hagemann-Jensen, F. Lauridsen, and S. Skov. 2013. Regulation 
of NKG2D-ligand cell surface expression by intracellular calcium after HDAC-
inhibitor treatment. Molecular Immunology 53:255-264. 
339. Pende, D., P. Rivera, S. Marcenaro, C. C. Chang, R. Biassoni, R. Conte, M. 
Kubin, D. Cosman, S. Ferrone, L. Moretta, and A. Moretta. 2002. Major 
histocompatibility complex class I-related chain A and UL16-binding protein 
expression on tumor cell lines of different histotypes: analysis of tumor 
susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer 
Research 62:6178-6186. 
340. Pende, D., C. Cantoni, P. Rivera, M. Vitale, R. Castriconi, S. Marcenaro, M. 
Nanni, R. Biassoni, C. Bottino, A. Moretta, and L. Moretta. 2001. Role of 




NKG2D in tumor cell lysis mediated by human NK cells: cooperation with 
natural cytotoxicity receptors and capability of recognizing tumors of 
nonepithelial origin. European Journal of Immunology 31:1076-1086. 
341. Turchinovich, G., and A. C. Hayday. 2011. Skint-1 identifies a common 
molecular mechanism for the development of interferon-gamma-secreting 
versus interleukin-17-secreting gammadelta T cells. Immunity 35:59-68. 
342. Lam, V., R. DeMars, B. P. Chen, J. A. Hank, S. Kovats, P. Fisch, and P. M. 
Sondel. 1990. Human T cell receptor-gamma delta-expressing T-cell lines 
recognize MHC-controlled elements on autologous EBV-LCL that are not HLA-
A, -B, -C, -DR, -DQ, or -DP. Journal of Immunology 145:36-45. 
343. Bhaduri-McIntosh, S., M. J. Rotenberg, B. Gardner, M. Robert, and G. Miller. 
2008. Repertoire and frequency of immune cells reactive to Epstein-Barr virus-
derived autologous lymphoblastoid cell lines. Blood 111:1334-1343. 
344. Micklethwaite, K. P., B. Savoldo, P. J. Hanley, A. M. Leen, G. J. Demmler-
Harrison, L. J. Cooper, H. Liu, A. P. Gee, E. J. Shpall, C. M. Rooney, H. E. 
Heslop, M. K. Brenner, C. M. Bollard, and G. Dotti. 2010. Derivation of human 
T lymphocytes from cord blood and peripheral blood with antiviral and 
antileukemic specificity from a single culture as protection against infection and 
relapse after stem cell transplantation. Blood 115:2695-2703. 
345. Torikai, H., A. Reik, P. Q. Liu, Y. Zhou, L. Zhang, S. Maiti, H. Huls, J. C. 
Miller, P. Kebriaei, B. Rabinovitch, D. A. Lee, R. E. Champlin, C. Bonini, L. 
Naldini, E. J. Rebar, P. D. Gregory, M. C. Holmes, and L. J. Cooper. 2012. A 
foundation for universal T-cell based immunotherapy: T cells engineered to 




express a CD19-specific chimeric-antigen-receptor and eliminate expression of 
endogenous TCR. Blood 119:5697-5705. 
346. Kebriaei, P., H. Huls, B. Jena, M. Munsell, R. Jackson, D. A. Lee, P. B. Hackett, 
G. Rondon, E. Shpall, R. E. Champlin, and L. J. Cooper. 2012. Infusing CD19-
directed T cells to augment disease control in patients undergoing autologous 
hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. 
Human Gene Therapy 23:444-450. 
347. Anderson, J., K. Gustafsson, and N. Himoudi. 2012. Licensing of killer dendritic 
cells in mouse and humans: functional similarities between IKDC and human 
blood gammadelta T-lymphocytes. Journal of Immunotoxicology 9:259-266. 
348. Himoudi, N., D. A. Morgenstern, M. Yan, B. Vernay, L. Saraiva, Y. Wu, C. J. 
Cohen, K. Gustafsson, and J. Anderson. 2012. Human gammadelta T 
lymphocytes are licensed for professional antigen presentation by interaction 
with opsonized target cells. Journal of Immunology 188:1708-1716. 
349. Anderson, J., K. Gustafsson, N. Himoudi, M. Yan, and J. Heuijerjans. 2012. 
Licensing of gammadeltaT cells for professional antigen presentation: A new 
role for antibodies in regulation of antitumor immune responses. 
Oncoimmunology 1:1652-1654. 
350. Kryczek, I., M. Banerjee, P. Cheng, L. Vatan, W. Szeliga, S. Wei, E. Huang, E. 
Finlayson, D. Simeone, T. H. Welling, A. Chang, G. Coukos, R. Liu, and W. 
Zou. 2009. Phenotype, distribution, generation, and functional and clinical 
relevance of Th17 cells in the human tumor environments. Blood 114:1141-
1149. 




351. DeBarros, A., M. Chaves-Ferreira, F. d'Orey, J. C. Ribot, and B. Silva-Santos. 
2011. CD70-CD27 interactions provide survival and proliferative signals that 
regulate T cell receptor-driven activation of human gammadelta peripheral 
blood lymphocytes. European Journal of Immunology 41:195-201. 
352. Ribot, J. C., A. deBarros, D. J. Pang, J. F. Neves, V. Peperzak, S. J. Roberts, M. 
Girardi, J. Borst, A. C. Hayday, D. J. Pennington, and B. Silva-Santos. 2009. 
CD27 is a thymic determinant of the balance between interferon-gamma- and 
interleukin 17-producing gammadelta T cell subsets. Nature Immunology 
10:427-436. 
353. Di Ianni, M., L. Moretti, A. Terenzi, F. Bazzucchi, B. Del Papa, M. Bazzucchi, 
R. Ciurnelli, A. Lucchesi, P. Sportoletti, E. Rosati, P. F. Marconi, F. Falzetti, 
and A. Tabilio. 2009. Activated autologous T cells exert an anti-B-cell chronic 
lymphatic leukemia effect in vitro and in vivo. Cytotherapy 11:86-96. 
354. Kang, N., L. Tang, X. Li, D. Wu, W. Li, X. Chen, L. Cui, D. Ba, and W. He. 
2009. Identification and characterization of Foxp3(+) gammadelta T cells in 
mouse and human. Immunology Letters 125:105-113. 
355. Lu, X., and Y. Kang. 2010. Hypoxia and hypoxia-inducible factors: master 
regulators of metastasis. Clinical cancer research : an official journal of the 
American Association for Cancer Research 16:5928-5935. 
356. Zhu, P., Y. Ning, L. Yao, M. Chen, and C. Xu. 2010. The proliferation, 
apoptosis, invasion of endothelial-like epithelial ovarian cancer cells induced by 
hypoxia. J Exp Clin Cancer Res 29:124. 




357. Turkman, N., A. Shavrin, R. A. Ivanov, B. Rabinovich, A. Volgin, J. G. 
Gelovani, and M. M. Alauddin. 2011. Fluorinated cannabinoid CB2 receptor 
ligands: synthesis and in vitro binding characteristics of 2-oxoquinoline 










Drew Caldwell Deniger was born on January 2, in Dallas, TX to William Southgate 
Deniger, Jr. and Jeanne Caldwell Deniger. He attended Dallas’ Hillcrest High School 
where he served as the art and design editor for the school’s newspaper, The Hurricane, 
and played varsity soccer and football. After graduating from Hillcrest in 1998, he 
enrolled at The University of Texas at Austin where he earned B.S. degrees in 
Chemistry and Biochemistry. He then worked as a research associate for three years in 
the lab of Robert A. Davey, Ph.D. at The University of Texas Medical Branch in 
Galveston, TX. In 2006, he enrolled at The University of Texas Graduate School of 
Biomedical Sciences in the M.S. program under the mentorship of Madeleine Duvic, 
M.D. and graduated two years later with a thesis focused on metastatic melanoma. He 
then enrolled in the Ph.D. program at The University of Texas Graduate School of 
Biomedical Sciences and joined the Immunology Program and the laboratory of 
Laurence J.N. Cooper, M.D., Ph.D. in the Division of Pediatrics at The University of 
Texas M.D. Anderson Cancer Center. 
 
